Investigating uptake in faecal immunochemical test (FIT) based colorectal cancer screening by Clarke, Nicholas
Title Investigating uptake in faecal immunochemical test (FIT) based
colorectal cancer screening
Author(s) Clarke, Nicholas
Publication date 2017
Original citation Clarke, N. 2017. Investigating uptake in faecal immunochemical test
(FIT) based colorectal cancer screening. PhD Thesis, University College
Cork.
Type of publication Doctoral thesis
Rights © 2017, Nicholas Clarke.
http://creativecommons.org/licenses/by-nc-nd/3.0/
Embargo information No embargo required
Item downloaded
from
http://hdl.handle.net/10468/4825
Downloaded on 2018-08-23T19:52:25Z
  
Investigating uptake in faecal immunochemical test 
(FIT) based colorectal cancer screening 
 
 
 
 
Nicholas Clarke (B.A., M.Sc.) 
 
A thesis submitted to the National University of Ireland, Cork for the 
degree of Doctor of Philosophy in the Department of Epidemiology 
and Public Health 
 
June 2017 
Head of Department 
Prof Ivan Perry 
 
Supervisors 
Prof Patricia M. Kearney 
Prof Linda Sharp 
1 
 
Contents          Page no. 
List of Tables…………………………………………………………………………4  
List of Figures………………………………………………………………………...5 
List of Abbreviations............................................................................................…...6 
Declaration……………………………………………………….…………………..8 
Acknowledgements……………………………………………….………………….9 
Thesis abstract………………………………………………...…………………….11 
1. Introduction…………………………………………………………………………13 
1.1. Introduction…………………………………………………………………………14 
1.2. PhD Aims and Objectives………………………………………..…………………33 
1.3. Thesis Outline………………………………………………..………………….…..33 
2. Increasing late stage colorectal cancer and rectal cancer mortality demonstrates the 
need for screening: a population based study in Ireland, 1994-2010 (Paper 1)….....46 
2.1. Abstract……………………………………………………………………………..47 
2.2. Introduction…………………………………………………………………………48 
2.3. Methods………………………………………………………………………….….50 
2.4. Results………………………………………………………………………...…….52 
2.5. Discussion…………………………………………………………………………..55 
2.6. Conclusion…………………………………………………………………………..60 
2.7. References……………………………………………………………………..……62 
3. Comparison of uptake of colorectal cancer screening based on faecal 
immunochemical testing (FIT) in males and females: A systematic review and meta-
analysis (Paper 2)………………………………………………………………..….73 
3.1. Abstract…………………………………………………………………………..…74 
3.2. Introduction……………………………………………………………………..…..75 
3.3. Materials and Methods………………………………………………………….…..76 
3.4. Results………………………………………………………………………………80 
3.5. Discussion…………………………………………………………………….…….85 
3.6. Conclusion…………………………………………………………………….…….89 
3.7. References…………………………………………………………………………..90 
2 
 
4. The role of area-level deprivation and gender in participation in population-based 
faecal immunochemical test (FIT) colorectal cancer screening (Paper 4)……..….100 
4.1. Abstract………………………………………………………………………........101 
4.2. Introduction………………………………………………………………….….…102 
4.3. Methods……………………………………………………………………………104 
4.4. Results……………………………………………………………………………..107 
4.5. Discussion…………………………………………………………………………109 
4.6. Conclusion……………………………………………………………………..…..114 
4.7. References……………………………………………………………………...….115 
5. Impact of gender on decisions to participate in Faecal Immunochemical Test-based 
colorectal cancer screening: A qualitative study (Paper 3)………………………..122 
5.1. Abstract……………………………………………………………………………123 
5.2. Introduction………………………………………………………………..………124 
5.3. Methods……………………………………………………………………..……..125 
5.4. Results………………………………………………………………..……………128 
5.5. Discussion…………………………………………………………………….……133 
5.6. Conclusion……………………………………………………………………..…..137 
5.7. References…………………………………………………………………………138 
6. Negative emotions and cancer fatalism are independently associated with uptake of 
FIT based colorectal cancer screening: Results from a population based study (Paper 
5)………………………………………………………………………….……….144 
6.1. Abstract………………………………………………………………….…….…..145 
6.2. Introduction……………………………………………………………….….……146 
6.3. Methods……………………………………………………………………………147 
6.4. Results……………………………………………………………………………..153 
6.5. Discussion……………………………………………………………..…………..157 
6.6. Conclusions……………………………………………………………..…………163 
6.7. References…………………………………………………………………………164 
7. Discussion……………………………………………………………………….…173 
7.1. Summary of main findings…………………………………………………….…..174 
7.2. Strengths and limitations……………………………………………….……….…179 
7.3. Implication of findings…………………………………………………..………...183 
7.4. Future recommendations for research………………………………………….….189 
3 
 
7.5. Conclusion…………………………………………………………………………193 
7.6. References……………………………………………………………………..…..194 
Appendix A Supplementary material (chapter 4)………………………………………197 
Appendix B Supplementary Material (Chapter 5)………………………………...……200 
Appendix C Supplementary material (Chapter 6)……………………………….……..207 
Appendix D (Published papers)………………………………………………………...232 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Tables 
Table 1.1: Characteristics of the 19 studies on FIT uptake in males and females 
included in the meta-analysis…………………………………………………..….95 
Table 1.2: Uptake figures by male and female for the 19 studies in meta-analysis 
with OR’, 95% CI and P value……………………………………………………..96 
Table 1.3: Newcastle-Ottawa Scale of included studies: reviewers judgement……98 
Table 1.4: Summary of primary and subgroup random effects meta-analysis……..99 
Table 2.1: Characteristics of screening invitees of the TTC-CRC-SP…………….120 
Table 2.2: TTC-CRC-SP Absolute uptake by participant characteristics (numbers 
and %) and univariable and multivariable relative risks (RR) for participation in FIT-
based colorectal cancer screening with 95% confidence interval and p values: 
primary analysis based on two screening rounds combined………………………121 
Table 3.1: Illustrative quotes for domains potentially influencing screening decisions 
in users, by gender……………………………………………………………..….142 
Table 3.2: Illustrative quotes for domains potentially influencing screening decisions 
in non-users, by gender………………………………………………………….....143 
Table 4.1: Absolute uptake by participant characteristics (numbers and %) and 
univariable and adjusted odds ratios (OR) for participation in FIT-based colorectal 
cancer screening with 95% confidence intervals and p values…………….………169 
Table 4.2: Multivariable odds ratios (OR) for participation in FIT-based colorectal 
cancer screening with 95% confidence intervals and p values………….…………171 
Table 4.3: Absolute uptake by gender with the final multivariable model of odds 
ratios (OR) for participation in FIT-based colorectal cancer screening with 95% 
confidence intervals and p values stratified by sex………………………….….…172 
 
5 
 
Figures 
Figure1.1: World age-standardised incidence and mortality rates of colorectal cancer 
by sex and population……………………………………………………………….37  
Figure 1.2: Aims and objectives and overview of thesis……………………….…..38 
Figure 2.1: Age standardised incidence rate and incident cases of colorectal cancer 
by site of primary tumour and sex, 1994-2010……………………………..………66 
Figure 2.2: Case fraction for stage of disease at presentation, by gender and site of 
tumour for diagnostic period 1994-2009. (A) COLON- FEMALES; (B) COLON 
MALES; (C) RECTUM- FEMALES; (D) RECTUM - MALES………………….67 
Figure 2.3: Percentage of patients treated with various modalities, 1995-2009…...69 
Figure 2.4: One and five year relative survival for colon cancer for diagnostic 
periods by sex with 95% confidence intervals…………………………………......70 
Figure 2.5: One and five year relative survival for rectal cancer by diagnostic period 
by sex, with 95% confidence intervals……………………………………………..71 
Figure 2.6: Age standardised mortality rate and number of deaths for colorectal 
cancer by site of primary tumour and sex, 1994-2009…………………………...…72 
Figure 3.1: Study flow diagram: result of systematic review search strategy…….94 
Figure 3.2: Forest plot corresponding to the main random effects meta-analysis of 19 
estimates quantifying the relationship between gender and uptake of FIT-based 
colorectal cancer screening……………………………………………….…….…97 
Figure 4.1: Consort diagram of TTC-CRC-SP invitees…………………………...119 
 
 
 
 
 
6 
 
List of abbreviations 
ABC  
 
Awareness and Beliefs about Cancer  
APC  
 
Annual percentage change  
ASR  
 
Age standardised rate 
CI 
 
Confidence Interval 
CSO 
 
Central Statistics Office 
CTC 
 
Computed tomography colonography 
DCO 
 
Death certificate only  
DNA 
 
Deoxyribonucleic acid 
ERUS  
 
Endo-rectal ultrasound  
ESP  
 
European Standard Population 
EU 
 
European Union 
FIT  
 
Faecal immunochemical test 
gFOBT  
 
Guaiac-based faecal occult blood Test 
GP 
 
General Practitioner 
HIQA  
 
Health Information and Quality Authority  
HP  
 
Haase Pratschke  
HSE 
 
Health Service Executive 
HTA  
 
Health Technology Assessment  
ICD10 
 
International Classification of Diseases 10th revision  
ICERs 
IQR  
 
Incremental cost-effectiveness ratios 
Inter Quartile Range  
LYG 
 
Life years gained  
MDM 
 
Multi-disciplinary meetings  
7 
 
MRI  
 
Magnetic resonance imaging  
NCRI  
 
National Cancer Registry Ireland 
NCSS  
 
National Cancer Screening Service   
NSS 
 
National Screening Service 
QALY  
 
Quality Adjusted Life Years 
RCT 
 
Randomised Control trial 
RR 
 
Relative Risks 
RS 
 
Relative survival 
TDF   Theoretical Domains Framework  
TTC-CRC-SP 
Tallaght Hospital/ Trinity College Colorectal Cancer Screening 
Programme 
WHO   
 
World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
 
 
Declaration 
 
I declare that this thesis has not been submitted for another degree at this or at any 
other University. The work, upon which this thesis is based, was carried out in 
collaboration with a team of researchers and supervisors who are duly acknowledged 
in the text of this thesis. 
 
Signed: __________________________ Date: __________________ 
 
 
 
 
 
 
 
 
 
9 
 
Acknowledgments 
First and foremost I would like to thank my supervisors, Prof Linda Sharp and Prof 
Patricia Kearney, both of whom provided such a superb learning experience for me 
over the course of the PhD. Thank you both for being so supportive and 
encouraging, especially in times when the challenge got tough. You are both a 
source of inspiration, and indeed wonder! I would particularly like to thank Linda, 
who, having known her for 8 years now, never fails to teach me something new each 
and every time we talk. I would not have been able to fully develop my ideas for the 
PhD scholarship or indeed complete the thesis without her help. 
I would like to thank the Irish Cancer Society who funded this PhD through a 
scholarship. In particular I would like to thank Robert O’Conner and Isabella Bray 
and all the research officers for all their help over the years and for championing this 
work. 
I would also like to thank Prof Harry Comber, Director of the National Cancer 
Registry (NCRI), who first read my two page idea for the PhD and agreed it would 
be a useful piece of work and informed me Linda was the person for the job.  
I would like to thank Prof Deirdre McNamara and Prof Colm O’Morain for 
facilitating access to Tallaght/ Trinity College Colorectal Cancer Screening 
Programme, without which this work would not have happened. Thanks also to 
Professor Pamela Gallagher of DCU who provided her expert knowledge, advice and 
feedback on the psychological aspects of the work. Thanks to Dr Katie O’Brien 
(NCRI) for her assistance with statistical analysis along the way and huge heartfelt 
thanks to Claire O’Callaghan (NCRI) for all her support throughout the course of the 
PhD. I would like to thank all staff at the National Cancer Registry who lent a 
10 
 
helping hand when I was in need. Thanks also to Ber Madden (UCC) for all her 
support over the last few years.  
I would also like to thank my parents, brothers and sister for their support and 
encouragement while completing this work. Finally I would like to thank my wife 
Deirdre, daughter Juno and sons Conn and Macdara. You are the light of my life and 
keep me focused on all that’s good in life. I would like to dedicate this work to you.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Thesis Abstract 
Colorectal cancer is a major public health issue, being one of the most diagnosed 
cancers in men and women and one of the leading causes of cancer related mortality. 
Almost 2500 people are diagnosed with colorectal cancer each year in Ireland and 
over 1000 die from the disease.  Males are at greater risk of developing and dying 
from colorectal cancer. Colorectal cancer is a highly treatable disease if detected at 
an early stage; however the disease can often take more than ten years to exhibit 
symptoms in those who develop it. Colorectal cancer will often be asymptomatic 
until signs and symptoms begin to express themselves, and often times this is when 
the disease has progressed to late stage disease, at which point treatment is more 
onerous and outcomes are not as good. In late 2013 Ireland began to roll out the 
National Colorectal Cancer Screening Programme (BowelScreen) using the new 
faecal immunochemical test (FIT) technology, the first time this technology was to 
be used in a national population based screening programme. This was the first time 
males had been invited to take part in a nationally organised cancer screening 
programme. This thesis investigates uptake of population-based FIT-based colorectal 
cancer screening and explores factors associated with uptake in males and females 
with the intent of providing evidence to improve uptake in screening programmes, 
thereby impacting on the detection and reduction of incidence and mortality from 
colorectal cancer within the population. The thesis presents an epidemiological study 
of colorectal cancer in Ireland during 1994 to 2010, prior to the establishment of the 
national colorectal cancer screening programme. A systematic review provides 
evidence that FIT uptake is low internationally, and furthermore that uptake using 
FIT screening is significantly lower in males, but importantly that it is not the 
screening programme design or organisation that influences uptake differences in 
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males and females. In attempting to understand drivers of non-use a qualitative study 
of users and non-users of a population based FIT-based screening programme was 
also carried out. Results indicated a number of factors influencing non-uptake in 
males and females including negative beliefs and emotions related to cancer and 
screening, poor knowledge and social influences. Additional quantitative analysis of 
a database of screening invitees provides evidence that increasing male gender and 
increasing deprivation are independently associated with lower uptake of FIT based 
screening. In order to test the results of the qualitative study at an aggregate level a 
survey of users and non-users of an organised FIT-based population-based screening 
programme confirms that non-use is influenced by negative beliefs and emotions 
related to cancer and screening, as well as the influence of a partner or spouse. 
However evidence of gender based differences in the factors influencing uptake of 
FIT based screening was not found. Further research is required to determine why 
males are significantly less likely to take part in FIT based screening. More 
importantly the thesis has begun to identify factors which may be amenable to the 
development of interventions to improve uptake in Irelands National Colorectal 
Cancer Screening Programme.   
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1.1 Introduction 
Colorectal cancer is a major public health problem in Ireland and worldwide. On 
average 2489 cases of colorectal cancer were diagnosed each year in Ireland  during 
2012-2014 (1). On average 1018 people died from the disease in Ireland each year 
during 2011-2013 (1).  Colorectal cancer is the second most commonly diagnosed 
cancer among males (after prostate cancer) and the third most commonly diagnosed 
among females (after breast and lung cancer). More cases were diagnosed in males 
(n=1476) compared to females (n=1013) and more male deaths occurred from the 
disease (594 vs 424) (1). Excluding non-melanoma skin cancer, 10% and 13% of all 
cancers in males and females respectively are colorectal cancers (1). The age-
standardised incidence rate is 63.8 per 100,000 in males and 38.1 per 100,000 in 
females and, for mortality 26.4 in males and 14.8 per 100,000 in females (1). 
Colorectal cancer accounts for 13.3% of all cancers in males and 10.4% of all 
cancers in females.  
 
Natural history of colorectal cancer 
 
Adenomatous polyps and the adenoma-carcinoma sequence 
Colorectal cancer occurs in the large bowel which includes the colon and the rectum. 
Most colorectal cancers develop in the lining of the bowel and often begin as benign 
non-cancerous tumours known as “adenomas”, “adenomatous polyps” or in some 
instances “serrated polyps” or “hyperplastic polyps”. The transition from 
adenomatous polyp to cancerous tumour is known as the adenoma-carcinoma 
sequence (2,3) while some other sporadic colorectal cancers have been identified 
through the development of some hyperplastic and serrated polyps (4,5). Most 
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polyps do not cause severe symptoms and are often excised through the use of 
colonoscopy (6). About 70% of polyps removed during colonoscopy have been 
shown to be polypoid adenomas (pre-cancerous lesions which develop through the 
adenoma-carcinoma sequence) and are known to be responsible for most colorectal 
cancer development (2,3).  It has been reported that the prevalence of colonic 
adenomas is about 30-40% at 60 years of age, although the lifetime cumulative 
incidence of colorectal cancer is 5.5% indicating many adenomas of the colon do not 
progress to cancer (7). However removal of these polyps has the potential to prevent 
the development of colorectal cancer and this is the basis upon which screening for 
the disease has been established (8–12).  
 
The transition from polyp to cancerous invasion often takes more than 10 years 
(3,13,14). Annual transition rates from advanced adenomas to colorectal cancer 
increase with age (2.6% in females and males between ages 55-59 and 5.6% in 
females and 5.1% in males in those aged older than 80 years) while 10 year 
cumulative risk increases from 25.4% (females) and 25.2% (males) at 55 years to 
42.9% (females) and 39.7% (males) in those aged over 80 (15).  
 
 Incidence from colorectal cancer invasion 
The International Association of Cancer Research has reported that colorectal cancer 
was the third most common cancer in men (746,000 cases) and the second most 
common in women (614,000 cases) worldwide representing almost 10% of all 
cancers diagnosed (16). Almost 55% of cases worldwide occur in more developed 
regions with rates being 10 times greater in the highest regions of incidence of 
Australia and New Zealand (Age standardised rate (ASR): 44.8 and 32.2 per 100,000 
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in males and females respectively) to the lowest region of incidence of Western 
Africa (4.5 and 3.8 per 100,000)(17). However the disparity in incidence in males 
and females holds across regions (Figure 1) (16).  Internationally age-standardised 
colorectal cancer incidence rates from 1982-1987 through to 1998-2002 increased in 
males and females in 27 of 51 cancer registries (18). Increases however were 
primarily in countries in economic transition (Czech Republic & Slovakia, most part 
of Asia and some South American countries) where rates also increased more 
prominently in males (18). Rates in more economically developed countries however 
began to stabilise during the periods 1982-1987 through to 1998-20002 (although the 
United states observed a decrease in rates) (18). Despite the stabilisation of the rates 
in longstanding economically developed countries the global incidence of the disease 
is expected to increase by 79%, mainly due to increasing and ageing populations, 
although lifestyle factors also play a role (19, 20).   
  
Colorectal cancer survival and disease stage 
In 29 European countries with cancer registries average five-year relative survival 
during the period 2000-2007 was 56.6 (95% CI 56.4-56.76) and Ireland was below 
this average at 54.3% (95% CI 53.29-55.37) but above countries in the United 
Kingdom (for instance England 52.08; 95% CI 51.8-52.35) and Eastern European 
countries (47.3 95% CI 48.0-46.88)(21). Once again as with incidence and mortality, 
relative survival was generally lower in males across Europe during this period 
(European average Males: 56.42 (95% CI55.3-56.05); Females 57.66 (95% CI57.4-
57.93) and this is also the case in Ireland (Males 52.51 (95% CI 51.08-53.98); 
Females 56.38 (95% CI 54.88-57.92)(21).  
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At diagnosis colorectal cancer is staged to determine the extent of the tumour size 
and if it has spread to lymph nodes and to other parts of the body. Early stage 
colorectal cancers are referred to as stages I and II and are localised (i.e. have not 
spread) while stage III has progressed to the lymph nodes and local organs and stage 
IV to other parts of the body (22). At earlier stages surgery to remove the cancer and 
nearby lymph nodes is most commonly used, while at later stages the use of 
chemotherapy, or chemotherapy in conjunction with radiation therapy, is often used 
and outcomes are poorer as observed in survival rates (23). In the US 5 year relative 
survival rates for those diagnosed at localised stage are 90%, 69% when spread to 
lymph nodes or adjacent organs and 12% when spread to distant organs (23). In 
Ireland, 3 year cancer-specific survival has improved over time and during the period 
2006-2009 survival of those diagnosed at stage I was 93% and 83% for those 
diagnosed at stage II. However 3 year cancer-specific survival at stage III was 67% 
and 20% for those diagnosed at stage IV (24).  
 
Mortality 
Approximately 694,000 deaths occurred from the disease globally, representing 
8.5% of all cancer deaths (16). Increasing mortality has been observed in countries 
within Eastern Europe and in populations in Asia and Latin America (20). 52% of 
deaths worldwide are in less developed regions with an estimated 175.4 deaths per 
100,000 in males and 157.7 deaths per 100,000 in females in more developed 
regions compared to 198.2 deaths in males and 162.5 deaths in females in less 
developed regions (16). As with incidence, age standardised mortality rates are 
generally higher in males (20) (Figure 1). Age-standardised mortality rate decreases 
have been observed in more developed regions such as the Northern Europe, Canada, 
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USA, Israel and Australia and New Zealand, and increasing rates have been 
observed in countries such as China, Croatia, Latvia, Russia Columbia and Costa 
Rica (20). Overall age-standardised mortality rates are estimated to increase by  85% 
by 2035 (19,20). The European Standard Population (ESP) mortality rate among 
males in Ireland was 26.4 per 100,000 and 14.8 per 100,000 in females in the period 
2011-2013(1). This represented 12% of all cancer deaths in Ireland (13% in males 
and 10% in females) in during that period (1).  
 
Risk factors for colorectal cancer 
Risk for the development of colorectal cancer can be categorised into modifiable and 
non-modifiable factors.  
Non-modifiable risk factors 
Non-modifiable risks are those that an individual has no control over. These include 
age and hereditary factors. Colorectal cancer is a cancer of older people and 90% of 
colorectal cancers are diagnosed in those over the age of 50 and incidence is 50 
times greater in those aged 60-79 than in those aged less than 40 (25). Other non-
modifiable risk factors include a personal history of adenomatous polyps (in the US 
lifetime risk of developing an adenoma is 19%), a personal history of Inflammatory 
Bowel Disease (relative risk of developing colorectal cancer is 4-20 fold), a family 
history of colorectal or adenomatous polyp (up to 20% of those diagnosed with 
colorectal cancer have family members who have had the disease) or an inherited 
genetic risk of developing the disease (5-10% of colorectal cancers are hereditary) 
(25).  
Modifiable risk factors 
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A number of risk factors have been identified which increase the  risk of developing 
colorectal cancer which are modifiable, meaning that the risk develops as a result of 
environmental factors which people have control over. These include nutritional 
factors such as the consumption of red meat and high fat diets, lack of physical 
activity, obesity (in particular abdominal obesity), tobacco use and heavy alcohol 
consumption (26).  
 
Differences in risk factors in males and females exist and contribute to the excess 
incidence and mortality of colorectal cancer among males. Smoking rates are almost 
five times higher in males than females, especially in low and middle income 
countries, but are somewhat similar in high income countries(27). In Ireland 
smoking prevalence is 21.6% in males and 17.6% in females. Other risk factors such 
as overweight and obesity have similar rates in males and females worldwide (37% 
of males and 38% of females) (28) while in Ireland males are more often overweight 
(43% of males and 31% of females) with similar rates of obesity in males and 
females (25% of males and 22% of females) (29). Males also exceed females in their 
consumption of alcohol, particularly high-volume consumption (30) and this is no 
different in Ireland (29). 
 
Screening and the adenoma-carcinoma sequence 
Colorectal cancer became a focus of screening development because of the 
establishment of the adenoma-carcinoma sequence and the association between 
survival and stage of disease. In 1968 the World Health Organisation (WHO) set out 
10 principles for the establishment of screening programmes aimed at detecting 
disease in populations (31). The principles stipulated that: 
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 (1) The condition sought should be an important health problem  
(2) There should be an accepted treatment for patients with recognized disease  
(3) Facilities for diagnosis and treatment should be available  
(4) There should be a recognizable latent or early symptomatic stage 
(5) There should be a suitable test or examination 
(6) The test should be acceptable to the population 
(7) The natural history of the condition, including development from latent to 
declared disease, should be adequately understood  
(8) There should be an agreed policy on whom to treat as patients  
(9) The cost of case-finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible expenditure on 
medical care as a whole  
(10) Case-finding should be a continuing process and not a "once and for all" project 
  
The existence of the adenoma-carcinoma sequence and the strong relationship 
between early stage disease at diagnosis and subsequent improved outcomes 
provides the rationale for screening. Population-based screening for colorectal cancer 
involves inviting a defined population who are at average risk of developing the 
disease to be screened for the disease (32). The aim of such a programme is to 
identify individuals with the disease at the earliest possible stage or to identify those 
with pre-cancerous adenomas who are at increased risk of developing colorectal 
cancer  in order to reduce incidence and mortality (32). Population-based screening 
for colorectal cancer has been present in large parts of Europe for over a decade (33–
35). However despite the growth of colorectal cancer screening as an important 
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public health initiative (36) only a small proportion of the world’s population has 
access to screening (37).  
 
National screening programmes have been established in many countries (34,38,39), 
on the basis that screening reduces both incidence and mortality through early 
detection of cancers and/ or detection and removal of adenomatous polyps (10,40–
42).  Several screening tests exist, including endoscopy-based tests (including 
flexible sigmoidoscopy and colonoscopy) and faecal tests (such as guaiac-based 
faecal occult blood Test (gFOBT) and faecal immunochemical tests (FIT)).  
 
Types of screening tests 
A number of screening tests exist and these include endoscopic based tests, faecal or 
blood based tests or computed tomography colonography (CTC). These tests can be 
divided on the basis of procedurally invasive tests and non-invasive tests. Invasive 
tests include the use of endoscopic based testing procedures including flexible 
sigmoidoscopy and colonoscopy, but also the less invasive CTC (also known as 
virtual colonoscopy) which uses x-ray technology. Non-invasive tests include the use 
of FOBT and FIT. Research is ongoing in efforts to develop DNA testing, either 
through blood testing (Blood based DNA methylation or protein markers) (43,44) or 
stool-based testing (45). However CTC nor the newer DNA based tests have been 
proven to be cost effective in screening and therefore are not recommended for 
population based screening (46) although CTC has been recommended in the US as 
an opportunistic screening test (11). Current screening guidelines in the US 
recommend screening using invasive procedures every 5-10 years  or annually using 
non-invasive procedures (11), while in Europe only FOBT has been recommended in 
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population based screening programmes (12). The tests recommended for screening 
for colorectal cancer are briefly described below. 
 
Endoscopic based tests 
Endoscopic based procedures such as colonoscopy and flexible sigmoidoscopy 
visualise the rectum and colon with the aim of identifying polyps or cancerous 
neoplasms and are carried out by a medical professional.  
 
Flexible sigmoidoscopy  
Flexible sigmoidoscopy involves the insertion of a flexible 60cm long tube into the 
anus which is advanced slowly into the colon. The procedure allows the practitioner 
to examine the rectum and sigmoid colon (where approximately two thirds of 
cancers are located) for abnormalities (47). Flexible sigmoidoscopy can be both a 
screening tool and a diagnostic tool, and can remove identified adenomas at the time 
of the procedure. In addition a single screening test can be sufficient to protect 
against colorectal cancer when offered between the ages of 55 to 64 (42). Screening 
using flexible sigmoidoscopy has been reported to reduce incidence by 32% and 
mortality by 50% (48) while meta-analysis of observational studies of colonoscopy 
have reported a 69%  reduction in incidence and  a 68% reduction in mortality from 
the disease (49). A recent Cochrane review indicated a 15% reduction in incidence 
and mortality when flexible sigmoidoscopy was compared to FOBT screening (50). 
US guidelines recommend screening using flexible sigmoidoscopy every 5 years 
(11).     
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Colonoscopy 
 Like flexible sigmoidoscopy, colonoscopy also employs the use of a flexible tube 
(colonoscope) which is inserted into the rectum and colon which allows the 
practitioner to visually examine the rectum and colon. Colonoscopy has a further 
advantage over flexible sigmoidoscopy in that it can reach further into the large 
intestine but is a more onerous procedure on the patient, being associated with higher 
levels of discomfort and complication rates (49). Colonoscopy is the diagnostic 
procedure within most screening programmes but is often the screening test of 
choice in US based opportunistic screening (51). In the absence of randomised 
control trials (which are underway but will take another decade to report results) a 
recent systematic review of observational studies reported a 61% reduction in the 
relative risk of  incidence and mortality from colorectal cancer  while in subgroup 
analysis of screening colonoscopy incidence there was an 89% reduction in 
incidence (52). US guidelines recommend screening using colonoscopy every 10 
years (11).     
 
Faecal based tests 
Adenomas are often asymptomatic but can produce blood in the stools, which may 
go undetected. Faecal based tests (FOBT, FIT and faecal DNA tests) aim to detect 
non-visible traces of blood in the faeces which can be a marker of upper or lower 
gastrointestinal bleeding as a result of adenomatous polyps or carcinomas. If blood is 
detected a recommendation for diagnostic testing using colonoscopy (or CTC if the 
individual is unsuitable for colonoscopy) will be made. As described above, faecal 
DNA test are not used within organised screening programmes due to a lack of 
evidence on cost-effectiveness(46). Currently two types of faecal test are available 
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which are used within organised population-based screening programmes, gFOBT 
and FIT.  
 
gFOBT 
The gFOBT test aims to detect blood in the stool through a reaction with guaiac 
(contained in the test) and the enzyme peroxidase (found in blood) (53). The test can 
be carried out at home and can be return to a laboratory via the postal system (38). 
For a successful test to be completed a 3 samples on consecutive days are usually 
required (54,55), using a sampler and placing the samples on a card (38). Laboratory 
results indicate if the sample is positive or negative for blood. However the reaction 
between guaiac and peroxidase  may detect blood which does not originate in the 
colon or rectum, or non-human blood from red meat (as well as some raw plant 
foods) (53).  For this reason, dietary and medicinal restrictions are required before 
completing the test. Reviews have reported reductions in mortality of between 15-
33% compared with no screening (41,56). In the European Union it is recommended 
the test be carried out biennially in population based screening programmes (12) 
while in the US annual opportunistic screening is recommended using gFOBT. 
FIT 
The FIT also detects blood in the faeces but unlike gFOBT it is specific to human 
blood. The test works through the reaction of antibodies specific for human 
haemoglobin with blood (53,57,58) and is more selective for blood originating in the 
colon and rectum compared to the gFOBT. The test can be carried out at home and 
requires either one sample or two samples on consecutive days depending on the 
sensitivity threshold set (59). Completed tests are sent via post to a laboratory for 
analysis. A positive result requires follow-up diagnostic colonoscopy (11,13). 
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Unlike FOBT, dietary and medicinal restriction are not required and this makes the 
test easier and more acceptable to screening populations while reducing the number 
of false positive results that may occur in gFOBT based screening (53). An 
additional advantage of FIT is that the test is quantitative and therefore the 
processing and reading of the test can be automated, and standard cut off values of 
haemoglobin detection can be set to a positivity rate that meets the capacity of 
colonoscopy resources available within screening programmes (60).   
 
Some evidence indicates FIT is a cost-effective alternative to gFOBT (reviewed in 
(12)), and more recently has been shown to outperform gFOBT with almost double 
the sensitivity in detecting advanced neoplasia (61). FIT has not been shown to 
reduce incidence or mortality as randomised control trials of have not been carried 
out. However Allison et al have argued that this is not necessary as FIT has 
demonstrated superior performance characteristics as described above and boasts a 
significant enhancement on the detection of occult faecal blood in faeces in subjects 
most likely to harbour advanced neoplasia (62). Screening using FIT is 
recommended annually in the US (11) or every two years in EU (12). 
 
Organised population-based screening 
At this point it has been established that screening for colorectal cancer has been 
shown to reduce incidence and mortality from the disease (13,41,42,56,58). High 
uptake in screening is vital in maximising the benefits to the population through 
reductions in incidence (by preventing the disease from occurring) and mortality (by 
detecting the disease at earlier stages) (12,63). Faecal-based tests, notably gFOBT, 
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are generally the route through which organised population-based colorectal cancer 
screening programmes are being delivered internationally (34). Uptake rates have 
been shown to be lower when using colonoscopy or sigmoidoscopy as the initial 
screening test (64), while uptake has been shown to be higher with the use of FIT 
compared to gFOBT (65). In addition Significant differences in screening uptake by 
gender have also been reported in the UK and US with females more likely to take 
part in screening when g-FOBT is offered as the initial screening test (66,67). 
Deprivation has also been reported in the UK gFOBT screening programme with 
35% uptake in the most deprived areas compared to 61% in the most affluent areas 
(66).  The deprivation gradient was steeper in females than males indicating better 
uptake in females as affluence increases (66). These findings on uptake by gender 
and deprivation are limited to g-FOBT screening, and no data is available on these 
factors in FIT based screening, which will be a focus of this thesis.  
Screening sigmoidoscopy and screening colonoscopy have been shown to prevent 
the majority of deaths from distal colorectal cancer, while screening colonoscopy can 
prevent deaths from proximal colon cancer (5,49). However risk reduction may vary 
according to factors such as the quality of endoscopy, age at screening or risk factor 
profiles (including genetic factors)(13). When compared to FIT, Colonoscopy has 
shown to have significantly higher rates of detection of advanced adenomas, 
advanced neoplasia and non-advanced adenomas, but similar detection rates of 
cancer (68). Alison et al has concluded that FIT has higher sensitivity and specificity 
for distal colon cancer when compared to gFOBT (62).  
Higher proportions of females and older people present with right-sided colon 
cancers and these cancers are often at a more advanced stage at diagnosis and have a 
higher mortality risk (69,70), although recently it has been suggested that the 
27 
 
prognosis of those diagnosed with right sided colon cancers at stages I-III is better 
compared to those diagnosed with left-sided colon cancers (71).  
Major sex differences have also been reported in the performance of gFOBT and 
FIT, with the detection of advanced neoplasia higher in males and corresponding 
lower sensitivity in males compared to females (72).  
Colorectal cancer screening in Ireland 
In 2007 the National Cancer Screening Service (NCSS now the National Screening 
Service (NSS)) board established an expert advisory group to examine the scientific 
evidence related to screening for colorectal cancer in Ireland. The group 
recommended that the FIT operating on an automated platform should be the 
primary screening tool for a population-based colorectal cancer screening 
programme in Ireland. It further went on to state that this would be the first 
international colorectal cancer screening programme utilising this technology as a 
primary screening tool (73).  
 
The NSS commissioned the Health Information and Quality Authority (HIQA) under 
the advice of an expert advisory group to undertake a Health Technology 
Assessment (HTA) of the relative cost effectiveness of various options for a 
population-based colorectal cancer screening  programme in Ireland compared to no 
programme and this was carried out and published in 2009 (32). The HTA also 
estimated the resource requirements (in terms of colonoscopy capacity) and potential 
health outcomes (number of cases of adenomas and cancers detected) that could 
result in the first decade following implementation of a screening programme. The 
HTA examined a number of options for the initial screening test for population-
based screening in Ireland. This was guided by the volume and strength of available 
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scientific evidence, knowledge of screening practices in other countries and 
consideration of the acceptability, feasibility and risk of serious adverse events as a 
result of screening (32). Three main screening scenarios were established by the 
expert advisory group:  
 Biennial gFOBT, with reflex FIT testing, in those aged 55-74 years; 
 Biennial FIT, in those aged 55-74 years; 
 Once-only flexible sigmoidoscopy, at age 60.   
Based on available evidence obtained from literature review it was assumed uptake 
of FIT and gFOBT would be 53% and 39% using once-only flexible sigmoidoscopy, 
Therefore in year one of a programme it was assumed that 189,640 completed kits 
would be returned using gFOBT or FIT (based on a screening age range of 55-74), 
while 18,617 individuals would undergo screening using flexible sigmoidoscopy. 
Given demographic changes in the population and assuming uptake remains constant 
the number screened by gFOBT or FIT would increase by 16-17% and by 11% using 
flexible sigmoidoscopy (32). 
 
The HTA team reported that all three options were likely to be cost effective in terms 
of the threshold set (historical, notional, cost effectiveness threshold of €45,000 per 
Quality Adjusted Life Year (QALY))(32). The results of the HTA cost-effectiveness 
analysis showed that a screening programme based on FIT would cost more than 
programmes based on gFOBT or flexible sigmoidoscopy, however FIT screening 
would provide the greatest health gain (QALYs or Life years gained (LYG)) 
compared to a policy of no screening, while remaining highly cost effective relative 
to other screening options, (32). Compared to no screening the following incremental 
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cost-effectiveness ratios (ICERs) were obtained for the three core screening 
scenarios: 
 Biennial FIT (55 to 74 years): €1,696/QALY 
 Biennial gFOBT (55 to 74 years): €4,428/QALY 
 Once-off FSIG at age 60 years: €589/QALY. 
 
HIQA recommended a biennial FIT based colorectal cancer screening programme 
with an age range of 55-74 as the one which would provide the greatest health gain 
to the population and would also result in: 
 The highest estimated lifetime reduction in the incidence (14.7%) and 
mortality (36.0%) from colorectal cancer 
 The highest percentage of lifetime cases of screen or surveillance-detected 
cancers (31.6% of all cancers versus 13.8% for gFOBT and 3.3% for flexible 
sigmoidoscopy) and adenomas.  
 
The authors also suggested that because screen-detected cancers are more likely to 
be detected at an earlier stage (stage I or II) than those detected symptomatically 
survival rates would also improve. HIQA was further requested by the Minister for 
Health and Children to undertake an evaluation (74) aimed at: 
 identifying the resources assigned colonoscopy services within the hospital 
system and assess the potential to apply or build upon these resources 
effectively within a national colorectal cancer screening programme  
 advising on a model for a national colorectal cancer screening programme, 
including options for phased implementation as set out in the HTA of a 
population-based colorectal cancer screening programme in Ireland 
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 advising how the national colorectal cancer screening programme can be run 
effectively in a quality assured manner within the existing resources available 
to the NCSS and the Health Service Executive (HSE)  
 examining potential synergies between the current and proposed population-
based cancer screening programmes with a view to maximising and optimising 
efficiencies 
The HIQA evaluation recommended a cost effective model for the delivery of 
colorectal cancer screening which would build upon existing capacity within 
the health system utilising a number of cost savings and efficiencies, identified 
within the evaluation (74). The key elements of a national screening 
programme included (74): 
 8-12 symptomatic services delivering colonoscopies generated from the 
screening programme which would be centres based within hospitals with 
those hospitals deciding upon the most effective solution matching their 
available facilities, resources and staff 
 Use of advanced nurse practitioners in the delivery of the service 
 Appropriate diagnostic and treatment pathways be put in place for other 
procedures (CTC or surgery) 
  Gap analysis to determine additional need for consultant radiologist, 
radiographer or specialised equipment 
 Development of a national quality assurance programme 
 the principles of good client care established within the breast screening 
programme should also be encompassed within this screening model 
 Operation of a multidisciplinary team approach with the screening programme 
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 Laboratories utilised for histology should have appropriate internal quality 
control and external quality assurance 
 
The next steps in the implementation of FIT based colorectal cancer screening was 
presented in 2010 (75) and was based on the findings of the HIQA HTA and 
evaluation outlined above (32,74). 
 
Prior to the HTA only a two studies of colorectal cancer screening existed in Ireland. 
The first was a program inviting construction workers to take part in screening with 
either gFOBT or FIT tests (76). Following from this a pilot screening programme 
was established in an area in Dublin. The Adelaide and Meath Hospital / Trinity 
College Dublin Colorectal Cancer Screening Programme (TTC-CRC-SP) was 
Ireland’s first population-based two-step (two FIT samples required on consecutive 
days) colorectal cancer screening programme and ran over two rounds during 2008-
2010 and 2011 to 2012 (77–79). Uptake in Round 1 was 51% and was slightly lower 
in round 2 at 47.5% (79). This programme provided valuable evidence on the 
potential success of implementing FIT based colorectal cancer screening in the 
population at large.   
 
The roll-out of a national population-based colorectal cancer screening programme 
in Ireland began in December, 2012 – the first national programme to be based on 
primary FIT (73). Initially, individuals aged 60-69 are invited for biennial screening 
with FIT, with follow-up of positive test results by diagnostic colonoscopy at one of 
twelve centres associated with the screening programme. While some evidence 
exists in terms of factors influencing uptake of colorectal cancer screening, very little 
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evidence exists in relation to FIT based screening specifically. In addition, very little 
is known about whether males are more or less likely to take part in screening, 
especially in light of their higher risk of developing and dying from the disease.      
 
Conception of this PhD 
This study was conceived after the author attended a conference on men’s health in 
2010 in which the then Irish minister for health gave the closing speech. The 
minister discussed the development of the national colorectal cancer screening 
programme and that this would be the first organised cancer screening programme 
available to men (Ireland having had breast cancer screening since 2000 and cervical 
cancer screening introduced the previous year in 2009). At the time, in collaboration 
with the National Cancer Registry Ireland (NCRI), the author, working for the 
Centre for Men’s Health, was conducting a study on the excess burden of cancer in 
men in Ireland. That study reported significantly higher rates incidence and mortality 
of five of the leading non-sex specific cancers (lung, colorectal, bladder, stomach 
and melanoma skin cancer) in males (80). The imminent implementation of 
colorectal cancer screening in Ireland, and the fact that males had significantly 
higher incidence and mortality from colorectal cancer, was the germ for the 
development of a PhD proposal aiming to investigate FIT-based colorectal cancer 
screening in males and females. The fact that this would be the first time men in 
Ireland would be offered the opportunity to be screened for cancer added value and 
relevance to the proposal. The author was successful in securing funding through an 
Irish Cancer Society scholarship. 
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1.2 PhD aims and objectives 
The objectives of this PhD project were: 
 Aim:  
The overall aim of this PhD project was to describe uptake in FIT based colorectal 
cancer screening and to explore the impact of gender on uptake. 
The specific objectives (Figure 1.2) were to:   
1. Describe the burden of colorectal cancer in Ireland (chapter 2) 
2. Review uptake in FIT-based colorectal cancer screening in males and females 
internationally (Chapter 3)  
3. Identify factors associated with use and non-use of FIT-based colorectal cancer 
screening in males and females including any differences and factors associated 
with these differences (Chapter 4 & 6) 
4. Explore specific barriers, motivators and facilitators associated with FIT-based 
colorectal cancer screening in males and females (Chapters 5 & 6)  
5. Inform future roll-out of colorectal cancer screening in Ireland (Chapter 7) 
 
1.3 Thesis Outline 
Chapter 2 of the thesis is a descriptive epidemiological study of colorectal cancer in 
Ireland from 1994 to 2010 using NCRI data. This chapter describes the overall 
patterns of colon and rectal cancer in males and females and describes incidence, 
mortality and survival from the disease prior to the introduction of national 
population based screening.  
 
Chapter 3 describes a systematic review and meta-analysis of FIT based screening 
uptake in males and females internationally. The analysis also investigated factors 
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associated with uptake as they pertain to study design and organisation of screening 
programmes.  
 
Chapter 4 reports a qualitative study nested within a population-based FIT-based 
colorectal cancer screening programme which explored factors associated with 
uptake in male and female users and non-users. The Theoretical Domains 
Framework (TDF) was employed to provide a theoretical framework for the study 
and to make sense of individual’s discourse on influences on their decisions about 
whether or not to participate in FIT based screening. 
 
Chapter 5 is a quantitative study, utilising the database of a population based FIT-
based colorectal cancer screening programme, investigating uptake in relation to sex, 
deprivation status and age.  
 
Chapter 6 describes the final phase of the overall study, again nested with the 
population based screening programme, and is a cross-sectional survey of male and 
female users and non-users of the screening programme. The study investigates some 
of the factors identified in the qualitative phase (described in chapter 4) in a 
population-based sample of FIT screening users and non-users and moves towards 
the identification of behaviours which may be amenable to the development of 
interventions to improve uptake in Ireland’s national colorectal cancer screening 
programme. 
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Chapter 7 is a discussion and final conclusion drawing together the evidence base 
established in the study, and presents implications for Irelands national screening 
programme and potential avenues for future research. 
 
Contributors to the work of this thesis 
In chapter 2 Dr Joseph McDevitt carried out the statistical analysis of data presented 
in this paper. Data was drawn from the National Cancer Registry. In chapter 3 Dr 
Aoife Osborne acted as second reviewer for the completion of the systematic review. 
In chapter 4 invitations to potential participants was managed by Claire O’Callaghan 
in the National Cancer Registry. Interview recordings were transcribed by a third 
party, Devon Transcription Ltd. Dr Mairead O’Connor double coded a number of 
transcripts to ensure rigour in the process of analysis. Prof Pamela Gallagher 
provided advice and support in use of the Theoretical Domains Framework and 
provided feedback of drafts of chapters 4 and 7.  In chapter 5 the TTC-CRC-SP 
database was geo-coded by Mr Neil McCluskey of the National Cancer Registry and 
Dr Katie O’Brien provided statistical advice in its analysis. For chapter 6 the cross-
sectional postal survey invitations and access database was managed by Ms Claire 
O’Callaghan. Ms O’Callaghan also managed the packaging of invitations and data 
entry for the survey. Further support in delivery and data entry of the survey was 
provided by research assistant Ms Antonia Virovska. Professor Linda Sharp and 
Professor Patricia Kearney supervised the entire PhD.  
 
Candidate’s contribution 
For the population based epidemiological study (chapter 2) the PhD candidate, 
Nicholas Clarke, lead on the write up of the data and submitted and defended the 
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manuscript throughout the journals peer review process. The candidate carried out all 
literature reviews, systematic review data collection and analysis including meta-
analysis (Rev-Man) described in Chapter 3. The candidate managed the population 
based screening database described in Chapter 4 and carried out all analysis. For the 
qualitative study (Chapter 5) the candidate was responsible for the design of the 
topic guide, recruitment of participants, conducted all interviews (N=50) and carried 
out all analysis (managed in NVivo software). The candidate designed the 
questionnaire and managed the database of invitees for the survey in Chapter 6. The 
candidate also jointly managed the recruitment and delivery of the postal 
questionnaire and reminders to the 7500 individuals invited to participate. All data 
cleaning was carried out by the candidate. All statistical analysis was carried out by 
the candidate using STATA 14 (except in the case of chapter two as described 
above). The candidate led on the write up of all five studies and the submission and 
defence of the each study throughout the peer review process within each journal.    
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Figure1.1: World age-standardised incidence and mortality rates of colorectal cancer 
by sex and population  
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Figure 1.2: Aims and objectives and overview of thesis
Aim 
Objective
s 
Describe the population 
burden of colorectal 
cancer by examining 
trends in colorectal 
cancer incidence, 
mortality and survival 
during 1994-2010, prior 
to nationwide 
screening. 
 
Conduct a systematic 
review and meta-analysis 
to determine if uptake of 
FIT-based screening 
differs by gender and to 
assess factors which may 
influence any gender-
based differences. 
 
Explore differences in 
male and female 
influences on use and 
non-use of a population-
based FIT colorectal 
cancer screening 
programme 
Investigate the effect of 
sex and deprivation on 
FIT-based screening 
uptake. 
Quantify associations 
between uptake of FIT-
based screening and 
knowledge and health 
literacy, beliefs and 
emotions about cancer 
and screening and social 
influences and determine 
if these differ by sex 
. 
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2.1 Abstract 
Background: This paper describes trends in colorectal cancer incidence, survival and 
mortality from 1994 to 2010 in Ireland prior to the introduction of population-based 
screening. 
Methods: We examined incidence (National Cancer Registry Ireland (NCRI) and 
mortality (Central Statistics Office) from 1994 to 2010. Age standardised rates 
(ASR) for incidence and mortality have been calculated, weighted by the European 
standard population. Annual percentage change was calculated in addition to testing 
for linear trends in treatment and case fraction of early and late stage disease. 
Relative survival was calculated considering deaths from all causes. 
Results: The colorectal cancer ASR was 63.7 per 100,000 in males and 38.7 per 
100,000 in females in 2010. There was little change in the ASR over time in either 
sex, or when colon and rectal cancers were considered separately; however the 
number of incident cancers increased significantly during 1994-2010 (1752 to 2298). 
The case fractions of late stage (III/IV) colon and rectal cancers rose significantly 
over time. One and 5 year relative survival improved for both sexes between the 
periods 1994-2008. Colorectal cancer mortality ASRs decreased annually from 
1994-2009 by 1.8% (95% CI -2.2, -1.4). Rectal cancer mortality ASRs rose annually 
by 2.4% (95% CI 1.1, 3.6) and 2.8% (95% CI 1.2, 4.4) in males and females 
respectively. 
Conclusions: Increases in late-stage disease and rectal cancer mortality demonstrate 
an urgent need for colorectal cancer screening. However, the narrow age range at 
which screening is initially being rolled-out in Ireland means that the full potential 
for reductions in late-stage cancers and incidence and mortality are unlikely to be 
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achieved. While it is possible that the observed increase in rectal cancer mortality 
may be partly an artefact of cause of death misclassification, it could also be 
explained by variations in treatment and adherence to best practice guidelines; 
further investigation is warranted. 
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2.2 Introduction 
Over 1.23 million colorectal cancers are diagnosed worldwide annually  with 609 
000 deaths(1). Colorectal cancer is highly preventable if diagnosed early and treated. 
Screening has been available for many years through several modalities, including 
colonoscopy, sigmoidoscopy, and faecal-based tests (2–4). Faecal-based tests, 
notably gFOBT, are generally the route through which colorectal cancer screening 
programmes are being delivered internationally (5,6). More recently FIT has been 
recommended for screening due to its improved sensitivity and specificity in 
detecting human haemoglobin and the fact that there is no need for test recipients to 
undergo dietary restrictions (which may be required for guaiac-based tests). Studies 
which have used FIT suggest improved uptake compared to other screening tests 
such as FOBT, possibly due to the absence of dietary restrictions, the need for fewer 
samples, absence of the need for storage if a one sample test, and ease of use (7). 
However the authors state that these results are inconclusive and require further 
investigation from the patient’s perspective (7). Recent European and US guidelines 
recommend FIT as the initial screening test in population-based screening 
programmes (8,9). 
Screening aims to detect colorectal disease either at a precancerous stage (when 
removal of polyps may prevent cancers developing) or when cancers are at an early 
stage (when treatment is more effective and patients may also benefit from improved 
quality-of-life). Screening therefore has the potential to reduce mortality, provided 
the services is high quality and coverage is high (8). 
Although many European countries have established screening programmes, until 
2013, no programme was in place in Ireland. In 2009, a health technology 
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assessment of population-based colorectal cancer screening found that biennial FIT 
at ages 55-74 would be considered the optimal screening strategy in Ireland in terms 
of potential for reducing incidence and mortality, and cost-effectiveness (10). The 
NCSS launched BowelScreen, a national population-based programme, in December 
2012. This paper aims to describe the population burden of colorectal cancer by 
examining trends in colorectal cancer incidence, mortality and survival during 1994-
2010, prior to nationwide screening. 
2.3 Methods 
We examined incidence for 1994-2010 and mortality for 1994-2009 (2009 was the 
latest year for which mortality data was available at the time of the study). 
Information on incident cases was abstracted from the NCRI. The NCRI records all 
cancers diagnosed in the population usually resident in Ireland through active case 
finding by tumour registration officers. The completeness of registration for all 
invasive cancers diagnosed to end 2008 was estimated to be over 97% (11). 
The NCRI has permission under the Health (Provision of Information) Act 1997 to 
collect and hold data on all persons diagnosed with cancer in Ireland. The use of that 
data for research is covered by the Statutory Instrument which established the 
Registry Board in 1991 All datasets were anonymised prior to analysis. 
Site of tumour was recorded according to the International Classification of Diseases 
10th revision (ICD10), and analysis included all primary invasive cancers of the 
colon (C18) and rectum (C19-C20) with a date of diagnosis during 01/01/1994 and 
31/12/2010. For each diagnosed cancer, summary stage was derived from primary 
tumour (T), regional nodes (N) and distant metastasis (M) as recorded in pathology 
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reports or, in the absence of these, from clinical staging, according to TNM 5
th
 
edition (12). Where a patient was classified as MX (“distant metastases cannot be 
assessed”), the M category was defaulted to “M0” (no distant metastasis). For 
example, a patient with stage composite T3N1MX was treated as T3N1M0, stage III 
(Dukes C). Data on treatment received during the first year post-diagnosis was 
defined as planned first course of tumour directed treatment administered within one 
year of the diagnosis date (-30 to 365 days) and aimed at removing, destroying or 
preventing further tumour growth and included four treatment scenarios: (Surgery 
(Y/N), chemotherapy(Y/N), radiotherapy(Y/N), or not treated [ICD9CM and 
ICD10-AM]). Analyses of stage and treatment included cases diagnosed 1995-2009, 
as this information was incomplete for 2010 cases and unreliable for 1994 cases, the 
first year of national registration. Colorectal cancer deaths (C18-20) were obtained 
from the Central Statistics Office (CSO) (13). 
Age-standardised rates (ASR) for incidence and mortality were weighted by the 
European standard population using the direct method (14). Trends presented as 
annual percentage change (APC) in ASRs of incidence (1994-2010) and mortality 
(1994-2009) were calculated using Joinpoint regression (15). Joinpoint regression 
was also used to test for linear trends in treatment (1995-2009) and case fraction of 
early (stage I/II) and late (stage III/IV) disease (1995-2009). For descriptive 
purposes, age category percentages and treatment category percentages were given 
for three diagnostic periods: 1995-1999, 2000-2004 and 2005-2009. 
In the Irish cancer registry, follow-up of cases is passive, where registered cancer 
cases are linked to death certificates provided by the Central Statistics Office (CSO) 
(16). For survival analysis, the dataset was divided into three diagnostic periods: 
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1994-1998, 1999-2003 and 2004-2008. Survival time was censored at 31 December 
2009 to ensure all cases had at least one year follow-up, and because this was the 
latest date for which death ascertainment was complete. Our manuscript was drafted 
in late 2013, a point in time when we were confident that all deaths certificates from 
the CSO were matched to the cancer registry database. Cases which were preceded 
by another cancer (other than non-melanoma skin cancer) were excluded from 
survival analysis as were autopsy-only cases, death certificate only cases (DCO), 
colorectal cancers concurrent with other invasive malignancy and colorectal cancers 
diagnosed 2009-2010. Relative Survival (RS), the ratio of observed survival among 
a group of cases to the expected survival among the general population of the same 
age, sex and country, was computed based on deaths from all causes and using 
national life-tables (17). 
2.4 Results 
Incidence 
The colorectal cancer ASR was 63.7 per 100,000 in males and 38.7 per 100,000 in 
females in 2010. There was little change in the ASR over time (Figure 2.1) in either 
sex, or when colon and rectal cancers were considered separately. However, the 
number of colorectal cancer cases in Ireland increased from 1752 in 1994 to 2298 in 
2010, an annual rise of 2.1% (95% confidence interval (CI) 1.8, 2.4; p < 0.001). The 
increase was somewhat higher in males (983 in 1994; 1343 in 2010; APC = 2.3%, 
95% CI 2.0, 2.7) than females (769 in 1994; 955 in 2010; APC = 1.8%, 95% CI 1.4, 
2.1). 
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In males, 62% of cases were in the colon; this was 71% in females. Increases in 
cases were observed in both colon (APC males = 2.6%, 95% CI 2.0, 3.2; APC 
females = 1.8%, 95% CI 1.4, 2.3) and rectal cancer (APC males = 1.9%, 95% CI 1.0, 
2.4; APC females = 1.7%, 95% CI 1.4, 2.5). 
Age distribution 
69% of cases in males and 67% in females occurred in those aged ≥65; similar 
proportions in each sex were diagnosed aged 55-64 (males: 20%; females: 19%) and 
<55 (males: 11%; females: 14%). Over the three periods 1995-1999, 2000-2004 and 
2005-2009 there was no change in the age distribution of either colon or rectal 
cancer in females or rectal cancer in males (data not shown). 
Stage 
During 1995-2009 early stage (I/II) colon cancers decreased by -1% annually in 
males (95%CI -1.8%, -0.1%) and in females by -0.7% (95% CI -1.4%, -0.1%). 
Conversely late stage (III/IV) colon cancers increased by 1.3% in males (95% CI 
0.6%, 2.1%) and by 1.6% in females (95% CI 0.9%, 2.3%). Similarly early stage 
rectal cancers decreased by -2.1% (95% CI -2.8%, -1.4%) in males and -1.8% (95% 
CI -2.9%, -0.7%) in females, while late stage disease increased significantly (males: 
APC = 2.0%, 95% CI 1.2%, 2.7%; females: APC = 1.8%, 95% CI 0.7%, 2.8%; 
Figure 2.2). Unstaged colon cancers decreased significantly in males by -2.2% (95% 
CI -4.1%, -0.2%; p-trend <0.05) and by -3.3% in females (95%CI -5.7%, -1.0%; p-
trend < 0.05) annually. There was no significant change in unstaged rectal cancers in 
males (APC 0.6%, 95% CI -2.3%, 1.2%; p-trend = 0.5) or females (APC = 0.2%, 
95% CI-2.3%, 2.8; p-trend = 0.8). 
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Treatment 
Use of cancer-directed surgery (i.e. resection) for colon cancer increased from 76% 
in 2009 to 79% in 2009 (APC 0.3%, 95%CI 0.0, 0.6; p = 0.027), while for rectal 
cancer there was little change, remaining at 74% over the same period (APC -0.1%, 
95%CI -0.5, 0.3; p = 0.54) (Figure 2.3). Use of chemotherapy for colon cancer rose 
significant from 21% in 1995 to 40% in 2006, thereafter levelling off to 38% up to 
2009(APC = 5.7%, 95%CI 4.3, 7.1; p < 0.001). Similarly, in rectal cancer, 
chemotherapy use increased significantly from 22% in 1995 to 48% in 2002 (APC = 
11.1%, 95%CI 8.7, 13.5; p < 0.001), reaching 49% by 2009 (Figure 2.3). Use of 
radiotherapy for rectal cancer increased significantly from 18% in 1995 to 37% in 
2001, thereafter levelling off to just under 40% (APC 12.3%, 95% CI 9.1, 15.7; p < 
0.001). The proportion of rectal cancer patients who received pre-surgery 
radiotherapy increased from 2% in 1995 to 13% in 2002 (APC 38.7%, 95% CI 28.7, 
49.5; p < 0.001). Thereafter, the proportion receiving this combination increased at a 
slower rate from 18% in 2003 to 26% in 2009 (APC 9.9%, 95% CI 1.9, 18.4; p = 
0.02) (Figure 2.3). 
Survival 
Relative survival improved over time for both sexes for colon and rectal tumours. 
From 1994-1998 to 2004-2008 1-year colon cancer survival in males increased by 8 
percentage points to 77% (95% CI 75%, 78%), and in females by 5 percentage 
points to 73% (95% CI 71%, 75%). Five-year colon cancer survival increased by 8 
percentage points to 58% (95% CI 56%, 61%) in males and by 7 percentage points 
to 59% (95% CI 56%, 62%) in females over the same time (Figure 2.4). One-year 
rectal cancer survival improved in males by 9 percentage points to 81% (95% CI 
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79%, 82%) and in females by 6 percentage points to 80% (95% CI 78%, 83%); 5-
year rectal cancer survival in males improved by 9 percentage points to 55% (95% 
CI 52%, 59%) and in females by 9 percentage points to 61% (95% CI 57%, 65%; 
Figure 2.5). 
Mortality 
In 2005-2009, on average 400 females (255 colon; 145 rectum) and 552 males (313 
colon; 239 rectum) died from colorectal cancer annually. Colon cancer deaths 
declined over time in both sexes (males: 360 in 1994; 302 in 2009; APC = -1.7%, 
95% CI -2.4%, -1.0%; females: 321 in 1994; 240 in 2009; APC = -2.1%, 95% CI -
3.0%, -1.2%). Rectal cancer deaths rose significantly in males from 148 in 1994 to 
262 in 2009 (APC = 4.6%, 95% CI 3.4%, 5.9%) and in females from 94 in 1994 to 
141 in 2002 (APC = 4.4%, 95% CI 3.0%, 5.9%). 
Colorectal cancer age-standardised mortality rates (ASR) decreased by -1.8% (95% 
CI -2.2%, -1.4%) annually during 1994-2009. Colon cancer ASRs fell in both sexes 
(males: APC = -3.7%, 95% CI 4.4%, -3.0%; females: APC = -4.2%, 95% CI -5.1%, 
-3.2%), but rectal cancer ASR (mortality) rose (males: APC = 2.4%, 95% CI 1.1%, 
3.6%; females: APC = 2.8%, 95% CI 1.2%, 4.4%; Figure 2.6). 
2.5 Discussion 
Over the past 20 years the number cases of colorectal cancer has increased 
significantly in Ireland; however once adjusted for changes in the age distribution of 
the population over time the rate has remained stable. Internationally colorectal 
cancer rates have stabilised in economically developed countries and Ireland is no 
exception in this regard (18). In comparison to other European countries, in 2008 
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Ireland had a higher incidence rate than the EU average and 23% higher than the rate 
in the United Kingdom (19). In the European region incidence has increased in 
males at a greater rate than female incidence during the period 1988 to 2008 (20). 
Survival was just below the EU average but similar to the United Kingdom (21). The 
improvements in survival reported in this paper were also seen in other European 
countries during the 1990s and early 2000s (21). European 5 year survival of colon 
cancer increased from 54.2% in the period 1999-2001 to 58.1% in 2005-2007, and 
from 52.1% to 57.6% for rectal cancer over the same period (22). Although Irish 
survival improved, it is still lower than the European average (22). Our data 
indicates that survival continued to improve for cases diagnosed during 2005-2009. 
While we did not have detailed information on the dose and intensity of 
chemotherapy and radiotherapy regimens, better uptake in and application of 
treatment options during 1995-2009 correlate with the improvement in survival. 
Stage 
One of the striking findings of this study was that almost half of cases had relatively 
late stage at diagnosis (stage III/IV) and, over the period under investigation, the 
proportion with stage III/IV disease increased from 42% to 50%. The increase in 
stage III/IV cancers is likely to be as a result of more comprehensive investigation in 
the peri-operative period, with improvements in imaging and diagnostic methods, 
resulting in a significant shift in stage allocation from stage I/II to stage III/IV over 
the years 1995-2009. Another possibility is that the number of nodes taken at 
resection increased over the period 1995-2009, thereby leading to a situation where 
the probability of finding a positive node(s) increased commensurately, which would 
have tipped the balance in favour of stage III/IV over stage I/II according to UICC-
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TNM, 5th edition. However, we do not have details on node count to support this 
hypothesis. This question will be addressed in a more comprehensive study of stage 
migration in colorectal cancer at this registry. 
If effective, screening has the potential to change the stage distribution of colorectal 
cancer in the population. As regards FIT-based screening, which is being 
implemented in Ireland, Cole et al reported that colorectal cancers were detected at 
significantly earlier stages in those invited to participate in a screening programme 
using FIT (23). In a health technology assessment for Ireland, it was estimated that, 
by year 10 of a programme, the percentage of cases diagnosed at stages I/II would 
increase from 46% to 53% and stages III/IV decrease from 54% to 47% (10). These 
estimates were based on screening targeted at those aged 55-74 with a best case 
scenario uptake of 53% (based on the UK experience of FOBT screening) (24). 
Similar uptake has been achieved in pilot FIT screening in Ireland (25). The 
BowelScreen programme, which has recently commenced, is initially inviting 
individuals aged 60-69. While the stated intention is to eventually include 55-74 
year olds, this is likely to take a number of years due to the development of 
colonoscopy capacity. Therefore the estimates of potential reductions in late stage 
disease are very unlikely to be achieved by year 10 of the programme. 
Mortality 
In 2008 Ireland ranked midway of 30 European countries in relation to mortality, 
similar to the EU average but marginally higher than the United Kingdom (19). 
Annual decreases in age standardised mortality rates for colorectal cancer in males 
and females were observed in this study. However this concealed significant 
increases in the mortality rate for rectal cancers of 2.4% in males and 2.8% in 
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females. Scrutiny of European data reveals that most countries have experienced 
static mortality rates over the past 15-20 years. However a few, in addition to 
Ireland, have described increases. These include Spain, with an APC of 3.5% during 
1994-2005, Malta with an APC of 5.2% during 1994-2008 and among selected 
registries in Germany with an APC of 17.1% during 1998-2007 (26). In terms of 
potential explanations for these trends, the first that must be considered is whether it 
might be an artefact of coding of rectal cancer deaths. We have shown that there was 
a significant decline in the annual death rate for pooled colorectal sites. Yet, there 
was a steeper decline in the rate of colon deaths, with a compensatory increase in the 
rate for ‘rectum’ deaths. This suggests that there may have been a subtle shift in 
death certificate coding allocation from ‘colon’ to ‘rectum’ over the period we have 
examined. It has long been recognised that physicians tend to report non-specific 
cancer sites on death certificates; thus, if physicians change how they record cause 
of death on the death certificate over time, this may induce an apparent change in 
mortality rates (27). In 1981, Percy et al reported that misclassification led to over 
reporting of colon cancer deaths and underreporting of rectal cancer deaths (27). 
More recently, in the US, Yin et al reported inaccurate coding of underlying cause of 
death, with the vast majority of misclassifications being colon cancers incorrectly 
classified as rectal cancers (28). Further investigation is warranted to explore the 
extent and nature of misclassification on death certificates in European countries in 
recent years, perhaps comparing countries with rising and static rectal cancer 
mortality rates. 
Another possible explanation of the observed increase in rectal cancer mortality is 
patterns in treatment utilisation. Pre-operative radiotherapy has been recommended 
for resectable rectal cancer in recent years (29,30) and in line with this the 
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proportion who received pre-operative radiotherapy has increased markedly since 
2000, in Ireland and in other countries (31). However Carsin et al have reported low 
use of radiotherapy in Ireland (27%) (31) compared to US and EU populations 
(46%-62%) (32–34). Moreover, although data from trials suggests that pre-operative 
use is more effective, a significant proportion treated with radiotherapy in Ireland 
receive it post-operatively rather than pre-operatively (31). These observations raise 
the possibility that underuse of radiotherapy, particularly preoperative radiotherapy, 
may be a contributor to rectal cancer mortality trends. Moreover, while the current 
study found that radiotherapy use was continuing to rise, any impact of this on 
mortality rates will not be seen for several years. 
In terms of surgery, evidence-based guidelines have been published in Ireland aimed 
at standardising surgical management of rectal cancer (30). An audit of all rectal 
cancers diagnosed in 2007 found that, while guidelines were in place, best practice 
was frequently not adhered to (35). Surgery for rectal cancer can result in significant 
morbidity if undertaken without appropriate and accurate pre-operative staging. 
Accurate localisation of the tumour (36–38), use of MRI (magnetic resonance 
imaging) (39) and ERUS (Endo-rectal ultrasound) (40–42) as diagnostic tools, and 
recording of accurate pre-operative histological data (43,44), are all essential for 
successful treatment. However the national audit revealed that there were often 
inadequate investigations and/or recording of such data (35). In addition while multi-
disciplinary meetings (MDM) have been shown to improve outcomes for rectal 
cancer (45,46), treatment options were only discussed at MDMs for around half of 
patients. Moreover patients treated at low volume centres were less likely to be 
discussed at MDMs and to have neo-adjuvant therapy (35). Further evidence 
suggests that comorbidity, rather than age, in elderly rectal cancer patients increases 
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risk of death after surgery (47). Therefore age alone should not dictate the use of 
restorative rectal resection (47). However, our analyses indicate lower use of surgery 
in elderly than younger patients (≥75; 81%; <75: 92-99%) as well as larger increases 
in age standardised mortality in those aged 70 and older (13). These observations, 
combined with likely under use of best practice, may provide a possible explanation 
for the observed trends in mortality. 
Biennial FIT-based screening in the 55-74 age group in Ireland could reduce 
colorectal cancers deaths in the population from as early as the second year of the 
programme (10). However, as noted earlier, screening is being introduced in those 
aged 60-69, suggesting that it is likely to take some considerable time to have any 
impact on the trends in rectal cancer mortality reported here. 
2.6 Conclusion 
Age standardised incidence has remained static in Ireland over the period 1994-
2010, although male incidence rates are significantly higher than female rates. 1-
year and 5-year survival continues to increase in both sexes and is reflected in 
decreasing overall colorectal cancer mortality. The proportion of cases with late 
stage disease has increased over time, as have mortality rates for rectal cancer. In 
order to reduce the incidence and mortality of colorectal cancer, particularly in 
males, there is an urgent need for the efficient and timely roll-out of BowelScreen. 
Reducing incidence and mortality through screening will likely have a beneficial 
effect on survival, by way of earlier detection and therefore more efficacious 
treatment. However the narrow age-range at which BowelScreen will operate in the 
first instance means that the potential benefits of screening, in terms of more 
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advantageous stage distribution and reductions in colorectal cancer incidence and 
mortality in the population, are unlikely to be achieved in the short-term. 
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Figure 2.1: Age standardised incidence rate and incident cases of colorectal cancer by site of 
primary tumour and sex, 1994-2010 
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 (A) COLON- FEMALES (B) COLON MALES 
 
  
Stage of disease From to APC 95%CI Trenda 
Stage I & II 1995 2009 -0.7% [-1.4, 0.10%] p=0.07↔ 
Stage III & IV 1995 2009 1.6% [0.9,  2.3%] p<0.05↑ 
 
Stage of disease From to APC 95%CI Trenda 
Stage I & II 1995 2009 -1.0% [-1.8, -0.1%] p<0.05↓ 
Stage III & IV 1995 2009 1.3% [0.6,  2.1%] p<0.05↑ 
 
 (C) RECTUM- FEMALES (D) RECTUM - MALES 
 
  
Stage of disease From to APC 95%CI Trenda 
Stage I & II 1995 2009 -1.8% [-2.9, -0.7%] p<.05↓ 
Stage III & IV 1995 2009 1.8% [0.7,  2.8%] p<.05↑ 
 
Stage of disease From to APC 95%CI Trenda 
Stage I & II 1995 2009 -2.1% [-2.8, -1.4%] p=0.0001↓ 
Stage III &IV 1995 2009 2.0% [1.2,  2.7%] p=0.0001↑ 
      
 
a
 The p-value results are derived from a test of trend. The null hypothesis is that the APC=0%: Alternative 
hypothesis is APC≠0%. The APC is the slope of a log-linear regression curve from 1994-2009.  
Figure 2.2: Case fraction for stage of disease at presentation, by gender and site of tumour for 
diagnostic period 1994-2009. (A) COLON- FEMALES; (B) COLON MALES; (C) RECTUM- FEMALES; (D) 
RECTUM - MALES. 
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Key: APC=annual percentage change 
Trends calculated with Joinpoint 
from to APC 95%CI p-value 
1995 2002 11.1 [8.7,13.5] <0.001 
2007 2009 1.2 [-0.9,3.4] 0.23 
 
 
Figure 2.3: Percentage of patients treated with various modalities, 1995-2009 
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Figure 2.4: One and five year relative survival for colon cancer for diagnostic periods by sex 
with 95% confidence intervals 
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Figure 2.5: One and five year relative survival for rectal cancer by diagnostic period by sex, 
with 95% confidence intervals 
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Figure 2.6: Age standardised mortality rate and number of deaths for colorectal cancer by site of primary tumour and sex, 1994-2009
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3.1 Abstract  
Background: Colorectal cancer is the third most common cancer in males and the 
second in females worldwide. Incidence and mortality are higher in men than 
women. CRC screening is effective in reducing mortality. Internationally, FIT is 
increasingly being recommended as the primary screening test. This systematic 
review and meta-analysis aimed to determine if uptake of FIT screening differs 
between men than women. 
Methods: We searched PubMed and Embase for peer-reviewed papers published 
in English during 2000-2013 for randomised controlled trials (RCTs) or 
observational studies of screening using FIT which quantified numbers invited 
and participating by gender. Meta-analysis was performed using a random effects 
model. 
Results: 685 citations were identified, 19 meeting the inclusion criteria. Random 
effects meta-analysis found male uptake was significantly lower than female 
uptake (odds ratio=0.84; 95% CI: 0.75-0.95; P <0.01). This generally persisted 
throughout subgroup analysis of study design (RCTs vs. observational studies and 
study quality), screening organisation (methods of invitation, number of samples, 
age-range of screening, recommendations and reminders) and setting. 
Conclusions: Meta-analysis of FIT screening studies indicates significantly lower 
uptake among men. 
Impact: Further investigation is required into factors influencing acceptability and 
participation of FIT screening in both sexes. 
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3.2 Introduction 
Colorectal cancer is the third most common cancer diagnosed in males and the 
second most common in females(1).Worldwide more cases and deaths occur in 
males than females; with the age standardised incidence rate 44% higher (20.6 vs. 
14.3 per 100,000) and age-standardised mortality 45% higher in males (10.0 vs. 
6.9 per 100,000) (1). Most colorectal cancers are considered to arise from 
precancerous polyps; if left in situ polyps can progress to cancer over a 10-15 year 
period (2). However colorectal cancer can be prevented, or treated effectively if 
detected early, through screening (3). Evidence indicates efficacy of screening in 
reducing cancer mortality and, in some instances, incidence (4–8). 
 
A number of countries have implemented population-based colorectal cancer 
screening programmes (9–11). Screening can be delivered through procedures 
conducted in a clinic or doctor’s office, such as colonoscopy or flexible 
sigmoidoscopy (FS), or through non-invasive methods which are suitable to be 
undertaken in an individual’s home, such as FOBT or FIT. Currently most 
programmes which use faecal-based tests employ FOBT (11,12). However, FIT is 
a more specific and sensitive test (8) and recent guidelines recommend it as the 
initial screening modality (3,13). In order for a screening programme to be 
effective in reducing mortality it needs to be well organised and requires high 
uptake (3). It is well established that uptake is higher for non-invasive, than more 
invasive, colorectal cancer screening tests(14). In addition, recent evidence 
suggests uptake is higher with FITs than FOBTs (15). Furthermore, some studies 
suggest gender differentials in uptake; uptake has been found to reverse by test 
modality and is higher among men for more invasive endoscopic based 
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procedures for both opportunistic and organised screening programmes and higher 
among women for non-invasive tests such as FOBTs (16–18). What remains to be 
established is whether there is gender difference in uptake of screening based on 
FIT. 
The aim of this study was to conduct a systematic review and meta-analysis to 
determine if uptake of FIT-based screening differs by gender. A secondary aim of 
the study was to assess factors which may influence any gender-based differences. 
 
3.3 Materials and Methods 
Search strategy and selection criteria 
Citations published in peer-reviewed English journals during January 2000 - 
December 2013 which reported uptake of FIT-based screening in males and 
females, were identified from Pubmed and Embase using a structured search 
strategy. MeSH terms included “neoplasms”, “malignancy”, “early detection of 
cancer”, “compliance”, “adherence”, “colon and “rectum”. Text word search 
terms included variations of ‘colorectal’, ‘bowel’, ‘colon’, ‘rectal’, ‘gastric’, 
‘cancer’, ‘neoplasm’, ‘malignant’, ‘participation’, ‘compliance’, ‘uptake’, 
‘attendance’, ‘FIT’, ‘faecal’, ‘fecal’, ‘immunochemical’, ‘test’, ‘kits’, ‘FOBT’, 
‘iFOBT’, ‘occult’, ‘blood’ and ‘test’. One author (NC) carried out the initial 
screening from the search strategy to remove ineligible citations such as 
duplicates, conference proceedings, letters, commentary and editorials. Two 
authors (NC & AO) then independently determined eligibility based on the 
inclusion and exclusion criteria by reading the full text of the remaining papers. In 
order to be included in the review FIT was required to be used as a primary 
screening (i.e. initial) test; studies in which FIT was used for triage of people with 
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a positive primary screening test (e.g. FIT following gFOBT) were excluded. 
Studies which offered individual participants a choice of different screening tests, 
such as FIT or colonoscopy (i.e. in which the participant decided which test to 
undergo) were excluded. Studies or trials with a single group/test or multiple 
arms/tests and in which the screening test was assigned by the investigator were 
eligible for inclusion. In those with multiple arms, FIT had to be the primary test 
in at least one arm and only the arm(s) using FIT were included in the analysis. 
Studies were included if they reported: randomised controlled trials (RCTs – 
experimental studies in which individuals are randomly allocated to receive or not 
receive an intervention and then followed to determine the effect of the 
intervention) in which one arm involved screening by FIT; observational studies 
(study designs that are not randomised control trials) in which FIT was the 
primary screening test; or screening programmes in which FIT was the primary 
screening test. Studies were included if they reported numbers of people invited 
and screened by FIT by gender. Differences of opinion on study eligibility were 
resolved through discussion among the authors. A standardised form was 
developed to abstract data from eligible studies, including invitation and uptake 
figures by gender, study design, screening age range, invitation and recruitment 
methods, use of recommendations and reminders and number of samples required. 
 
Quality assessment 
Eligible studies were assessed for methodological quality using two instruments: 
the Cochrane risk of bias tool (19) for RCTs and the Newcastle-Ottawa Scale for 
observational studies (20). The Cochrane risk of bias tool assesses bias on six 
domains covering selection, performance, detection, attrition, reporting and any 
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other bias. For our review we assessed only selection bias (random sequence 
generation), reporting and other bias (comparability of confounding factors and 
appropriate use of statistical tests). Assessments of performance and detection bias 
were not carried out as many screening trials are unblinded; it is therefore likely 
that participants are aware of the arm to which they are assigned (21). Attrition 
bias or incomplete outcome data (including non-response, non-compliance or 
withdrawal) was not assessed because non-compliance was the outcome of 
interest. Cohort (study of groups of individuals, some of whom are exposed to an 
intervention and followed over time to determine the effect of the intervention on 
the outcome of interest) and cross-sectional studies (observation of a defined 
population at a single point in time or during a specific time interval where 
outcome and exposure are determined simultaneously) were assessed using the 
Newcastle-Ottawa Scale by awarding stars as an overall rating of three 
methodological factors: selection (sample representativeness (1 star) and sample 
size (1 star)), comparability (authors controlled for or reported confounding 
factors for uptake by sex and age (1 star), and for other factors such as education, 
marital, income or employment status (1 star)) and outcome (clear description of 
statistical analysis (1 star) and measurement of association or difference with 
confidence intervals and p values and use of appropriate statistical test (1 star)). 
After risk of bias assessment RCTs were also assessed for quality using the same 
criteria as observational studies. Studies were assessed overall based on the 
number of stars they had been awarded of a possible six, with 5-6 stars being 
considered high quality, 3-4 stars moderate quality and 2 or less stars low quality. 
 
Statistical methods 
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Within each study participants were invited to complete one test. Studies which 
compared screening tests (multiple arms in RCTs) did not offer more than one 
choice of screening to each participant. Uptake was defined as the number of 
persons targeted (i.e. persons invited to participate in screening) who returned a 
completed FIT kit. 
 
Studies were combined in a meta-analysis, conducted in Review Manager 5 (The 
Cochrane Collaboration, Oxford). Due to the high level of heterogeneity a random 
effects model was used. Subgroup analysis was also carried out to determine if the 
effect estimates varied by study characteristics. Subgroups were defined based on: 
study quality (high, moderate or low), study design (RCT or observational), age 
range of those invited to screening (40-75, 50 or older with no upper age limit), 
number of FIT samples required for test completion (1 or 2 or more samples), 
letter of invitation (with advance notification or without advance notification), test 
delivery method (test mailed to recipient or test collected by recipient) use of 
recommendations or endorsement of test (yes or no) and use of reminders 
(reminder provided or no reminder provided). Studies which did not report on 
these methods or which used different methods were excluded from relevant 
analysis. Only one study reported multiple screening rounds. This study (22) was 
very large (comprising 92% of the invited population and 87% of the screened 
population when all studies were combined) and reported six screening rounds 
(22). In the primary analysis this study was included with data from 2004 (round 
1). Six sensitivity analyses were conducted in order to determine their impact on 
the effect estimate: (i) excluding this study entirely; (ii) using round 2 data (2005), 
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(iii) using round 3 data (2006), (iv) using round 4 data (2007), (v) using round 5 
data (2008) and (vi) using round 6 data (2009). 
 
3.4 Results 
Study selection and characteristics 
In total 685 potentially eligible citations were identified. Following review 19 
studies were eligible for inclusion in the review and meta-analysis (22–40). A 
flow chart of the search strategy results is provided in Figure 3.1. Study 
characteristics are summarized in Table 1.1. Six were RCTs, 12 were cross 
sectional studies and one was a cohort study. Nine studies originated from Europe, 
3 from Asia, 3 from North America, 3 from Australia and 1 from South America. 
Fifteen studies were population-based (i.e. studies in which screening is 
systematically offered by invitation to a defined population). 
 
Across the 19 studies, a total of 2,650,358 (round 1 Park and colleagues(22)) 
individuals were invited to participate in FIT screening and 407451 were screened 
(uptake=15.4%). Excluding the largest study(22), 384,979 were invited and 
169,586 screened (uptake=44.1%). 
 
Meta-analysis 
Uptake in males and females combined ranged from 11% (round 1 (22)) to 90% 
(26; Table 2). Meta-analysis of all included studies indicate significantly lower 
male uptake (Odd ratio (OR) =0.84; 95% CI: 0.75-0.95; P<0.01) (Figure 3.2). Of 
the 19 studies only 3 reported lower female uptake, while the remaining studies 
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reported lower male uptake ranging from 60% (Klushman et al: OR 0.40: 95% CI 
0.21-0.80; P<0.05) to 1% (Quintero et al: OR 0.99: 95% CI 0.94-1.05; P=0.82). 
 
Park and colleagues (22) account for 85% (round 1; round 2: 92%) of the entire 
screening population in the meta-analysis. In round 1 of this study, uptake was 
significantly higher in males than females (Odds ratio (OR) =1.16; 95% CI: 1.15-
1.17; P<0.01) (Table 1.2), while in the subsequent five rounds uptake was 
significantly lower in males than females (Table 1.2). 
 
When the meta-analysis was repeated replacing the round 1 results of Park and 
colleagues (22) with those from each of the subsequent five rounds, this had little 
impact on the overall risk estimate which ranged between 0.83 and 0.84 (Round 2: 
overall meta-analysis OR=0.84; 95% CI: 0.77-0.90; P<0.01; round 3: overall 
meta-analysis OR=0.83; 95% CI: 0.77-0.90; P<0.01; round 5: overall meta-
analysis OR=0.83; 95% CI: 0.77-0.90; P<0.01 and round 6: overall meta-analysis 
OR=0.83; 95% CI: 0.77- 0.90; P <0.01). When Park and colleagues (22) was 
excluded entirely from the meta-analysis male uptake remained significantly 
lower (OR=0.83: 95% CI: 0.74-0.92; P<0.01). 
 
Quality assessment 
Of the 19 studies, 7 were deemed to be of low-quality, and 12 were considered 
moderate quality, while none were deemed to be of high quality. Results are 
summarised in Table 1.3. Moderate quality studies had significantly lower uptake 
in males (OR=0.81; 95% CI: 0.76-0.85; P <0.01) while low quality studies had 
non-significantly lower uptake in males (OR=0.89; 95% CI: 0.63-1.26; P=0.51) 
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however there was no significant difference in these subgroups (P=0.58) (Table 
1.4). In addition we repeated the meta-analysis restricted to moderate quality 
studies only; the lower uptake in males persisted and the effect size was very 
similar to that seen when all studies were included (moderate quality studies only: 
OR= 0.83; 95% CI: 0.71-0.96; P=0.01). 
 
Study design 
Uptake was significantly lower in males than females in both RCTs (OR=0.83; 
95% CI: 0.71-0.97; P=0.02) and observational studies (OR=0.83; 95% CI: 0.76-
0.91; P <0.01) (Table 1.4). There was non-significantly lower male uptake in 
studies which were not part of an organised screening programme (OR=0.74; 95% 
CI: 0.51-1.07; P=0.11) as was the case for studies which were not population-
based (OR=0.88; 95% CI: 0.73-1.07; P=0.20). 
 
Setting 
Uptake was significantly lower among males in studies based in Europe and 
Australia, non-significantly lower in studies based on North America and South 
America, and not different in studies based in Asia (Table 1.4) but, overall, 
subgroup differences for setting were non-significant (P=0.16). 
 
Letter of invitation 
The recruitment methods used in the 16 studies which described this were 
heterogeneous. Invitations were made from a central screening location (n=10), 
GP clinics (n=4), or through an index subject invited for cervical cancer screening 
(n=1; Table 1.1). Nine studies used a letter of invitation mailed to subjects while 
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three studies used an advance notification letter of invitation, mailing letters to 
inform subjects they would be invited and subsequently mailing a letter of 
invitation to participate. One study used an advanced notification letter inviting 
subjects to complete a bowel cancer survey, subsequently mailing a test to 
responders. Subgroup differences for invitation methods were non-significant 
(P=0.41). Male uptake was significantly lower in studies which did not use an 
advance notification letter of invitation (OR=0.77; 95% CI: 0.73-0.82; P <0.01) 
while there was non-significantly lower male uptake in studies using a letter with 
advance notification (OR=0.89; 95% CI: 0.64-1.23; P=0.47) (Table 1.4). 
 
Test delivery method 
Several studies (n=7) required the participant to collect the test from a GP, nurse 
or pharmacist, while 9 studies mailed the test. Subgroup differences for test 
delivery methods were non-significant (P=0.65). Male uptake was significantly 
lower in studies which mailed the test to participants’ homes (OR=0.79; 95% CI: 
0.75-0.83; P <0.01) and non-significantly lower in studies which required 
participants to collect the test (OR=0.83; 95% CI: 0.66-1.05; P=0.13) (Table 4). 
 
Screening recommendations 
Eight studies used recommendations or endorsement of screening, either by a GP, 
nurse or local Mayor. Subgroup differences were non-significant for use or non-
use of recommendations (P=0.54). Those studies that provided a screening 
recommendation had non-significantly lower uptake in males (OR=0.85; 95% CI: 
0.68-1.05; P=0.13) while there was significantly lower male uptake in studies that 
did not use recommendations (OR=0.79; 95% CI: 0.76-0.82; P <0.01) (Table 1.4). 
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Screening age range 
Subgroup differences were non-significant for screening studies targeting different 
age ranges (P=0.28). Uptake was significantly lower in males when screening was 
targeted at those aged 40-75 (OR=0.79; 95% CI: 0.74-0.84; P <0.01) while uptake 
targeted at those aged 50 and over with no upper age limit was similar in males 
and females (OR=0.92; 95% CI: 0.70-1.19; P=0.51) (Table 1.4). 
 
Fenocchi and colleagues (26) and Ferrari and colleagues (36) reported uptake by 
age and gender. In the former, uptake was non-significantly lower in males in 
people aged 50-69 (OR=0.93; 95% CI: 0.81-1.07; P=0.32) and those aged 70 or 
older (OR=0.71; 95% CI: 0.41-1.29; P=0.22). In the latter, uptake in males was 
significantly lower in those aged 50-59 (OR=0.76; 95% CI: 0.72-0.81; P <0.01) 
and in those aged 60-69 (OR=0.94; 95% CI: 0.88-0.99; P=0.02), but did not differ 
in those aged 70-71 (OR=1.05; 95% CI: 0.87-1.27; P=0.56). 
 
Number of FIT samples required 
Fourteen studies reported the number of samples requested; 10 studies requested 
one sample and four requested two or three samples over varying time intervals. 
The subgroup differences for the number of samples required were non-significant 
(P=0.42). The odds ratio for male uptake was significantly lower in both 
subgroups (One sample: OR=0.84; 95% CI: 0.71-0.98: P=0.03; two/ three 
samples: OR=0.78; 95% CI: 0.74-0.82; P <0.01) (Table 1.4). 
 
Screening reminders 
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Ten studies reported the use of reminders (varying from 2 weeks to 6 months; 
Table 1.1) and two studies reported using no reminders. Male uptake was 
significantly lower in both subgroups (Table 1.4) with no difference in these 
subgroups (P=0.51). 
 
3.5 Discussion 
This systematic review and meta-analysis is the first to examine whether there are 
gender differences in uptake of FIT-based colorectal cancer screening. It provides 
valuable information for screening agencies relating to the implementation and 
delivery of programmes. Overall, uptake in males was 16% (OR 0.84 or a relative 
risk of 0.95: 95% CI 0.94-0.95; P<0.001) lower than in females, and this was 
statistically significant. While there was notable heterogeneity between studies in 
terms of design and screening organisation, as well as overall uptake, lower 
uptake in males persisted across subgroups by study design, setting, methods of 
invitation and delivery, use of recommendations, screening age range, number of 
samples and use of reminders. 
 
Of note was the similar uptake in males and females in studies based in Asia, 
which contrasted with studies from other settings. Studies from Asia had similar 
uptake in males and females whereas studies from Europe reported lower uptake 
among men. While subgroup differences were nonsignificant across countries, 
much of the data required for inclusion in subgroup analysis was not reported in 
the studies from Asia. Therefore the possibility that cultural or social factors may 
be responsible for differential uptake in males and females cannot be entirely 
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discounted. It will be interesting to observe uptake of FIT-based screening in 
future studies within countries in Asia in comparison to Europe and Australia. 
 
There was also no significant difference in male and female uptake in studies of 
low quality. Most of these required the participant to collect the test, so the effect 
estimate may reflect this. Test collection from a GP clinic, pharmacist or 
distribution centre (nurse) requires the participant to make face-to-face contact 
with a health professional and may act as an encouragement or endorsement of the 
test in addition to providing access to information about the test and how to carry 
it out. Studies of low quality also had quite high overall uptake, and the effect 
estimate may reflect this rather than the low quality per se. 
 
Although there was no formal difference in subgroups defined by whether or not 
there was a recommendation or endorsement of the test, it was noteworthy that 
uptake was only significantly lower in males than females in studies where no 
recommendation was used. Other evidence suggests that lack of a doctor 
recommendation is an important barrier to colorectal cancer screening (41). Our 
findings suggest that contact with, or endorsement of the test through a health 
professional (GP, nurse, pharmacist) may serve to encourage men to complete the 
screening test. This has been noted elsewhere, where male compliance with 
medical procedures is increased when encouraged by a medical professional (42). 
 
While subgroup differences were (once again) non-significant, studies which were 
not population-based did not have significantly lower uptake in males. Although 
the studies which were not population-based differed in many ways, in three of 
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four the screening invitation was endorsed through a GP or GP practice while two 
required the participant to collect the test. Therefore it cannot be ruled out that the 
non-significantly lower uptake in males may be a result of test collection and GP 
recommendation. 
 
Age is an important predictor of colorectal cancer risk. Here male uptake was not 
significantly different from female uptake in studies targeting those aged 50 and 
over with no upper age limit. However this may be a result of the fact that some 
studies involved test collection (3 of the 5 studies) and/or recommendations to 
complete the test by a GP (4 of the 5 studies), as opposed to older men being more 
likely to participate in screening. Further investigation is required to assess if there 
is differential uptake between younger and older males in FIT-based screening 
and, if so, what may be driving such differences. 
 
Cole and colleagues (24) have reported that participation in their study was 
significantly improved (increase in relative risk of participation of 30%) through 
simplification of the sampling method (using two rather than three samples); this 
did not differ by gender, age or socioeconomic status. In this meta-analysis, there 
were no subgroup differences in effect estimates according to whether studies 
required a single, or more, samples. Further investigation is required to assess if 
there is differential uptake in males and females when different FIT sampling 
strategies are used. 
 
While there is tentative evidence from this review that requiring participants to 
collect the test, using a GP recommendation and using an advance notification 
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results in similar uptake in males and females, the general lack of significant 
subgroup differences suggest that study design or screening organisation may not 
be the important drivers of poorer male uptake. However results of the sub-group 
analysis are not necessarily definitive and reflect findings in terms of the 
availability of data within the included studies. There are small numbers of studies 
in particular sub-groups (such as advance notification). Caution is therefore 
warranted in the interpretation that such interventions may reduce gender based 
disparities. In addition not all studies reported multivariable analysis and therefore 
cannot definitively report that gender is independently associated with uptake. 
Despite this, these elements may help inform development of a taxonomy of 
compliance in particular groups, such as those based on sex or other background 
characteristics. Further research in identifying and expanding on such taxonomy is 
warranted. Given the dearth of evidence regarding reasons for non-participation in 
FIT screening in males and females, and the fact that FOBT and FIT may be 
considered somewhat similar from the point of view of screening invitees, it is 
worth considering what is known about drivers of home-based FOBT screening 
(non)participation. An early review of colorectal cancer screening uptake using 
FOBT reported that the main factors for non-compliance with screening were: 
conflicts with work or family, inconvenience, being too busy, or being away, lack 
of interest and costs (43). In addition the same review reported that non-
compliance was associated with having no current health problems, being too 
embarrassed to complete the test, feeling the test was too unpleasant, being 
anxious and not wanting to know the test results (43). These findings are in line 
with Chapple and colleagues(44) in the UK FOBT screening programme. 
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The evidence base for reasons underlying gender-based differences in colorectal 
cancer screening uptake is very limited, and even less is known about uptake in 
FIT based screening specifically. Recently Ritvo and colleagues (45) suggested 
that males may procrastinate about colorectal cancer screening, but that, 
underlying this, is a deeper fatalism about cancer disease and a disbelief in the 
preventative-protective elements of screening. It has also been reported that males 
use primary care services less frequently than women (46) perhaps making them 
less inclined to be screened when offered the opportunity. In addition White and 
colleagues (46) suggest that, in Europe, the general absence of male targeted 
health care programmes may hinder men’s ability to identify as participants in 
health care. These observations indicate that studies are now required exploring 
cultural norms surrounding, psychological and other barriers to, and facilitators of, 
FIT screening and how these may differ between the sexes. It would be useful to 
explore these barriers and facilitators through theory-based research into gender 
differences in preventive health behaviours. 
 
3.6 Conclusion 
Uptake of FIT-based colorectal cancer screening among males is significantly 
lower than among females. While studies differed in design and screening 
organisation methods, poorer male uptake persisted throughout subgroup analysis. 
Further investigation is required into why men are less likely to attend FIT 
screening and what factors may act as barriers or facilitators to screening uptake 
in men and women. 
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Figure 3.1: Study flow diagram: result of search strategy 
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Table 1.1: Characteristics of the 19 studies on FIT uptake in males and females included in the meta-analysis 
 
Study & Year
Population 
based Age range Letter of invitation
Test delivery 
method Recruitment location
Recommendation/ 
Endorsement Reminder
Number of samples 
and interval Test Country
Cohort studies
Senore and colleagues,      2012 (33) Yes 58 & 60 No advance notification Test collected GP Yes No reminder 1 OC Sensor Italy
Cross-sectional studies
Fenochi and colleagues, 2006 (26) No 50+ Not reported Test collected GP Yes 2 month reminder 1 OC Hemodia Uruguay
Gregory and colleagues, 2011 (32) Yes 50-74 Advance notification letter 
to screening survey
Test mailed Central No 6 week reminder Not reported InSure  Australia
Klushman and colleagues, 2012 (38) No 50+ Face to face recruitment Test collected GP Yes 2 weeks Not reported INSure USA
Crotta and colleagues, 2004 (25) Yes 50-74 No advance notification Test collected Central Yes 2 month reminder 1 OC Sensor, Japan Italy
Chen and colleagues, 2007 (27) Yes 50+ Not reported Test collected  Out-reach Yes Not reported 1 Not reported Taiwan
Parente and colleagues, 2009 (29) Yes 50-69 No advance notification Test collected Central No No reminders 1  HM-Jack Italy
Levy and colleagues, 2010 (30) No 50-64 Advance notification Test mailed Central No Not reported Not reported Clearview ULTRA FOB USA
Park and colleagues, 2011 (22) Yes 50+ Not reported Not reported Not reported Not reported Not reported Not reported Not reported Republic of Korea
Cai and colleagues, 2011 (31) Yes 40-74 Not reported Not reported Not reported Not reported Not reported 2 at interval of 1 week Not reported China
Ferrari and colleagues, 2012 (36) Yes 50-69 Not reported Not reported Not reported Yes Reminder - interval not 
reported
Not reported Test tube Italy
McDonald and colleagues, 2012 (37) Yes 50-74 No advance notification Test mailed Central No Not reported 1 Eiken Scotland
Kelley and colleagues, 2013 (40) Yes 50-75 No advance notification Test mailed Not reported Not reported Not reported 2 at interval of 1 day OC Sensor Ireland
Randomised control trials
Cole and colleagues, 2002 (23) No 50+ No advance notification Test mailed Central & GP No in 1 arm/                       
Yes in 2 arms
6 week reminder 3 interval not reported Flexsure OBT Australia
Cole and colleagues, 2003 (24) Yes 50-69 No advance notification Test mailed Central No 6 week reminder 3 (FlexSure OBT) 
interval not reported           
2 (Insure) Interval not 
reported
FlexSure OBT / InSure Australia
Gupta and colleagues, 2013 (39) Yes 54-64 No advance notification Test mailed Central No  3 week reminder 1 OC-Auto FIT CHEK USA
Hol L and colleagues, 2012 (34) Yes 50-74 Advance notification Test mailed Central No 6 week reminder 1  OC Sensor The Netherlands
Quintero and colleagues, 2012 (35) Yes 50-69 Advance notification Test collected Central Yes 3 and 6 month reminders 1 OC Sensor Spain
van Rossum and colleagues, 2008 (28) Yes 50-75 No advance notification Test mailed Central No 2 week reminder 1 OC Sensor The Netherlands
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Table 1.2: Uptake figures by male and female for the 19 studies in meta-analysis with 
OR’, 95% CI and P value 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author/ Year Invited Invited Invited OR's (95%CI) P  value
n n % n n % n n %
Park et al, 2011 Round 1 (22) 2265379 237865 10.5% 969813 105710 10.9% 1295566 123148 10.2%  1.16 (1.15, 1.17) P <0.05               
Park et al, 2011 Round 2 (22) 3473958 538463 15.5% 1576872 238108 15.1% 1897086 299740 15.8% 0.95 (1.15, 1.17) P <0.05
Park et al, 2011 Round 3 (22) 4406700 691754 15.7% 2062961 307381 14.9% 2343739 384373 16.4% 0.89 (0.89, 0.90) P <0.05
Park et al, 2011 Round 4 (22) 4344708 782047 18.0% 2025745 350454 17.3% 2318963 433646 18.7% 0.91 (0.91, 0.91) P <0.05
Park et al, 2011 Round 5 (22) 4640365 983757 21.2% 2183041 447523 20.5% 2457324 538154 21.9% 0.92 (0.92, 0.92) P <0.05
Park et al, 2011 Round 6 (22) 4625557 1211896 26.2% 2150635 535508 24.9% 2474922 675654 27.3% 0.88 (0.88, 0.89) P <0.05
Cole et al, 2002 (23) 2400 857 35.7% 1094 375 34.2% 1306 482 36.9%  0.89 (0.75, 1.05) P =0.18                                           
Cole et al, 2003 (24) 1212 425 35.1% 592 196 33.1% 620 229 36.9% 0.85 (0.67, 1.07) P =0.33
Crotta et al, 2004 (25) 2961 1631 55.1% 1403 710 50.6% 1558 921 59.1% 0.71 (0.61, 0.82) P <0.05
Fenocchi et al, 2006 (26) 11734 10573 90.1% 3663 3282 89.6% 8071 7291 90.3% 0.92 (0.81, 1.05) P =0.22
Chen et al, 2007 (27) 56968 22672 39.8% 21502 9481 44.1% 35466 13191 37.2% 1.33 (1.29, 1.38) P <0.05
van Rossum et al, 2008  (28) 10322 6157 59.6% 5037 2820 55.9% 5285 3337 63.1% 0.74 (0.69, 0.80) P <0.05
Parente et al, 2009 (29) 78083 38693 49.6% 37838 18314 48.4% 37950 20379 53.7% 0.81 (0.79, 0.83) P <0.05
Levy et al, 2010 (30) 297 235 79.1% 131 106 80.9% 166 129 77.7% 1.22 (0.69, 2.15) P =0.50
Cai et al, 2011 (31) 31963 24409 76.4% 16169 11962 74.0% 15794 12447 79.0% 0.76 (0.73, 0.81) P <0.05
Gregory et al, 2011 (32) 375 192 51.2% 181 86 47.5% 194 106 54.6% 0.75 (0.50, 1.13) P =0.17
Senore et al, 2012 (33) 37691 7281 19.3% 17223 2719 15.8% 20468 4562 22.3%  0.65 (0.62, 0.69) P <0.05
Hol L et al, 2012 (34) 4407 1092 24.8% 2221 472 21.3% 2186 620 28.4% 0.68 (0.59, 0.78) P <0.05
Quintero et al, 2012 (35) 26599 9089 34.2% 12156 4145 34.1% 14443 4944 34.2% 0.99 (0.94, 1.05) P = 0.82
Ferrari et al, 2012 (36) 42245 1744 41.3% 20311 7980 39.3% 21,934 9461 43.0% 0.85 (0.82, 0.89) P <0.05
McDonald et al, 2012 (37) 66225 38720 58.5% 32318 18058 55.8% 33907 20662 60.9% 0.81 (0.79, 0.84) P <0.05
Klushman et al, 2012 (38) 200 145 72.5% 50 29 58.0% 150 116 77.0% 0.40 (0.21, 0.80) P <0.05
Gupta et al, 2013 (39) 1593 648 40.7% 600 232 38.7% 993 416 41.9% 0.87 (0.71, 1.08) P = 0.20
Kelley et al, 2013 (40) 9704 5023 51.8% 4499 2177 48.4% 5205 2846 54.7% 0.78 (0.72, 0.84) P <0.05
Total Males Females
Screened Screened Screened
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Figure 3.2: Forest plot corresponding to the main random effects meta-analysis of 19 estimates quantifying the relationship between 
gender and uptake of FIT-based colorectal cancer screening. 
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Table 1.3: Newcastle-Ottawa Scale of included studies: reviewers judgement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
representativeness 
(Selection)
Sample size 
(Selection)
Counfounding 
controlled 
(comparability)
Statistical tests 
(Outcome)
Total stars and 
quality rating
Park et al, 2011 (22) * * * 3/6 moderate
Cole et al, 2002 (23) * * ** 4/6 moderate
Cole et al, 2003 (24) * * ** 4/6 moderate
Crotta et al, 2004 (25) * * 2/6  low
Fenochi et al, 2006 (26) * 1/6 low
Chen et al, 2007 (27) * 1/6 low
van Rossum et al, 2008 (28) * * ** 4/6 moderate
Parente et al, 2009 (29) * * 2/6 low
Levy et al, 2010 (30) * 1/6 low
Cai et al, 2011 (31) * * ** 4/6 moderate
Gregory et al, 2011 (32) * * 2/6 low
Senore et al, 2012 (33) * * * 3/6 moderate
Hol L et al, 2012 (34) * * ** 4/6 moderate
Quintero et al, 2012 (35) * * ** 4/6 moderate
Ferrari et al, 2012 (36) * * ** 4/6 moderate
McDonald et al,  2012 (37) * * * 3/6 moderate
Klushman et al, 2012 (38) * 1/6 low
Gupta et al, 2013 (39) * ** 3/6 moderate
Kelley et al, 2013 (40) * * ** 4/6 moderate
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Table 1.4: Summary of primary and subgroup random effects meta-analysis 
 
 
 
 
Sub group Number of studies OR 95% CI I
2
P value
Primary meta analysis 19 0.84 0.75, 0.95 99% <0.01
Study quality
Moderate 14 0.81 0.76, 0.85 95% <0.01
Low 5 0.89 0.63, 1.26 96% 0.51
Sub group differences - - 0% 0.58
Study design
RCTs 6 0.83 0.71, 0.97 91% 0.02
Observational 13 0.83 0.76, 0.91 98% <0.01
Sub group differences 0% 0.99
Study setting
Europe 9 0.78 0.73, 0.84 95% <0.05
North America 3 0.79 0.49, 1.28 68% 0.35
Asia 3 0.97 0.73, 1.28 100% 0.81
South America 1 0.92 0.81, 1.05 - -
Australia 3 0.86 0.76, 0.98 0% 0.03
Sub group differences - - 38% 0.16
Letter of invitation
Letter without advance notification 9 0.77 0.73, 0.82 87% <0.01
Letter with advance notification
a
3 0.89 0.64, 1.23 92% 0.47
Sub group differences - - 0% 0.41
Test delivery
Test mailed 9 0.79 0.75, 0.83 45% <0.01
Test collected 7 0.83 0.66, 1.05 99% 0.13
Sub group differences - - 0% 0.64
Recommendation
Recommendation provided 8 0.85 0.68, 1.05 99% 0.13
No recommendation provided 7 0.79 0.76, 0.82 45% <0.01
Sub group differences - - 0% 0.54
Screening age range
40-75 14 0.79 0.74, 0.84 92% <0.01
50+ (5) 5 0.92 0.70, 1.19 99% 0.51
Sub group differences - - 13% 0.28
Number of samples
1 sample (10) 10 0.84 0.71, 0.98 99% 0.03
2 or more samples (4) 4 0.78 0.74, 0.82 13% <0.01
Sub group differences - - 0% 0.42
Screening reminders
No reminder provided 2 0.85 0.75, 0.96 73% 0.01
Reminder provided 10 0.81 0.73, 0.89 87% <0.01
Sub group differences - - 0% 0.51
Note: Values in bold indicate P<0.05
a
Advance notification indicates pre-invitation letter, followed by invitation letter
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4.1 Abstract 
This study aimed to investigate the effects of sex and deprivation on participation 
in a population-based FIT-based colorectal cancer screening programme. The 
study population included 9785 individuals invited to participate in two rounds of 
a population-based biennial FIT-based screening programme, in a relatively 
deprived area of Dublin, Ireland. Explanatory variables included in the analysis 
were sex, deprivation category of area of residence and age (at end of screening). 
The primary outcome variable modelled was participation status in both rounds 
combined (with “participation” defined as having taken part in either or both 
rounds of screening). Poisson regression with a log link and robust error variance 
was used to estimate relative risks (RR) for participation. As a sensitivity analysis, 
data were stratified by screening round. Over both rounds of screening uptake 
among males was 56% and 62% among females. In both the univariable and 
multivariable models deprivation was strongly associated with participation. 
Increasing affluence was associated with higher participation; participation was 
26% higher in people resident in the most affluent compared to the most deprived 
areas (multivariable RR=1.26: 95% CI 1.21-1.30). Participation was significantly 
lower in males (multivariable RR=0.96: 95%CI 0.95-0.97) and generally 
increased with increasing age (trend per age group, multivariable RR=1.02: 
95%CI, 1.01-1.02). No significant interactions between the explanatory variables 
were found. The effects of deprivation and sex were similar by screening round. 
Deprivation and male gender are independently associated with lower uptake of 
population-based FIT colorectal cancer screening, even in a relatively deprived 
setting. Development of evidence-based interventions to increase uptake in these 
disadvantaged groups is urgently required. 
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4.2 Introduction 
Colorectal cancer is the second most common cancer diagnosed in women and the 
third in men worldwide (1). Worldwide men have higher incidence (world age 
standardised rate (ASR) 20.6 vs. 14.3) and mortality (ASR 10.0 vs. 6.9) from the 
disease  (1). Higher mortality has also been observed among lower socio-
economic groups in the US and Europe (2).   
Screening is efficacious and effective in reducing colorectal cancer incidence and 
mortality in the population (3–8). A range of screening tests are available, which 
detect either pre-malignant adenomatous polyps or colorectal cancers, including 
endoscopic-based procedures (colonoscopy and flexible sigmoidoscopy) and 
faecal-based tests (gFOBT and FIT).  Current guidelines recommend population-
based screening of asymptomatic people aged 50 years and over on an annual or 
biennial basis using non-invasive methods (gFOBT or FIT) or every 5 to 10 years 
using other - invasive - approaches (flexible sigmoidoscopy or colonoscopy) 
(9,10). Screening programmes require high uptake among their target population 
in order to maximise the health benefits, (9,11,12)  and uptake of non-invasive 
methods is generally higher than invasive methods (13). Therefore, many 
population-based screening programmes use gFOBT as the initial screening test. 
However, FIT is increasingly being recommended as it has higher sensitivity and 
specificity, does not require dietary and medicinal restriction (9,10) and has been 
associated with higher uptake than gFOBT-based screening (14,15). Nevertheless, 
in current FIT-based screening programmes uptake remains low overall (16). 
Moreover, uptake is significantly lower among men than women and a recent 
systematic review concluded that screening programme design or organisation 
(i.e. use of letters of invitation, use of screening recommendation, test delivery 
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methods, use and number of reminders, number of samples required and screening 
age range) do not appear to be the important drivers of lower male uptake (16). 
Given the differences observed in uptake in males and females in Europe, 
Australia and Asia (significantly lower male uptake in Europe and Australia but 
similar uptake in males and females in Asia) it is possible that other gender-
specific socio-cultural factors may be important in influencing screening 
acceptability. 
 In the UK socio-economic deprivation has been shown to affect participation in 
gFOBT-based colorectal cancer screening (17). Results from a Scottish study 
showed that use of FIT as the primary screening test improved uptake compared 
to  gFOBT, particularly among the most deprived and men, although many 
participants had been exposed to gFOBT for a number of years prior to the offer 
of FIT (15). As far as we are aware these are the only studies that have examined 
how FIT might reduce disparities over gFOBT screening. In addition relatively 
little is known about whether there are deprivation gradients in uptake of FIT-
based screening and, in particular, whether gender and deprivation might operate 
independently in influencing participation.  
Understanding socio-demographic predictors of screening participation is 
important because unequal access across groups runs the risk of creating or 
widening health inequalities (18).  During 2008-2012 a population-based FIT-
based screening programme ran in Tallaght, a district of Dublin (19). In this 
setting, we investigated the effect of sex and deprivation on FIT-based screening 
uptake.  
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4.3 Methods 
Study setting 
Tallaght is one of the largest towns in the County of Dublin and has a population 
of just under 70,000 people (20). The area is identified as one of the most 
disadvantaged in Dublin (and, therefore, in Ireland).  Ireland has a mixed public-
private healthcare system.  Care within the public system is available to all 
citizens. Unless an individual has a “medical card” (which is available to those on 
reduced means) they must pay to see a general practitioner (GP) and make modest 
co-payments for hospital in-patient and out-patient services. Just under half of the 
population have private health insurance; this generally covers hospital care. The 
screening programme, and any associated follow-up investigations or treatment, 
was provided free of charge to all invitees. 
The Tallaght Hospital/ Trinity College Dublin Colorectal Cancer Screening 
Programme (TTC-CRC-SP) offered two rounds of biennial screening. 9785 
individuals between the ages of 50-74, and resident in Tallaght, were identified 
through seven primary care practices and invited to participate in screening (21).  
Individuals were sent a FIT kit with an initial invitation letter. The invitation pack 
also contained information on colorectal cancer and an Irish Cancer Society help-
line telephone number was also provided. The programme was not promoted 
beyond the invitation letter; therefore all invitees received identical information. 
Participation in the programme was free to all participants, as was treatment if 
cancer was detected. Reminders were sent to non-responders. The first screening 
round was completed during 2008-2010 and the second during 2011-2012. At the 
commencement of round two individuals were excluded if they had left the 
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catchment area after round one, had been diagnosed with colorectal cancer in 
round one or were known to have died. Non-responders to round one invitation 
were included sent an invitation to participate in round two.  
For analysis we included the available explanatory variables which were sex, age 
and deprivation category of the area in which the individual lived (21). The NCRI 
geo-coded the addresses of residence of those invited to participate in the TTC-
CRC-SP, in order to enable individuals to be assigned to an area-level deprivation 
category based on the Pobal Haase Pratschke (HP) Deprivation index (21). This 
index (based on the 2006 and 2011 census waves), which is assigned to small 
areas, is based on the following characteristics of the population resident in the 
area: population density, age dependency ratio, lone parent ratio, primary 
education only, third level education, unemployment rate and proportion living in 
local authority rented housing (21). The index is divided into 8 categories ranging 
from extremely disadvantaged to extremely affluent.  Age (at completion of the 
two screening rounds) was divided into five categories for analysis: (i) <60, (ii) 
60-64, (iii) 65-69, (iv) 70-74 and (v) 75+. As all invitees were included in both 
rounds some invitees were older than the initial screening criteria age range at the 
outset of round 2 (i.e. those who were aged 74 years during round 1 were aged 75 
or over during invitation to round 2). 
The outcome variable was uptake status (participant or non-participant) and the 
primary analysis was based on the two screening rounds combined. In the primary 
analysis, participants were defined as those who took part in either or both 
screening rounds; non-participants took part in neither round. Uptake was 
calculated as the percentage of individuals who completed a screening test out of 
the total number invited to participate. We excluded individuals from the analysis 
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if: they had died prior to screening (n=201); they self-referred to screening 
(n=16); they had completed someone else’s test (n=16) they were medically 
unsuitable for screening (n=94); the recorded address was incorrect (n=245); or a 
deprivation category could not be assigned to their address (n=62) (Figure 4.1). A 
sensitivity analysis was undertaken to investigate uptake separately by screening 
round. 
All analysis was conducted using Stata 11. We compared characteristics of 
participants and non-participants using chi-square tests. As the outcome was 
common (greater than 10%), (22) we did not use logistic regression for estimation, 
rather we modelled participation status using Poisson regression with a log link 
and robust error variance (23) to estimate relative risks (RR) for participation. All 
three explanatory variables were fitted separately, then simultaneously. Variables 
were included in the final multivariable model if the p value from the associated 
Wald test was <0.05. We tested for interactions between the explanatory variables 
by fitting cross-product terms to a model containing all main effects. 
Three sensitivity analyses were conducted. We stratified the data by screening 
round and analysed the following three outcomes separately: uptake in round 1 
(participants in round 1 vs. non-participants in round 1); uptake in round 2 
(participants in round 2 vs. non-participants in round 2); and uptake in both rounds 
(participants who participated in both round 1 and round 2 vs. non-participants in 
either round (those who participated in only one round of screening were excluded 
from this sensitivity analysis)) (Figure 3.1). 
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4.4 Results 
Table 2.1 summarises the characteristics of the 9151 screening invitees included 
in the analysis. Of these, 46% were male.  The mean age at the end of screening 
was 62 years (Inter Quartile Range (IQR): 57-66. Invitees were resident in only 
five of the eight possible deprivation categories (very disadvantaged, 
disadvantaged, marginally below average, marginally above average and affluent). 
None of the study participants were resident in areas classified as extremely 
disadvantaged, very affluent and extremely affluent (21); and almost half (48%) 
were from very disadvantaged or disadvantaged areas.   
Overall, uptake in males was significantly lower than uptake in females 
(p<0.001). This was also seen for round one only (p=0.002). There was no 
difference in uptake in males and females in round two only (p=0.146). Among 
invitees, the distribution of deprivation did not differ by sex (p=0.145; similar to 
the national population (24)) but the distribution of age did (p=0.002); 38% of 
female invitees were aged <60 compared to 35% of males, with a slightly higher 
proportion of males in the 70-74 age group (13% vs 11%).  
 
Uptake in both screening rounds combined was 60%; 41% of invitees took part in 
both rounds, 8% in round 1 only and 10% in round 2 only; 40% did not take part 
in either round. A higher percentage of females participated in screening (both 
rounds combined: females 62% vs. males 56%) (Table 2.1). This translated into a 
significantly lower relative risk of participation in males than females in 
univariable analysis (RR=0.96: 95%CI 0.95-0.98) (Table 2.2). Uptake was 
significantly higher in all age groups compared to those aged less than 60 (Test of 
linear trend across groups: RR=1.02: 95%CI 1.01-1.02; p (trend) <0.001) (Table 
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2). Deprivation was strongly associated with uptake; compared to those in very 
deprived areas the relative risk for those resident in affluent areas was 1.22 (95% 
CI 1.17-1.27; Table 1.2). In a test for trend the relative risk of uptake increased by 
6% for each category of increasing affluence (RR=1.06: 95% CI 1.05-1.06; p 
(trend) <0.001).  
In the multivariable model sex remained a significant predictor of uptake after 
adjusting for deprivation and age; males had a 4% lower relative risk of 
participation than females (RR=0.96: 95% CI 0.95-0.97; Wald test p <0.001)). 
Age was also a significant predictor of uptake (Wald test p <0.001); those in older 
age groups had higher relative risks of participation than those aged less than 60 
(although the effect was not significant in those aged over 75). In a test for trend, 
uptake increased by 2% (RR 1.02: 95% CI 1.01-1.02; p (trend) <0.001) for each 
increasing age category. Deprivation was a strong predictor of uptake (Wald test 
p<0.001) and the relative risk of participation was 26% higher in those resident in 
affluent compared to very disadvantaged areas (RR=1.26: 95% CI 1.21-1.30) 
(Table 2.2). In a test for trend, the relative risk of uptake increased by 6% per unit 
increase in affluence (RR=1.06: 95%CI 1.05-1.07). Therefore the effect of 
deprivation was not attenuated by age or sex. No significant interactions were 
found between the socio-demographic variables (age*sex; p (interaction)=0.35; 
sex*deprivation; p (interaction)=0.16; deprivation *age; p (interaction)=0.17) 
(data not shown). 
In the sensitivity analysis, the effects of deprivation and sex were most 
pronounced in screening round 1. For round 1, relative risk of participation was 
more than three-times higher in those resident in affluent compared to very 
deprived areas (multivariable RR=3.32: 95% CI 2.28-4.83) and males had almost 
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20% lower relative risk of participation than females (multivariable RR=0.81: 
95% CI 0.71-0.92). For round 2, deprivation was a significant predictor of uptake, 
but sex was not. Participation in both rounds was significantly associated with 
affluence (affluent vs. very deprived multivariable RR=2.34: 95% CI 2.04-2.67), 
female sex (males vs. females multivariable RR=0.87: 95% CI 0.83-0.91), and 
older age (over 75 vs. <60): multivariable RR=1.22: 95% CI 1.07-1.39) 
(Supplementary table 1.1).  
4.5 Discussion 
Poor screening uptake and socio-economic status are a largely unmet challenge in 
research and threaten potential increases in inequalities in cancer mortality (18).  
Our study shows - for the first time as far as we are aware - that deprivation is the 
strongest socio-demographic predictor of uptake in population-based FIT-based 
screening. This effect remained after adjustment for gender and age, and persisted 
across screening rounds. Given that our study was based in a predominantly 
deprived area of a large European city it was also notable that there was a 
significant difference in uptake even within the least affluent sectors in our study 
population (i.e. uptake was significantly higher among people resident in 
disadvantaged compared to very disadvantaged areas). While our study primarily 
set out to examine gender based differences in uptake, the stark differences in 
uptake by deprivation warrant particular attention given the much greater effect of 
deprivation on screening uptake. This should also be a focus of future research 
and interventions as an area in which uptake gains can be achieved. A nationwide 
FIT-based screening programme, BowelScreen, began to roll-out in Ireland in late 
2013 (www.bowelscreen.ie). Given our study was conducted in an area which 
does not contain the extremes of the deprivation index (i.e. extremely deprived 
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and extremely affluent) we would speculate that, in BowelScreen, the differences 
in uptake observed may be even larger than those seen in our study.  
Associations between poor uptake of colorectal cancer screening (using a range of 
tests other than FIT) and lower socioeconomic status (measured at both the 
individual and area level) have been reported in the literature (17,25–28). Our 
results are consistent with – and extend - these.  Others have found that, overall, 
FIT-based screening is usually associated with higher uptake than gFOBT-based 
screening (which has traditionally been used in population based screening 
programmes) (14). If we compare uptake rate by area –level deprivation category 
in this study, with those reported in the English gFOBT-based screening 
programme, rates in the current study exceed those in England in every 
deprivation category. While some caution is needed here, as the deprivation 
indices and categorisations differ in the two populations, our findings tentatively 
suggest that use of FIT may result in higher uptake (compared to gFOBT-based 
screening; (17)) even among those resident in more deprived areas. 
Solmi et al found that after controlling for several socio-demographic, economic 
and health variables there was an independent association between limited wealth 
and lower probability of participation in colorectal screening (27).  This study was 
a longitudinal cohort study based on self-reported data of ever taking part in 
screening.  In a decomposition analysis the authors report that health literacy 
contributed to 8% of the inequality in screening uptake; inadequate health literacy 
was associated with lower screening uptake and this was independent of 
individual-level measures of socio-economic status (27). Health literacy is the 
degree to which individuals have the capacity to obtain, process and understand 
basic health information and services in order to make appropriate health 
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decisions (29). Educational attainment and social status are positively associated 
with health literacy (30). While we did not have data on education in our study, 
data is available on the levels of educational attainment for the area in which our 
study was carried out. More than one-third (33% - 39% across sub-areas) of the 
adult population of Tallaght have only primary education, more than twice the 
national average (16%; (21). In the UK having adequate health literacy has been 
associated with higher participation in gFOBT-based colorectal cancer screening 
(OR=1.20: 95% CI 1.00-1.44) (31). Von Wagner et al have suggested that written 
invitations, the route through which individuals are invited to participate in 
colorectal cancer screening in the UK, may be difficult to process and understand 
for adults with limited health literacy (32). In our study individuals were invited to 
participate in writing and the invitation contained a printed leaflet with 
information about the screening test and how to complete it. However the 
possibility does exist that differences in health literacy between those resident in 
deprived and more affluent areas could explain some of our findings. While health 
literacy is correlated with reading ability they are different. Further research on 
uptake, education, reading and health literacy is warranted in exploring the 
potential underlying mechanisms of poorer uptake in males and more deprived 
areas in this screening population.  
Generally uptake reported here (60%) was broadly similar to uptake of population 
based studies reported in the systematic review in chapter 3 where uptake ranged 
from 25% to 60% in studies in the Netherlands, from 19% to 55% in studies from 
Italy and 35% to 51% in studies from Australia (note that many of these studies 
had different methodologies). Our study also shows that male sex is associated 
with lower relative risk of participating in FIT-based screening and that this effect 
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is independent of age and deprivation. The absence of interaction between 
deprivation and gender suggest that lower uptake in males is not moderated by 
deprivation levels. This extends findings from our recent systematic review which 
observed that men had lower FIT uptake in almost every setting, but which was 
unable to determine if this effect was independent of other socio-economic factors 
(16). The systematic review on male uptake reported an odds ratio of lower male 
uptake of 16% (OR 0.84), which when converted to a relative risk (excluding the 
largest study which is unlikely to be compatible with the situation in Ireland or 
indeed Europe), is 0.95 (95% CI 0.94-0.95; P<0.001) which is almost identical to 
the RR for male uptake reported here (RR 0.96: 95% CI 0.95-0.97; P<0.001).  
Men in Ireland have significantly poorer health literacy and functional literacy 
than women, (33) suggesting that health literacy could also explain the observed 
lower uptake in men. However, other factors could be in operation. For example, 
Miles et al have reported that poor self-rated health significantly mediated the 
relationship between uptake and socio-economic status (34). In a qualitative study 
nested within the TTC-CRC-SP, we found that several factors appeared to 
influence non-use of FIT-based screening, and that these factors differed by 
gender; drivers of non-participation in males included fear of cancer, fatalism, 
lack of knowledge and being misinformed whereas negative attitudes, beliefs, 
emotions and social influences influenced females non-use (35). In a study on late 
stage colorectal and lung cancer diagnosis, females had  higher fatalism scores 
than males, (36)  and those with lower income and lower educational attainment 
also had higher levels of fatalism. Other studies have found associations between 
cancer fatalism, lower income/educational attainment, poor self-rated health 
(34,37) and lower screening uptake. We have also found differences in fatalistic 
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beliefs in our qualitative work in this population (35) suggesting differences may 
exist at the screening population level in cancer fatalism between men and women 
(or, indeed by deprivation status). This however needs to be investigated further.  
However, these explanations are speculative and further research is required to 
better understand what underlies the observed differences in uptake.  It would be 
particularly useful to examine if a gender difference exists in screening 
information comprehension and subsequent decisions to participate in FIT-based 
screening – both in Ireland and more widely. It is important also to understand the 
mechanisms by which fatalistic beliefs and lack of cancer knowledge (which are 
not necessarily exclusive of one another) may contribute to low screening uptake 
and how these may differ by sex and socio-economic status. Some evidence is 
beginning to emerge on success in intervention trials aimed at tackling the 
socioeconomic gradient in colorectal cancer screening uptake through mailed 
materials (38). Future investigations should examine if poorer health literacy in 
males (and/or the most disadvantaged groups of the population) may be amenable 
to interventions to improve screening uptake in this population. In the meantime, 
we concur with Von Wagner et al (32) that screening programmes should seek to 
simplify messages and make screening information more accessible to different 
sectors of the population.  
Our study had several limitations. Firstly there was limited data available to us 
and the variables on which we did have information were not modifiable. In 
addition screening history was not available to us and as such we could not 
determine the extent to which prior screening may have influenced uptake. 
However when the TTC-CRC-SP started, no other organised colorectal screening 
programme was in operation in Ireland, so any previous related tests participants 
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may have had would have been opportunistic or diagnostic. We were also unable 
to determine any effect of multiple invitations in individual households on uptake. 
4.6 Conclusion 
In conclusion, our study shows that FIT-based screening uptake is lower in more 
deprived sectors of the population and in men, and that these are independent 
effects. It is important to investigate what underlies these findings to inform the 
development of interventions to reduce and, ideally, eliminate these disparities. 
Failure to intervene effectively will ultimately mean that these groups will 
experience a disproportionately greater burden of colorectal cancer.  
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Figure 4.1: Consort diagram of TTC-CRC-SP invitees
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Table 2.1: Characteristics of screening invitees of the TTC-CRC-SP 
  Total Male            Female           
Participant characteristics N (%) N (%) N (%) 
       Participation   
      Participation overall 5451 (60) 2364 (56) 3087 (62) 
Both rounds 3788 (41) 1612 (38) 2176 (44) 
Round 1 only 737 (8) 319 (8) 418 (8) 
Round 2 only 926 (10) 433 (10) 493 (10) 
Non-participant 3700 (40) 1829 (44) 1871 (38) 
Age
a
 
      Mean age (IQR
b
) 62 (57-66) 62 (58-67) 61 (57-66) 
<60 3276 (37) 1419 (35) 1857 (38) 
60-64 2633 (30) 1212 (30) 1421 (29) 
65-69 1899 (21) 896 (22) 1003 (21) 
70-74 1048 (12) 522 (13) 526 (11) 
75+ 66 (1) 27 (1) 39 (1) 
       Deprivation
c
 
      Very disadvantaged 1193 (13) 521 (12) 672 (14) 
Disadvantaged 3068 (34) 1374 (33) 1694 (34) 
Marginally below average 3851 (42) 1800 (43) 2051 (41) 
Marginally above average 872 (10) 416 (10) 456 (9) 
Affluent 167 (2) 82 (2) 85 (2) 
              
a
 Age was not available for 229 invitees; 
b
IQR: Inter quartile range; 
c
Missing categories 
from POBAL HP deprivation index: Extremely Disadvantaged, Very Affluent and 
Extremely Affluent 
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Table 2.2: TTC-CRC-SP Absolute uptake by participant characteristics (numbers and %) and univariable and multivariable relative risks 
(RR) for participation in FIT-based colorectal cancer screening with 95% confidence interval and p values: primary analysis based on two 
screening rounds combined
a
 
  Invited Participated   Univariable model Wald Multivariable model
b
 Wald 
  N N (%) 
 
RR 95%CI p RR 95%CI p 
           Sex 
          Female 4958 3087 (62) 
 
1.00 - 
 
- - 
 Male 4193 2364 (56) 
 
0.96 0.95 - 0.98 <0.001 0.96 0.95 - 0.97 <0.001 
           Age 
          <60 3276 1874 (57) 
 
1.00 - 
 
- - 
 60-64 2633 1618 (61) 
 
1.03 1.01 - 1.04 
 
1.03 1.01 - 1.04 
 65-69 1899 1260 (66) 
 
1.06 1.04 - 1.08 <0.001 1.06 1.04 - 1.08 <0.001 
70-74 1048 650 (62) 
 
1.03 1.01 - 1.05  
 
1.03 1.01 - 1.05 
 75+ 66 44 (67) 
 
1.06 0.99 - 1.14 
 
1.05 0.98 - 1.12 
 
Test of trend
c
 
    
1.02 1.01 - 1.02 
 
1.02 1.01 - 1.02 
 
           Deprivation 
          Very disadvantaged 1193 548 (46) 
 
1.00 - 
 
- - 
 Disadvantaged 3068 1643 (54) 
 
1.05 1.03 - 1.08 
 
1.06 1.04 - 1.08 
 Marginally below average 3851 2542 (66) 
 
1.14 1.11 - 1.16 <0.001 1.14 1.12 - 1.16 <0.001 
Marginally above average 872 588 (67) 
 
1.15 1.12 - 1.18 
 
1.16 1.13 - 1.19 
 Affluent 167 130 (78) 
 
1.22 1.17 - 1.27 
 
1.26 1.21 - 1.30 
 
Test of trend
c
 
    
1.06 1.05 - 1.06 
 
1.06 1.05 - 1.07 
                       
a
 Participation defined as taking part in either or both screening rounds; 
b
 Mutually adjusted for sex, age and deprivation; c Linear trend across 
categories 
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5.1 Abstract 
Introduction: FIT is increasingly being used in population-based colorectal cancer 
screening programmes. Uptake of FIT is lower in men than women however the 
reasons for this are not well understood. We aimed to explore gender differences 
in influences on decisions to participate in FIT screening.  
Methods: A qualitative study using in-depth face to face interviews of four groups 
of screening invitees (male and female screening users; male and female screening 
non-users), purposively sampled from the database of a population-based FIT 
screening programme. Recruitment continued until saturation was reached. 
Interviews were audio-recorded and transcribed verbatim. Thematic analysis using 
the Framework approach was employed with the Theoretical Domains Framework 
(TDF) guiding analysis. 
Results: 47 screening invitees (8% response rate [56% among users and 3% 
among non-users]) were interviewed. Six TDF domains influenced screening 
uptake: “environmental context and resources”, “beliefs about capabilities”, 
“beliefs about consequences”, “emotions”, “social influences” and “knowledge”. 
Male non-users were often fatalistic, less knowledgeable, and misinformed about 
cancer and FIT screening compared to other groups. Female non-users expressed 
negative attitudes, beliefs and emotions towards FIT screening, cancer, social 
influences and the medical profession, and were over-confident about their health. 
Conclusions: Negative attitudes and emotions to screening dominated non-user 
decision-making but differed by gender. Opportunities to improve uptake in men 
and women exist. Greater national discussions on the benefits of FIT screening, 
and development of screening materials tackling negative attitudes and beliefs 
while recognising male/female differences, may improve screening uptake. 
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5.2 Introduction 
Worldwide, colorectal cancer is the second most common cancer diagnosed in 
women and the third most common in men although men have higher incidence 
and mortality from the disease. (1) Screening is effective in reducing colorectal 
cancer incidence and mortality. (2–7) Current guidelines recommend population 
based-screening of asymptomatic people aged  50-74 years  or ≥50 years annually 
or biennially using non-invasive methods ( gFOBT or FIT) or every 5-10 years 
using other procedures (flexible sigmoidoscopy/colonoscopy). (8, 9) Many 
population-based screening programmes employ FOBT as the initial screening 
test. However FIT is increasingly being recommended because it has higher 
specificity and sensitivity (8) and higher uptake. (10, 11) 
In order to be effective in reducing incidence and mortality, population-based 
screening programmes require high uptake. Males have higher uptake of 
endoscopy-based screening procedures, while females have higher uptake of non-
invasive tests such as FOBT and FIT. (12–14) For FIT specifically, a recent 
systematic review and meta-analysis estimated that the odds of screening 
participation was significantly lower in males compared to females (odds ratio 
[OR], 0.84; 95% CI, 0.75–0.95). (15)  However the drivers of lower male uptake 
did not appear to be related to screening programme design or organisation. (15)   
 
Lower colorectal cancer screening uptake in men has been associated with poorer 
knowledge of colorectal cancer and screening (16,17); lower perceived severity of 
colorectal cancer; fatalistic beliefs about cancer; procrastination; lower beliefs 
about capabilities of successfully completing testing; machismo and homosexual 
sensitivities. (16,18,19) Higher uptake in women has been associate with having a 
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family member with colorectal cancer [20] while lower uptake has been 
associated with fear of endoscopic based procedures and  fear of a positive 
diagnosis. (16) However, this evidence relates to FOBT or endoscopic based tests; 
evidence on reasons for gender differences in uptake of FIT specifically is 
lacking.  
We used a qualitative approach to explore differences in male and female 
influences on use and non-use of a population-based FIT colorectal cancer 
screening programme.  
 
5.3 Methods 
Design 
In-depth semi-structured interviews were conducted among people invited to 
participate in the Tallaght Hospital/ Trinity College Dublin Colorectal Cancer 
Screening Programme (TTC-CRC-SP), a population-based FIT-based colorectal 
cancer screening programme in Tallaght, one of the most disadvantaged areas of 
Ireland. (20, 21) Approximately 10,000 people aged 50-74 were identified through 
primary care practices and invited by mail to participate in screening; the FIT kit 
was sent with the initial invitation. Round 1 operated during 2008-2010 (uptake 
was 51%) and Round 2 during 2011-2012 (uptake was 47.5%). (22) In both 
rounds uptake was significantly lower among men than women (e.g. round 2: 
44.5% vs. 50%; OR 0.79: CI 0.73-0.89). (22) The TTC-CRC-SP ceased in 
December 2012 after two screening rounds and, in 2013 a national FIT based 
screening programme (BowelScreen) began (http://www.bowelscreen.ie). 
 
Theoretical Framework 
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The Theoretical Domains Framework (TDF) (23) was used as a framework for 
examining potential influences on whether individuals accepted an invitation to 
participate in the TTC-CRC-SP. The TDF integrates 33 psychological and 
organisational theories to provide a comprehensive framework of possible 
influences on behaviour. (23)  It consists of 14 domains (23): knowledge, skills, 
social/ professional role and identity, beliefs about capabilities, optimism, beliefs 
about consequences, reinforcement, intentions, goals, memory attention and 
decision processes, environmental context and resources, social influences, 
emotion, and behaviour regulation.   
 
Recruitment and interviews 
A purposive sample was drawn from the TTC-CRC-SP database (supplementary 
figure 1). “Users” were defined as those who had taken part in either or both 
screening rounds; “non-users” did not take part in any screening round. Screening 
invitees were stratified into four groups according to participation status 
(users/non-users) and gender (male/female). Each group was sorted alphabetically 
in Microsoft Excel by surname and forename and a random number assigned to 
each person (using the RAND function). We re-sorted each group from lowest to 
highest number and approached people in sequence, starting with the lowest 
numbered individual.  The study was approved by the St James/Adelaide Meath 
Hospital incorporating the National Children’s Hospital Research Ethics 
Committee (REC Reference 2013/12/05).  
 
Potential interviewees were contacted by mail and invited to be interviewed. 
Those who returned a reply slip were telephoned by the male interviewer (NC) 
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who answered any questions and arranged a convenient time and place for the 
interview. All participants provided written informed consent. Interviews were 
conducted face-to-face, at the participant’s home, the local hospital or another 
venue, according to the interviewee’s preference, during May-August 2014. 
Everyone who accepted and was available to take part was interviewed.  
Recruitment continued until saturation was reached (i.e. no new themes emerging 
across all interviews). Interviews were audio recorded with the interviewee’s 
permission and lasted 15-90 minutes (mean=41 minutes).   
 
Topic guide 
The topic guide (Supplementary Table 2.1) was informed by the TDF. Questions 
were developed for each domain to explore potential influences on screening 
invitees’ decisions regarding FIT screening use.  
 
Analysis 
Transcripts were imported into NVivo 9. Data were analysed thematically using 
the Framework approach; this involved familiarisation, construction of a thematic 
framework (the TDF domains), indexing and sorting data, and reviewing data 
extracts. (24) Two researchers independently read four transcripts, coded these to 
the TDF domains then discussed coding to reach consensus. The remaining 
interviews were then coded to the TDF by one researcher (NC). A health 
psychologist (PG) was consulted when necessary. Domains were compared and 
contrasted by strata. Selected illustrative quotes are presented in Tables 3.1 (users) 
and 2 (non-users), with additional quotes in Supplementary Tables 2.2 (users) and 
2.3 (non-users). 
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5.4 Results 
Interviews were conducted with 47 people (response rate of 8%), 28 users of FIT-
based screening (16 male, 12 female) (response rate of 56%) and 19 non-users (9 
male, 10 female) (response rate of 3%). Interviewees’ characteristics are 
summarised in Supplementary Table 2.4.  
Six TDF domains were identified as influencing interviewees’ decisions on 
participation in FIT-based screening: ‘environmental context and resources’, 
‘beliefs about capabilities’, ‘beliefs about consequences’, ‘social influences’, 
‘emotions’ and ‘knowledge’ (Supplementary Table 2.5). 
 
Environmental context and resources 
Screening users 
A prominent influence on screening behaviours was salient events in 
interviewees’ lives. These acted as a catalyst encouraging screening participation 
in male and female users. Generally these related to others diagnosed with cancer 
or other gastric/bowel conditions and were a context within which screening was 
validated as a positive health behaviour.  
 
Resources and materials relating to the FIT kit also influenced participation. Most 
female users found the test equipment simple and easy to use.  In a few instances 
females raised concerns with the kit (e.g. paper for catching stool, sampling tool, 
packaging for storing the sample in the refrigerator); these issues were overcome 
and did not act as barriers to participation. Male users were very positive about the 
screening resources and materials provided. 
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Screening non-users 
Female non-users referred to salient events related to colorectal cancer, other 
cancers or other gastric conditions; these events were seen in a negative light and 
presented as reasons not to participate. Male non-users also mentioned salient 
events acting as barriers to screening; these were generally unrelated to medical 
matters or illness (e.g. relationship breakdown, child custody battle).   
 
Uniquely female non-users had poor trust in the medical profession, particularly 
their local hospital, and this influenced their decision not to take part. Some male 
non-user had issues with the environmental context, specifically delivery of mail, 
implying the screening invitation did not reach them. 
 
Female non-users’ attitude to FIT test materials was often negative and related to 
the sampling kit (e.g. catching of the stool using the paper provided, using the 
sampling stick) and packaging for storing the sample in their refrigerator (e.g. 
concerns about food contamination).  Male non-users had few or no issues with 
the resources and material. 
 
Beliefs about capabilities 
Screening users 
Both male and female users had strong confidence in their ability to do the test, 
describing how they carefully followed the test instructions and pointing out “it’s 
not rocket science”.  
 
Screening non-users 
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Male non-users generally believed they would have had no problems conducting 
the test despite not participating. Female non-users raised several issues impacting 
on their perceived ability to carry out the test, including an inability to deal with 
faecal matter and lack of confidence in sampling stool with the equipment 
provided. Others suggested that they felt confident to recognise illness in 
themselves observing that they did not participate in screening because they felt 
they were not ill or that they had no bowel symptoms; several made statements 
such as “you know your own body” and “if it’s not broke don’t fix it”.  
 
Beliefs about consequences 
Screening users 
Both female and male users were very positive about the implication of a 
colorectal cancer diagnosis, often stating that they considered that early detection 
is the key to successful treatment. 
  
Screening non-users 
Both female and male non-users were generally negative about the implication of 
a colorectal cancer diagnosis. Many female non-users discussed undergoing 
surgery and the potential need for a colostomy bag in negative terms. Male non-
users often held fatalistic beliefs that a diagnosis inevitably resulted in death. 
 
Social influences 
Screening users 
Male users spoke about the positive influence of female partners in their decision 
to participate.  Female users discussed social influences outside the family on their 
131 
 
screening participation including the impact of media campaigns for other cancer 
screening and quitting smoking.   
 
Screening non-users 
Female non-users raised a range of social influences which were generally 
negative and influenced their decision not to participate in screening (e.g. a 
neighbour who experienced colonoscopy-related complications, lack of 
encouragement from one’s GP, discouragement by one’s mother). While there 
were fewer social influences on male non-users’ screening decisions, some 
discussed a female relative’s unsuccessful attempt to encourage them to 
participate. 
 
Emotions 
Screening users 
Male and female users spoke of their decision to be screened with positive 
emotional affect feeling it was a “brilliant idea”. Although male users sometimes 
mentioned fear of cancer and embarrassment (with respect to the test), these did 
not inhibit their participation.  Instead fear of cancer was a catalyst to screening, 
providing “peace of mind” in knowing that one has a “pretty good chance of not 
getting it”. 
 
Non-users 
Female non-users expressed negative emotions around screening including disgust 
(related to handling faeces or storing the sample in the fridge), anger (timing e.g. 
receiving test while grieving a spouse’s death) and fear (of cancer). Some female 
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non-users described emotional burnout due to other conditions leaving them 
emotionally unequipped to deal with a potential colorectal cancer diagnosis, 
leading them to decide not to participate. Male non-users expressed negative 
emotions relating to a fear of cancer, and dying (considered as potential 
consequences of screening) influencing their decision not to participate. 
 
Knowledge 
Screening users 
Generally female users considered their risk of developing colorectal cancer as 
low, based on their family history of the disease and lifestyle (which they 
considered “healthy”). Some male users considered they had low risk because 
they had previously had a colonoscopy (either having a negative result or polyps 
removed) and therefore were in no immediate danger or because they had a 
healthy diet and lifestyle; others considered that they had high risk because of 
other gastrointestinal conditions (e.g. Crohn’s disease). Overall, users had a very 
considered view of their colorectal cancer risk and felt screening participation 
would sustain a low risk or reduce a high risk. Male and female users often knew 
other people with colorectal cancer and this motivated them to participate in 
screening. 
 
Screening non-users 
Female non-users generally believed that their risk was low, mainly because they 
had no family history or symptoms of the disease (generally understood as 
frequent bowel motions). This perceived low risk led them to believe they did not 
need to be screened. Male non-users generally stated they did not know their risk 
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of developing colorectal cancer and were often unsure if they knew anyone with 
colorectal cancer. 
  
Female non-users were often unclear about the screening procedure, and 
sometimes described having not read the information sent with the test kit. Male 
non-users stated that they were clear about how the test was carried out but upon 
discussion several had misunderstood how to complete it. 
 
5.4 Discussion 
 
We used qualitative methods to explore influences on males’ and females’ 
decisions to participate in FIT-based colorectal cancer screening. Considering FIT 
based screening is increasingly being used in population-based programmes, and 
that uptake is variable (19%-76% in population-based programmes, average 44% 
(15)), this study provides valuable information on factors influencing non-
participation, examining these differences by gender. Six TDF domains emerged 
as influencing individuals’ decisions on FIT-based screening participation. 
Although all of these domains were evident for users and non-users, issues within 
domains differed between groups, or the same issues played out differently in the 
two groups and sometimes by gender.  
 
Negative attitudes, beliefs and emotions, pervaded decisions of non-users, while 
positive attitudes, beliefs and emotions were evident among users. Negative 
attitudes are associated with lower colorectal cancer screening participation. (25, 
26) Our study found differences in these attitudes and beliefs by gender especially 
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among male and female non-users. These included differences in salient events 
(medical matters in females and non-medical matters in males); response to 
materials and resources (test kit, storage and faecal sampling in females; non-test 
related factors in males); perceived consequences of screening and diagnosis 
(males’ fatalism); and social influences (negatively impacting on females’ 
decisions, but less apparent in males). 
 
Fear of cancer and fatalistic beliefs result in low adherence to screening 
recommendations (27) but fear may have different effects on screening decision-
making around participation (28); this has not been explored by gender.  In our 
study, although male users had some fear around a cancer diagnosis, this did not 
impede participation whereas in non-users fear was an impediment to screening. 
Fatalism has been associated with poor screening uptake (19,29–31) and those 
with greater fatalistic beliefs are more likely to believe they have a greater risk of 
cancer and that it is a more severe disease. (31)  Where our study extends these is 
that we found fatalistic beliefs were present among male non-users only and 
influenced their decision not to participate.  
 
Non-users, particularly male non-users had poorer knowledge of colorectal cancer 
than users and less often knew of others with cancer. Knowledge about cancer 
generally, and knowing someone with colorectal cancer, is positively associated 
with screening intention and participation (25,32,33) while low health literacy has 
been identified as influencing non-participation. (34) Our findings suggest that 
health literacy and social supports which provide opportunities to learn about 
illnesses or screening may be especially poor among male non-users thereby 
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influencing non-participation. Von Wagner et al, have suggested the use of a 
wider range of communication strategies in raising awareness of screening (35) 
and we concur with this.  
 
Disgust influenced females’, but not males’, decisions to participate in screening. 
Different forms of disgust, such as trait disgust (the stable tendency to experience 
disgust) and state disgust (current emotional experience), might influence 
particular types of decisions such as taking part in screening. A recent study found 
that while females had higher scores for both forms of disgust, between-gender 
differences were not significant, but the authors acknowledged methodological 
limitations. (36) There is a need for research identifying how screening 
information could address anticipated disgust (36,37) and our finding suggests this 
should be considered with gender differences in mind. 
 
There were few differences between male and female users in influences on 
screening decisions, but female relatives often influenced male users’ decisions to 
be screened but this influence did not operate in the other direction. Spouses play 
an important role in colorectal cancer screening decision making; (38,39) and 
women have been described as the guardians of men’s health (40); our study 
appears to be the first to show that this positive influence operates only for men. 
Among male non-users, while social influences were fewer, females relatives had 
sometimes attempted to influence them, albeit unsuccessfully. Further 
investigation of the influence of females on male screening decision-making is 
warranted.   
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Male non-users were less clear about their non-participation than female non-
users, citing external circumstances or that they had forgotten or didn’t have time. 
Those who cited external circumstances or forgetting as reasons for non-
participation could have been masking their true reasons.  Elsewhere it has been 
reported that unscreened males often procrastinated about screening, being vague 
and emotionally distant around screening decisions. (19) In our study a small 
number of male non-users revealed that they unconsciously resisted doing the test 
due to an underlying fear of the potential outcome of screening. Further 
investigation on resistance to screening in males is warranted.  
 
This is the first study to employ the TDF within a qualitative study investigating 
influences on FIT-based colorectal cancer screening decisions. Although 
interviewees were recruited from a population-based screening programme, this 
operated in a specific area in one city and it is possible that themes/influential 
domains may not generalise to other settings/populations. Our sample was drawn 
from a screening programme which had finished two years prior to recruitment 
and interviewees may have had difficulty with recall, although we provided recall 
aids. One (male) interviewer conducted all interviews and while this provided 
consistency across interviews, it is possible that the interviewer’s gender 
influenced interviewees’ responses. Finally, while we reached saturation of 
themes across the entire dataset, and in all strata except male non-users, the 
relatively small number of non-users who were interviewed is a limitation. 
Recruitment of non-users was challenging: 550 individuals were approached in 
order to obtain interviews with19 people. It is possible that if more non-users had 
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participated further domains might have been identified as influencing screening 
decisions.  
 
5.6 Conclusions 
Our study provides novel information on influences on FIT uptake in men and 
women. Further investigation is required of whether and how the influences 
identified in this study operate independently and together at the population-level. 
Our findings may be used to inform the development of gender-specific 
interventions designed to improve uptake in FIT-based screening programmes. 
Moreover, the opportunity exists, within Ireland at least, where colorectal cancer 
screening is relatively new, to open a national discussion on the benefits of FIT-
based screening, tackling the issues raised in this study and ultimately seeking to 
improve screening participation in both genders. 
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Table 3.1: Illustrative quotes for domains potentially influencing screening decisions in users, by gender 
Domain Female compliers Male compliers 
Environmental 
context and 
resources                
She had bowel cancer. Well, her bowel burst, actually, 
she’s lucky to be alive. I thought, oh no, I need to get 
this done, because there’s slight changes, do you 
know.(P-9) 
And certainly in light of the two guys, friends of mine 
who are in trouble now. So I would certainly be very 
conscious of it.(P-28) 
 Beliefs about 
capabilities        
Well, I thought so. I mean, it’s pretty simple to do, just 
take the little stick and... It’s not exactly rocket 
science.(P-7) 
 It was easy enough, yeah. Yeah, you just prepare 
whatever you have to do upstairs and do it.(P-32) 
Beliefs about 
consequences             
But I always feel that if you had to get a cancer, it 
wouldn’t be one of the worst [colorectal cancer], 
because it is treatable, and if it’s caught in time I think 
you have a better chance than you have if you got 
pancreatic cancer.(P-3) 
  If they got it in time, if they were screening, and all 
that, that’s the way I believe in it. Well, it’s like 
anything, I suppose, if you get it in time.(P-26) 
Social Influences If I came to a bowel cancer awareness week or  breast 
cancer or bowel cancer or whatever, it would make me 
think, and it’s "oh I must follow up on that and have 
all that checked out for myself".(P-3) 
She nagged me into it [female spouse], so I did it.(P-
35) 
Emotions I thought brilliant....Great idea. Any of those tests for 
prevention, I would say, is a great idea.(P-1) 
The more people you’ve met or have known that have 
had cancer, and the closer you are to getting it, the 
more frightening it becomes, especially when people 
die, obviously.(P-29) 
Knowledge    I suppose it’s one of the cancers I would think, no, you 
won’t get that...it’s just maybe to do with diet and 
lifestyle, is a lot to do with it probably.(P-6) 
Well, at the moment, after doing this [colonoscopy] I 
think I’m okay.(P-29) 
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Table 3.2: Illustrative quotes for domains potentially influencing screening decisions in non-users, by gender 
Domain Female non-compliers Male non-compliers 
Environmental 
context and 
resources               
I got it the morning after my young fellow nearly died 
the night before and I just... I’m sick of hospitals...and 
it was all bowels .(P-19) 
So I just kept putting it off. I mean, in and out of the 
courts for the last… I mean, I’m going to the High 
Court now [custody battle].  So I’ve been down the 
courts for the last 12 years.(P-45) 
 Beliefs about 
capabilities        
Well, when I saw what you had to do, I couldn’t cope 
with that [faecal sampling].(P-15) 
 Yeah...I’d do it myself now. I’ve no problem doing it 
now.      (P-39) 
  
Beliefs about 
consequences             
It’d probably be fairly invasive and end up with bags 
and all sorts of things.(P-18) 
I’d say they'd be dead. Because there's no cure for 
cancer is there, not that I know of anyway.(P-47) 
Social Influences Well, it was my mother, when I got the letter my 
mother said, “Throw that in the bin, you don’t want to 
know anything about yourself.”(P-16) 
  And she [wife] said to me, “Did you do it?” “Aye,” I 
said. But I didn’t.(P-46) 
Emotions I thought, ‘I’m not doing that’ [faecal sampling]. 
Yes... If it had been probably- oh God, it sounds 
disgusting.(P-13) 
At the time it was, yeah, it was a fear of dying.(P-47) 
Knowledge    That would have been on my mind, opening that pack, 
and looking at it and thinking, ‘Well, I don’t have the 
symptoms that [sister] had. If I have, I’ll go.’(P-22) 
But you wiped your bottom and you sent this piece of 
paper off to the...wherever, the lab.(P-40) 
 
 
144 
 
 
6 Negative emotions and cancer fatalism are independently 
associated with uptake of FIT based colorectal cancer screening: 
Results from a population based study 
Nicholas Clarke 
1, 2
,  
Patricia M. Kearney
2
,  
Pamela Gallagher
3
  
Deirdre McNamara
4   
Colm A. O’Morain5,  
Linda Sharp
6  
1
Department of Epidemiology and Public Health Medicine, Royal College of 
Surgeons of Ireland (RCSI), Ireland 
2 
Department of Epidemiology and Public Health, University College Cork, 
Ireland 
3
 School of Nursing and Human Sciences, Dublin City University
 
4
Department of Clinical Medicine, Trinity Centre for Health Sciences, Adelaide 
and Meath Hospital, Dublin, Ireland  
5
Faculty of Health Science, Trinity College Dublin, Dublin, Ireland 
6
Institute of Health & Society, Newcastle University, England 
 
This paper is under review in the British Journal of Cancer – August 2017 
 
 
 
145 
 
6.1 Abstract 
Background: Few behavioural or attitudinal factors have been identified in 
improving participation in population-based colorectal cancer screening. We 
explored knowledge and beliefs about cancer, health literacy, emotional attitudes 
to screening, and social influences among individuals invited to a population-
based screening programme. 
Methods: A cross-sectional survey of 2299 individuals (users and non-user) of a 
population-based FIT screening programme was conducted in the latter half of 
2016. Factors of interest were explored using previously used and validated 
measures. The primary outcome variable modelled was uptake status (User or 
Non-User); multivariable logistic regression was used to estimate the odds ratios 
(OR) for participation.   
Results: Stronger fatalistic beliefs independently predicted lower uptake (OR 
0.94; 95% CI 0.90-0.98; P=0.003), while being younger and disagreeing that 
“cancer can often be cured” also independently influenced lower uptake (OR 
0.45; 95% CI 0.24-0.84: P=0.019). Stronger negative emotional attitudes to 
screening independently predicted lower uptake (OR0.83: 95% CI 0.83-0.80-
0.87: p<0.001), while the influence of a partner on decision to be screened 
independently predicted higher uptake (OR 1.37; 95% CI 1.20-1.57: P<0.001). 
Conclusion: Key barriers to uptake in FIT-based screening include cancer 
fatalism, the belief that cancer cannot be cured and negative emotional attitudes 
to the FIT test, while the influence of a partner facilitates use. Challenges now 
exist in how to improve uptake by exploring if these negative beliefs and 
emotions are modifiable in terms of intervention development. An additional 
challenge lies in improving uptake among those not in co-habiting relationships. 
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6.2 Introduction 
Colorectal cancer is the second most common cancer diagnosed in females and 
third most common in males (1). Rates of the disease are highest in the most 
developed countries (2) and, both in more and less developed regions both 
incidence and mortality rates are higher in males (1).  Colorectal cancers develop 
from adenomas polyps;  polyps are usually asymptomatic in earlier stages (6,7) 
and transition to invasion often takes more than 10 years (3–5) (6,7). Screening 
for adenomas or early cancers has proven efficacious in reducing cancer 
incidence and mortality (3,5,8,9) and several screening tests exist. Current 
colorectal cancer screening guidelines recommend population-based screening in 
those aged 50 or over using invasive tests (colonoscopy or flexible 
sigmoidoscopy) or in those aged 50-74 using non-invasive tests gFOBT or FIT 
(10,11). In Europe, screening programmes tend to employ non-invasive methods 
(12,13) and guidelines in recent years have recommended programmes move 
from gFOBT to FIT as the latter has higher sensitivity and specificity and does 
not require dietary restriction (10,11), Indeed, FIT is now recognised by most 
countries as the screening test of choice and the marker against which new tests 
should  be compared and assessed (14).  
 
In order to achieve health gains at the population-level, colorectal cancer 
screening programmes require high uptake (10,15,16). FIT-based screening 
achieves higher uptake than screening using other tests (17,18) yet uptake is 
suboptimal overall, and significantly lower among males and lower 
socioeconomic groups (19,20). (In)equity in screening, if left unchecked, may 
lead to further disparities in health outcomes among those who are most at risk. 
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Therefore, while improving overall uptake is important, focus is also needed on 
reducing differentials in uptake (15,21). While many strategies to improve uptake 
have been tested (22), most have had no effect on uptake. This suggests that 
greater understanding of why people (and particular subgroups of people) decide 
to participate or not in colorectal cancer screening would be valuable in informing 
the content for future interventions. 
 
Evidence relating to reasons for non-participation with colorectal cancer 
screening is very limited, particularly for FIT. In a recent systematic review of 
FIT screening uptake, we found that while males were significantly less likely to 
take part, the drivers of lower uptake did not appear to be related to screening 
programme design or organisation (19).  Our subsequent qualitative research 
suggested that negative beliefs about cancer and negative emotional attitudes 
towards screening, poor knowledge about cancer and health literacy, and social 
support, may play a role in low uptake overall, and especially among males (23), 
but whether these factors are related to uptake of FIT-based screening at the 
population-level is unknown.  We undertook this population-based study to 
quantify associations between uptake of FIT-based colorectal cancer screening 
and (i) colorectal cancer knowledge and health literacy, (ii) beliefs about cancer 
and emotional attitudes to cancer and FIT based screening and (iii) social 
influences. Our secondary aim was to determine whether these associations 
differed in males and females. 
 6.3 Methods 
Study population. 
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The study setting was the Tallaght region of Dublin, which has a population of 
70,000 and is one of the most disadvantaged areas of the country (CSO, 2011). 
The Tallaght Hospital/Trinity College Dublin Colorectal Cancer Screening 
Programme (TTC-CRC-SP) was a population-based screening programme and 
offer two rounds of screening using FIT during 2008 to 2012, (round 1: 2008-
2010: round 2: 2010-2012). Individuals aged 50-74 were identified through seven 
primary care practices in Tallaght. Participants with a severe inter-current illness 
precluding bowel preparation or colonoscopy were excluded, as were those who 
had undergone a colonoscopy within the previous 2 years(24). 9785 individuals 
were invited to participate in screening. These individuals were sent an invitation 
letter which also contained a FIT test kit. To participate, they were required to 
provide a single faecal sample which they posted to the laboratory using a prepaid 
envelope. An information sheet on colorectal cancer was also included in the 
initial invitation and all invitees received identical information. A reminder at 12 
weeks was sent to those who did not respond. Upon commencement of round 2, 
individuals who had left the catchment area after round one, had been diagnosed 
with colorectal cancer or were deceased were excluded; everyone else was invited 
to take part (irrespective of whether they had participated in round 1) A positive 
result on the FIT was followed up with a diagnostic colonoscopy. Participation in 
screening was free, as were follow-up investigations, procedures and treatment if 
cancer was detected. 
 
Study design 
In September 2015 we selected a sample of individuals from the TTC-CRC-SP 
database to be invited to complete a questionnaire. The database was stratified by 
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participation status and sex. Non-participation (henceforth “non-users”) was 
defined as having not taken part in either screening round and participation 
(henceforth “users”) was defined as taking part in either or both rounds of 
screening. We invited the entire sample of non-users (n=3738; 1830 males & 
1908 females)) to take part in the study.  We stratified the user sample by sex,  
randomly sorted each group then selected 1830 men and 1908 women (the same 
numbers as in the non-users groups) to participate in the study . The non-user and 
users were mailed the questionnaire, a participant information leaflet and a 
prepaid reply envelope. Reminders were sent at 3 and 6 weeks (with a second 
copy of the questionnaire at 6 weeks) to those who had not responded. The study 
was approved by the Research Ethics Committee of St James/Adelaide &Meath 
Hospital incorporating the National Children’s Hospital (REC Reference 
2013/12/05). 
Questionnaire 
The questionnaire (supplementary material – appendix C) was developed to 
explore factors impacting on uptake and was informed from our  previous 
exploratory qualitative study (23). Information was collected on age, highest level 
of education completed, employment status, medical card status (those on 
reduced means (i.e. below a certain income threshold) are provided with a 
medical card which entitles them to access health care, including primary care, in 
the public health system, free at the point of delivery), private health insurance, 
smoking status and self-rated health (25). The National Cancer Registry geocoded 
all addresses in the screening database and an area level deprivation score (26) 
was assigned to each individual (20).   
 
 
 
150 
 
Measures 
Cancer knowledge and health literacy  
To gauge cancer knowledge participants were asked two questions: (i) if they 
knew of anyone who had been diagnosed with bowel cancer and (ii) if they knew 
anyone who had been diagnosed with any cancer (27). Response options for both 
questions were “Yes me”, “Yes someone close to me”, “Yes me and someone 
close to me”, “Yes, but prefer not to say” and “No” with responses collapsed into 
two categories (No knowledge of someone or self with cancer (No) or knowledge 
of other or self with cancer (all other responses)). Health literacy was measured 
using a single item measure (28) which has demonstrated ability to detect 
inadequate health literacy in screening populations (28–30). Respondents were 
asked “how confident are you filling out medical forms by yourself?” with 
responses on a five point scale (“Extremely”, “Quite a bit”, “Somewhat”, A little 
bit” and “Not at all”).  Responses were combined to measure inadequate and 
adequate health literacy (Inadequate: “Somewhat”, “A little bit” and “Not at all”). 
 
Beliefs about cancer and emotional attitudes to cancer and screening 
Beliefs about cancer were measured using six separate single item statements 
(three negatively framed and three positively framed) from the Awareness and 
Beliefs about Cancer (ABC) questionnaire (27) (supplementary material); 
response options on a four point Likert-type scale (from “strongly agree” to 
“strongly disagree”) were reduced to two categories (“agree” or “disagree”). 
Fatalistic beliefs about cancer were measured using the Powe Fatalism Inventory 
which was amended to be specific to bowel cancer (31) and contained  fifteen 
 
 
151 
 
items with two response options (“Agree” or “Disagree”). Items responses were 
summed. Higher scores indicated greater cancer fatalism (scale ranging from 0-
15). Internal consistency here was adequate (α =.86). Negative emotional 
attitudes toward the FIT screening test were assessed using a five item scale 
developed by Smith et al, which includes  items on disgust, tempting fate, 
embarrassment, worry and being afraid (32). Responses were on a four-point 
scale from “strongly agree” to “strongly disagree” with higher scores (ranging 
from 5-20) indicating more negative emotional attitudes.  Internal consistency 
was adequate (α =.85).  Three separate aspects of cancer fear - cognitive , 
affective and psychobiologic - were measured using questions adapted by Vrinten 
et al, all of which were measured on a five point Likert type scale (strongly agree 
to strongly disagree)(33). We collapsed the strongly agree and strongly disagree 
responses to give three response categories (Agree, Disagree or Uncertain).  
Social influences 
Social influences were measured in three ways.  Firstly, four questions on 
perceived beliefs about key references’ (two questions on partner’s and two 
questions on GP’s) attitudes towards colorectal cancer screening (34,35) were 
included. Responses were summed to give an aggregate score from 1-4 (strongly 
agree to strongly disagree), with higher scores equating to greater social 
influence. Our primary interest was in the influence of a partner on screening 
decision so we also ran separate analysis assessing the influence of a partner 
alone. Internal consistency was adequate (Partner and GP α =.86; Partner alone 
α= 0.82). We used the Oslo Social Support Scale to measure the extent of social 
support (36). Responses were summed and categorised as poor, moderate or 
strong social support, as recommended (36). Internal consistency was low (α 
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=.56). We also included relationship status (married/cohabiting or not) as the 
third measure. 
Statistical analysis 
Characteristics of users and non-users were compared using chi-square tests for 
categorical variables. Age at the time of the survey was collected further grouped 
into two categories (“64 or less” and “65 or more”). Continuous scale variables 
were summarised using means and standard deviation, and differences between 
users and non-users and males and females tested using the Mann Whitney U test. 
Differences between categorical variables in users and non-users were tested 
using chi square tests. We then developed a multivariable model for factors 
associated with uptake. This was done in three stages. In stage 1 we established a 
“base model” of socio-demographic factors. Candidate variables for inclusion in 
this model were socio-demographic factors  previously shown to be associated 
with uptake of FIT or FOBT  both in this population and elsewhere (20,37) (i.e. 
age, sex and deprivation) and other available  demographic and health variables 
(education, employment status, medical card status, private health insurance, 
smoking status and self-rated health). These were each tested individually for 
associations with uptake and those which were significant were fitted 
simultaneously. Variables which remained significant (likelihood ratio p <0.05) 
when mutually adjusted were retained in the base model. In stage 2 we fitted 
three separate blocks of explanatory variables (Block 1; cancer knowledge and 
health literacy, Block 2; beliefs and emotions and Block 3; social influences) to 
the base model. Within each block, individual variables were added to the base 
model separately. In stage 3, variables which were significant in stage 2 were 
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added to the base model to build the final multivariable model. Variables were 
included in the final multivariable model if the p value from the associated 
likelihood ratio test (LRT) was <0.05, and the variable was not collinear with 
another in the model.  Akaike information criterions (AIC) and Bayesian 
information criterions (BIC) were used to inform choice of variables in the final 
model.   The final model had adequate fit, based on the Hosmer & Lemeshow 
test. Variance inflation factors and tolerance of the final model were above 0.1 
and less than 10 (38). We then tested for interaction between sex and the 
explanatory variables which remained in the final model by fitting cross-product 
terms, one at a time. We also re-ran the final model after stratifying the dataset by 
sex. All analysis was carried out using Stata 14.  
6.4 Results 
Response rates 
Of the 7476 individuals invited to participate in the study, 31% (n=2299; males, 
n=1198; females, n=1101) returned a completed questionnaire. The response rate 
among FIT screening users was 53% (n=1988; males, n=1014(55%); females, 
n=974 (51%): P=0.139) and non-users was 8% (n=311; males, n=184 (10%); 
females, n=127 (7%): P<0.001)  
Stage 1: Base model 
There was a significantly greater proportion of male non-users compared to 
female non-users (males: 59% vs females: 41%; P=0.007). Compared to users, 
significantly greater proportions of non-users were resident in more deprived 
areas (52% of non-users were resident in the very disadvantaged and 
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disadvantaged areas compared to 35% of users; P<0.001), and a significantly 
greater proportion of non-users were aged under 64 (<=64: 60% of non-users vs 
49% of users; P<0.001) (Supplementary table 3.1). No other factors (education, 
employment status, medical card status, private health insurance, smoking status 
and self-rated health; data not shown) differed significantly between users and 
non-users. 
Three socio-demographic variables were significantly associated with uptake, 
once mutually adjusted - sex (OR males: 0.68; 95% CI 0.53-0.87; P=0.002), 
deprivation (Test of trend for increasing affluence, OR: 1.47; 95% CI 1.28-1.69; 
P<0.001) and age group (OR 1.01; 95% CI 1.00-1.01; P<0.001). These comprised 
the base model.  
Stage 2: Univariable associations and minimally adjusted models 
Block 1: Knowledge and health literacy 
In univariate analyses, knowledge and health literacy variables did not differ by 
uptake status overall. However this masked significantly higher proportions of 
inadequate health literacy among female non-users compared to female users 
(Supplementary table 3.1).  
Knowledge or health literacy did not influence uptake when fitted separately to 
the base model (Table 4.1).  
Block 2: Beliefs and emotions   
In univariate analyses, for measures of beliefs about cancer, higher proportions of 
non-users disagreed with two positive statements and higher proportions of non-
users agreed with all negative statements (supplementary Table 3.1). Cancer 
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fatalism was also significantly higher among non-users (mean 4.15; SD= 3.07) 
compared to users (2.90; SD=3.81: P<0.001) (Supplementary Table 3.2). There 
were no differences between non-users and users in fear related to cancer 
(cognitive, affective or psychobiologic). In relation to emotional attitudes to the 
FIT test non-users had significantly higher mean scores indicating more negative 
emotional attitudes to screening (Supplementary Table 3.2).  
When fitted individually to the base model, five beliefs about cancer influenced 
uptake. There were significantly lower odds of participation if in disagreement 
with two positive statements (“These days many people with cancer can continue 
with normal activities” (47% lower) and “cancer can often be cured” (50% 
lower)) and significantly higher odds of participation if in disagreement with all 
three negative statements (“the treatment is often worse” (40% higher),“they 
would not want to know if they had cancer” (66% higher) and “cancer is a death 
sentence” (47% higher)) (Table 1). For each unit increment in cancer fatalism the 
odds of participation decreased by 9% when fitted to the minimally adjusted base 
model.  
Those with stronger negative emotions related to screening had significantly 
lower odds of participation in the minimally adjusted base model with a 16% 
decrease per unit increase in negative emotional attitudes (Table 4.1).  
Block 3: Social Influence 
In univariate analyses, there was a significant difference in the influence of a 
partner (or partner and GP (data not shown)) on the decision to be screened with 
higher mean scores (i.e. stronger partner influence) among users compared to 
non-users (Supplementary Table 3.2).  
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When added to the base-model, relationship status was significantly associated 
with non-use among those who were not in a co-habiting relationship (32% lower 
odds of participation). The social influence of a partner scale also influenced 
uptake in the minimally adjusted base model with each unit increase in the 
influence of a partner resulting in a 30% increase in the odds of participation 
(Table 4.1). The Oslo Social Support scale was non-significant.  
Stage 3: Final multivariable model 
The variables in the final model were sex, deprivation, fatalism, emotional 
attitudes to screening, influence of a partner and a term representing an 
interaction between the belief that cancer can be cured and age (Table 4.2). 
The odds of screening uptake were 40% lower in males than females (OR 0.58: 
95% CI 0.43-0.79; P<0.001) (Table 4.2). The odds increased by 30% for each 
unit increment in affluence (test of trend OR, 1.30: 95% CI 1.10-1.53; P=0.002).  
For each one unit increase in cancer fatalism score the odds of uptake decreased 
by 6% (test of trend OR, 0.94: 95% CI 0.90-0.98; P=0.003). For the composite 
variable of age and the negative cancer belief that “cancer can often be cured”, 
compared with those aged 64 or less who agreed with the statement, there was a 
66% lower odds of participation only among those aged 64 or less who disagreed 
with the statement (OR, 0.45: 95% CI 0.24-0.84; P=0.019). With the inclusion of 
this factor co-linearity with the fatalism index did not destabilise the model. 
Stronger negative emotions about screening were significantly associated with 
lower uptake with a 17% decrease in the odds of uptake for each unit increase in 
negative emotional attitudes to screening (test of trend OR, 0.83: 95% CI 0.80-
0.87: P<0.001). In addition, for each one unit increase in the influence of a 
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partner (social influence), the odds of uptake increased by 37% (OR 1.37; 95% CI 
1.20-1.57; P<0.001). 
Secondary analysis: factors associated with uptake by sex 
When the final model was stratified by sex, the association between uptake and 
affluence was somewhat stronger in females than males (43% in females and 20% 
in males for each unit increase in affluence) (Table 4.3). The estimates for partner 
influence was slightly greater in males than females but the interaction with sex 
was non-significant (Influence of a partner*sex; p (interaction) = 0.996). The 
strength of the association with negative emotions and uptake was similar in 
males and females, and the test of interaction was not significant (Screening 
emotions*sex; p (interaction) = 0.643). Cancer fatalism was also similar in males 
and females when stratified and the test of interaction was not significant (cancer 
fatalism*sex; p (interaction) =0.859).  The estimate of the odds of participation in 
males aged 64 or less who disagreed that “cancer can often be cured” decreased 
slightly in males, however there was no significant interaction between the 
composite variable and sex (Age & Belief cancer can be cured*sex; p 
(interaction) =0.0.384). 
6.5 Discussion 
Screening uptake for colorectal cancer is relatively low in most (if not all) 
settings (19) and often below levels achieved in other established population 
based cancer screening programmes  (21). We conducted this study to inform the 
development of strategies to improve uptake of FIT-based colorectal cancer 
screening and, indeed, our study presents new evidence on factors influencing 
FIT-based screening uptake. Weller et al have pointed to the need to focus on 
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areas of uncertainty and unrealised potential, while taking into account the 
complexity of factors associated with screening uptake (15).  In this regard 
obtaining data on such a hard to reach group is of great value in attempting to 
understand low uptake and this is enhanced through the verification of 
participation through screening records as opposed to self-reported screening. In 
attempting to understand what factors may be a focus for interventions aimed at 
increasing uptake our study marks a starting point for FIT based interventions. 
Our study shows significantly lower uptake among those with more negative 
beliefs about cancer (in particular fatalistic beliefs), and among those with more 
negative emotional attitudes towards FIT-based screening. In addition the 
influence of a partner on ones decision to be screened increases uptake.    
As far as we are aware this is one of the first studies to examine the relationship 
between beliefs and emotions related to FIT-based cancer screening. Younger 
participants who disagreed that “cancer can often be cured” were less likely to 
take part in FIT based screening, but this was not seen in older people. Although 
five of the six negative beliefs remained in the minimally adjusted models only 
the statement “cancer can often be cured” remained in the final model. This 
focuses attention on those with negative beliefs about cancer and, in particular, 
those who disbelieve that “cancer can often be cured” require particular attention, 
especially in view of the fact that colorectal cancer is a highly treatable disease if 
detected early, which is (of course) one of the aims of screening (10). While this 
belief is similar to holding fatalistic beliefs about cancer we choose to keep this 
factor in our final model. As part of a broader set of beliefs about cancer 
disagreement with the specific belief “cancer can often be cured” may represent a 
specific belief held among non-users particularly in relation to concepts of 
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destiny and personal agency (39). The decision to keep this belief in the final 
model is further strengthened by the fact that co-linearity between this belief and 
the fatalism index did not destabilise the final model. Further investigation would 
be useful on this specific view in terms of its influence on uptake and how it may 
operate differently to fatalistic beliefs in non-use of screening.  
Fatalistic beliefs about cancer  have been found to be a factor in late stage 
presentation of colorectal and other cancers (40) as well as a marker of  poor 
uptake in studies of  FOBT colorectal cancer screening (31,41). This study 
extends this evidence and demonstrated that this association also holds for FIT-
based screening. Drew et al have suggested that fatalism (defined as a belief in a 
lack of personal power or control over destiny or fate) constitutes a major barrier 
to participation in positive health behaviours, adversely affecting health 
outcomes, and that fatalistic ideas are potentially located within communities in 
economically resource constrained or more deprived conditions (42). Our study 
may well support this assumption being based in a highly deprived geographical 
area; moreover, our final model was adjusted for deprivation, so the observed 
effect of fatalism is independent of this. Von Wagner et al have pointed out that 
ill health and premature death are more common among lower socio-economic 
groups and may lead these groups  to experience a greater sense of fatalism as a 
result of cancer diagnosis (43). Cancer fatalism is not well understood and studies 
often measure the construct differently (40,41,44). While some studies have 
reported some level of success in decreasing fatalism (45,46) little is known about 
how fatalism can be a focus of behavioural interventions aimed at increasing 
screening uptake (46,47). While deprivation did not attenuate the relationship 
between uptake and gender it would be useful to extend our analysis through the 
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use of mediation analysis and structural equation modelling to explore the extent 
to which beliefs may explain a potential association between deprivation and 
uptake.  
A recent study among a FOBT screening population has shown that intent to take 
part in screening is lower among those with high emotional barriers and lower 
levels of education  (48). Our study confirms and extends these findings by 
showing that these negative emotions are a barrier to actual uptake, rather than 
just intent, as we have verified participation through screening records.   
While negative beliefs and emotions centring on the screening test, and on cancer 
itself, were associated with screening participation, we did not find evidence of 
differences in males and females in terms of the influence of these factors. This is 
at odds with our previous qualitative work. A possible explanation is that the 
negative emotions themselves may not be driving screening decisions, but rather 
they are driven by how people process information that presents a risk to their 
health, and this processing may be different in males and females. Recent 
research has provided some insight into how individuals may process risk 
information defensively, such as opting out at a behavioural or informational 
level, blunting, suppressing or counter arguing against such information (49,50). 
It has been reported also that substantial and important differences exist between 
knowledge, attitudes and defensive processing (primarily related to numeracy; a 
factor related to health literacy) (32). McQueen et al report that males in their 
study examining patterns of association with  defensive information processing 
about colorectal cancer screening had significantly higher mean defence scores 
than females (49). This may be an explanation for why males are significantly 
less likely to participate in screening. Further research would be valuable to 
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investigate the role of defensive information processing in FIT-based screening 
uptake, particularly in terms of the observed associations between negative 
beliefs and uptake and whether its influence varies in men and women. To this 
end we have also collected data on Defensive Information Processing and plan to 
carry out this analysis in the very near future.  
Marital status has been noted as a key influence on individual’s health and health 
behaviours (51,52). A recent systematic review reported that the positive 
influence of a partner is the most common facilitator to health screening for males 
(53). It has also been reported that intention to be screened for colorectal cancer is 
stronger among married individuals compared to non-married individuals (54). 
We have also found that the influence of a partner on decision to be screened is a 
key influence on decision to take part in colorectal cancer screening using FIT. 
Elsewhere marital status and a member of the opposite sex have been shown to be 
a strong influence on men’s decisions to seek health care (55). Within our 
stratified model, while significant in both sexes, the effect of the influence of a 
partner was greater in males than females. Jaarsveld et al have reported that 
inviting the two partners together for colorectal cancer screening increased 
attendance rates in both males and females (54). It would be useful to examine 
the effect of inviting partners together as this may have a beneficial effect on FIT-
based screening uptake, especially among males (19). Therefore it may be useful 
for screening programmes to design their invitation strategies in relation to 
households. This aside, those who are not in a relationship have significantly 
lower uptake and this group warrants particular attention.  
We found no evidence that either cancer knowledge or health literacy influences 
uptake of FIT in our population, a finding that is counter to other colorectal 
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cancer screening uptake research (56,57). However our results may well be null 
due to how we have measured health literacy. Although the measure we have 
used to determine inadequate health literacy has been validated elsewhere (among 
veterans and patients attending a primary care clinic in the US) it may not have 
applied well to our screening population. Using a single item question to gauge 
inadequate health literacy may lack sufficient sensitivity. It would be useful to 
use a more extensive measure in future. Given that  health literacy is associated 
with education and socio-economic status (41,43,58), another possible 
explanation for our null result might be the generally deprived nature of the study 
population; it is possible that we may not have had sufficient discrimination in 
levels of health literacy within the study population to find differences. We 
measured knowledge of others with cancer or bowel cancer (23,59) to assess if 
this had any effect on uptake and found this did not influence uptake. Future 
studies will likely benefit from a broader investigation of cancer knowledge. 
As far as we are aware, this is the first study to examine the relationship between 
beliefs and emotions related to FIT-based cancer screening.  It is also one of the 
few studies to verify screening status using screening programme records rather 
than self-report. A limitation of the study is the low response rate of screening 
non-participants (8%). As our interest was in understanding reasons for non-
uptake, we aimed to maximise the numbers of screening non-users responding to 
the survey. We therefore utilised the entirety of the sample of non-users and 
selected at random an equal number of users (based on sex). Given the response 
rate, it is likely that those non-users who took part are a selected group. However, 
analyses of associations between age, deprivation and sex and uptake in the 
survey responders produced identical patterns (and very similar risk estimates) as 
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when the entire screening programme dataset was analysed (20), which is 
reassuring. Nevertheless the low non-user response rate highlights the difficulties 
of involving hard-to-reach groups in screening research. Waller et have recently 
reported the heterogeneity of  female non-participants of cervical cancer 
screening in the Britain, 28% of whom were unaware of screening and 15% of 
whom had decided not to attend (60). This would be a useful exercise to repeat in 
Ireland’s colorectal cancer screening population.    
6.6 Conclusion 
Overall our study suggests that, after adjusting for socio-demographic influences, 
key barriers to uptake in FIT based screening include fatalistic and negative 
beliefs about cancer and negative emotional attitudes to the screening test; in 
contrast influence of a partner appears facilitate use. Future research needs to 
investigate influences on uptake among those not in cohabiting relationships and 
if negative beliefs and emotional attitudes to cancer and screening are modifiable 
in terms of designing interventions to improving uptake.  
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Table 4.1: Absolute uptake by participant characteristics (numbers and %) and 
univariable and adjusted odds ratios (OR) for participation in FIT-based colorectal 
cancer screening with 95% confidence intervals and p values 
  Total   Users    Adjusted model*    
  N   N %   OR 95% CI P 
           Base model* 
         Sex 
         Female 1,101 
 
974 88.5 
 
- - - 
 Male 1,198 
 
1014 84.6 
 
0.68 0.53 0.87 0.002 
          Age 
         <65 1133 
 
950 83.9 
 
- - - 
 65+ 1126 
 
1002 89.0 
 
1.01 1.00 1.01 <0.001 
          Deprivation 
         Very disadvantaged 206 
 
161 78.2 
 
- - - 
 Disadvantaged 640 
 
524 81.9 
 
1.17 0.79 1.74 
 Marginally below average 1156 
 
1034 89.5 
 
2.22 1.51 3.27 
 Marginally above average 241 
 
218 90.5 
 
2.57 1.49 4.44 
 Affluent 56 
 
51 91.1 
 
2.67 1.00 7.13 
 Test of trend** 
     
1.47 1.28 1.69 <0.001 
          Block 1***; Knowledge and health literacy 
                  Health literacy 
         Adequate 1486 
 
1300 87.5 
 
- - - 
 Inadequate 753 
 
638 84.7 
 
0.84 0.65 1.09 0.191 
          Knowledge of others with CRC 
         No 1499 
 
1307 87.2 
 
- - - 
 Yes 733 
 
624 85.1 
 
1.13 0.84 1.53 0.425 
          Knowledge of others with cancer 
         No 437 
 
374 85.6 
 
- - - 
 Yes 1805   1564 86.7   0.84 0.65 1.09 0.185 
*Mutually adjusted for sex, age and 
deprivation 
        ** linear trend across categories 
         ***Separately adjusted for sex, age and deprivation 
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Table 4.1 continued…. 
  Total   Users    Adjusted model   
  N   N %   OR 95% CI P 
Block 2***; Beliefs and 
emotions 
         Positive belief: People with cancer can continue with normal activity 
    Agree 2033 
 
1775 87.3 
 
- - - 
 Disagree 148 
 
113 76.4 
 
0.53 0.35 0.79 0.004 
          Positive belief: Cancer can often be cured 
        Agree 2012 
 
1757 87.3 
 
- - - 
 Disagree 112 
 
85 75.9 
 
0.50 0.31 0.79 0.005 
          Positive belief: Going to doctor as quickly as possible increases survival chance 
  Agree 2103 
 
1822 86.6 
 
- - - 
 Disagree 85 
 
74 87.1 
 
1.10 0.57 2.11 0.784 
          Negative belief: Treatment worse than  the cancer 
      Agree 1128 
 
960 85.1 
 
- - - 
 Disagree 995 
 
881 88.5 
 
1.40 1.08 1.83 0.011 
          Negative belief: Would not want to know I have cancer 
      Agree 244 
 
196 80.3 
 
- - - 
 Disagree 1913 
 
1674 87.5 
 
1.66 1.16 2.35 0.007 
          Negative belief: Cancer diagnosis is death sentence 
      Agree 460 
 
378 82.2 
 
- - - 
 Disagree 1726 
 
1516 87.8 
 
1.47 1.10 1.95 0.010 
          Cancer Fatalism inventory 
         User 1948 
  
86.9 
 
- - - 
 Non-User 293 
  
13.1 
 
0.91 0.87 0.94 0.000 
          Fear: Cognitive: Cancer is greatest health fear 
      Strongly / agree 1356 
 
1167 86.1 
 
- - - 
 Uncertain 483 
 
420 87.0 
 
1.10 0.81 1.51 
 Strongly / disagree 342 
 
302 88.3 
 
1.15 0.79 1.66 0.395 
          Fear: Affective : Worry about cancer 
        Strongly / agree 885 
 
758 85.7 
 
- - - 
 Uncertain 453 
 
401 88.5 
 
1.30 0.91 1.84 
 Strongly / disagree 836 
 
725 86.7 
 
1.06 0.80 1.41 0.649 
          Fear: Psychobiologic: Discomfort thinking about cancer 
      Strongly / agree 1161 
 
989 85.2 
 
- - - 
 Uncertain 442 
 
387 87.6 
 
1.21 0.87 1.69 
 Strongly / disagree 576 
 
511 88.7 
 
1.34 0.98 1.82 0.052 
          Emotional attitudes to screening scale 
        Users 1940 
  
87.2 
 
- - - 
 Non-users 285 
  
12.8 
 
0.84 0.80 0.87 0.000 
          Block 3***; Social Influences 
         Relationship status 
         Co-habiting 1720 
 
1508 87.7 
 
- - - 
 Not co-habiting 556 
 
465 83.6 
 
0.68 0.52 0.90 0.009 
          Social Support 
         Poor 228 
 
193 84.7 
 
- - - 
 Moderate 957 
 
828 86.5 
 
1.26 0.84 1.91 
 Strong 1066 
 
928 87.1 
 
1.33 0.88 2.00 
 Test of trend 
     
1.12 0.93 1.34 0.246 
          Social influence of partner 
         Users 1769 
  
86.7 
 
- - - 
 Non-users 272     13.3   1.30 1.16 1.46 0.000 
***Separately adjusted for sex, age and deprivation 
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Table 4.2: Multivariable odds ratios (OR) for participation in FIT-based colorectal 
cancer screening with 95% confidence intervals and p values 
  Multivariable  95 % CI P 
  OR       
Sex 
    Female 1.00 - - 
 Male 0.58 0.43 0.80 <0.001 
     Deprivation  
    Very disadvantaged 1.00 - - 
 Disadvantaged 1.12 0.70 1.79 
 Marginally below average 1.93 1.22 3.06 
 Marginally above average 1.65 0.90 3.03 
 Affluent 1.80 0.59 5.50 
 Trend 1.30 1.10 1.53 0.002 
     Cancer fatalism Inventory 
    1 unit increase in fatalistic 
beliefs 0.94 0.90 0.98 0.003 
     Age & Belief cancer can be cured 
   0-64 Agree 1.00 - - 
 65+ Agree 1.26 0.94 1.71 
 0-64 Disagree 0.45 0.24 0.84 
 65+ Disagree 0.92 0.36 2.35 0.019 
     Emotion attitudes to screening 
   1 unit increase in negative 
screening emotions 0.83 0.8 0.87 <0.001 
     Influence of partner 
    1 unit increase in influence 
of partner 1.37 1.2 1.57 <0.001 
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Table 4.3: Absolute uptake by gender with the final multivariable model of odds ratios (OR) for participation in FIT-based colorectal cancer 
screening with 95% confidence intervals and p values stratified by sex 
  Males   Females 
 
Total Users  
 
Multivariable  95 % CI P 
 
Total Users  
 
Multivariable  95 % CI P 
  N N %   OR         N N %   OR       
Deprivation index 
                 Very disadvantaged 107 82 76.6 
 
- - - 
  
99 79 79.8 
 
- - - 
 Disadvantaged 314 257 81.9 
 
1.61 0.85 3.05 
  
326 267 81.9 
 
0.77 0.37 1.60 
 Marginally below average 616 532 86.4 
 
1.88 1.04 3.38 
  
540 502 93.0 
 
2.06 0.97 4.37 
 Marginally above average 129 113 87.6 
 
1.39 0.65 2.97 
  
112 105 93.8 
 
2.35 0.81 6.78 
 Affluent 32 30 93.8 
 
5.70 0.71 45.50 
  
24 21 87.5 
 
0.62 0.15 2.59 
 Total/ Trend 1198 1014 84.6 
 
1.20 0.97 1.49 0.092 
 
1101 974 88.5 
 
1.43 1.10 1.86 0.007 
                  Cancer fatalism Inventory* 
                 1 unit increase in fatalistic beliefs 1,178 1000 84.9 
 
0.93 0.88 0.98 0.013 
 
1063 948 89.2 
 
0.95 0.89 1.01 0.088 
                  Age & Belief cancer can be cured* 
                 64 or less Agree 477 406 85.1 
 
- - - 
  
502 430 85.7 
 
- - - 
 65+ Agree 42 27 64.3 
 
1.01 0.68 1.49 
  
27 21 77.8 
 
1.76 1.08 2.87 
 64 or less Disagree 555 478 86.1 
 
0.40 0.18 0.90 
  
445 412 92.6 
 
0.54 0.19 1.55 
 65+ Disagree 21 18 85.7 
 
0.92 0.25 3.43 0.176 
 
20 17 85.0 
 
0.95 0.25 3.59 0.055 
                  Negative screening emotions scale* 
                1 unit increase in negative screening 
emotions 1164 996 85.6 
 
0.82 0.77 0.87 0.000 
 
1061 944 89.0 
 
0.85 0.79 0.91 0.000 
                  Influence of partner* 
                 1 unit increase in influence of partner 1,100 937 85.2 
 
1.49 1.23 1.80 0.000 
 
941 832 88.4 
 
1.28 1.06 1.53 0.009 
                  
*Interactions with sex: cancer fatalism*sex; p (interaction) =0.85; Age & Belief cancer can be cured*sex; p (interaction) =0.384; Screening emotions*sex; p (interaction) 
= 0.643;  (Influence of a partner*sex; p (interaction) = 0.996)  
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The aim of this PhD project was to investigate uptake in FIT based colorectal cancer 
screening and to compare and contrast factors associated with use or non-use of FIT 
in males and females in Ireland. The use of a number of different methods - as part 
of a single project - has allowed new insights into uptake of FIT-based colorectal 
cancer screening. Analysis of Ireland’s population based cancer registry data on 
colorectal cancer, a systematic review and meta-analysis, secondary analysis of a 
FIT population based screening dataset, qualitative in-depth interviews, and a large 
quantitative cross-sectional survey has provided valuable new evidence. Firstly, the 
work has established that colorectal cancer screening uptake is poor in Ireland (as in 
many settings internationally) and that there are inequalities in uptake, not only by 
gender (which was the primary focus of this thesis) but also by deprivation and age. 
Secondly, the work has identified that uptake is influenced by certain individual 
beliefs and attitudes, some of which may vary between men and women. This final 
chapter summarises and synthesizes the main findings, and the strengths and 
limitations of the project. Future areas of research and consideration of the 
implications of the work are discussed and a brief conclusion is presented.  
 
7.1 Summary and synthesis of main findings    
In Chapter 2, data from the National Cancer Registry was used to describe the 
epidemiology of colorectal cancer in Ireland from 1994-2010, prior to the 
introduction of the national screening programme, BowelScreen. Although 
increasing incidence of the disease was observed (mainly due to a growing 
population over the period) there was no increase in the age-standardised rates of the 
disease, consistent with stabilisation of the rates in economically developed 
countries (1). Importantly the case fractions of late stage colon and rectal cancer 
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increased over time, but 1 and 5 year survival also rose significantly over time, 
likely due to advances in staging, diagnostic work-up and treatment of the disease, 
which has observed here and elsewhere (2–4). While age-standardised mortality 
rates for colorectal cancer overall decreased by 1.8% annually, rectal cancer 
mortality rates rose in both males and females.  
 
These trends indicated the need for an efficient and timely roll out of a National 
Colorectal Cancer Screening Programme (BowelScreen). However BowelScreen 
began roll-out using a narrow age range and the first round took longer than initially 
planned (5). It is unlikely that the full extent of potential benefits from the screening 
programme, such as altering the stage distribution of the disease and reducing 
incidence and mortality in the population, will be achieved.  
 
Uptake of colorectal cancer screening differs by test modality with invasive 
endoscopic based screening studies often reporting lower female uptake. The 
systematic review and meta-analysis in Chapter 3 provides evidence of low uptake 
overall, and significantly lower uptake among males than females, in non-invasive 
FIT-based colorectal cancer screening programmes internationally. 19 studies were 
included in the review; these revealed that, on average, uptake was 44% (95% CI 
43.9%-44.2%) internationally and this was slightly lower when excluding non-
population based studies (43%; 95% CI; 42.4%-42.8%). Random effects meta-
analysis revealed males were 16% (95% CI0.75-0.95: P<0.001) less likely to 
participate in FIT based colorectal cancer screening, and this was statistically 
significant. Lower uptake in males persisted across subgroup analyses by study 
design, study setting, and screening organisation factors (methods of invitation, 
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number of samples, age-range of screening, recommendations and reminders). This 
study provided – for the first time – clear and comprehensive evidence of the 
disparity in uptake of FIT-based colorectal cancer screening in males and indicated 
that this disparity is not as a result of programme design or organisational factors. 
This demonstrated that there is a need to seek explanations for lower uptake among 
males, and indeed lower uptake overall. 
 
Following from this, the next step was to identify levels of uptake of FIT-based 
screening in Ireland, and whether these varied by sex after other socio-demographic 
factors often related to uptake are taken into account. The Tallaght/ Trinity College 
Colorectal Cancer Screening Programme (TTC-CRC-SP) was a biennial population-
based FIT screening programme conducted over two rounds during the periods 
2008-2010 and 2011-2012 and prior to the introduction of national screening. 
Having accessed the TTC-CRC-SP for the qualitative study we investigated the 
effect of sex, age and deprivation status on uptake within the entire population of the 
screening programme and this is reported in chapter 5. The National Cancer Registry 
geo-coded individual’s addresses allowing a deprivation index (and category) to be 
assigned to each person. Overall uptake was 60% over the two rounds of the study. 
The results show that participation was significantly lower in males (multivariable 
RR=0.96: 95%CI 0.95-0.97) and generally increased with increasing age. The 
conversion of the odds ratio reported in the systematic review to a relative risk also 
shows that our results are largely in line with international studies on FIT based 
uptake.  In addition deprivation was strongly associated with participation with a 
26% difference in uptake (multivariable RR=1.26: 95% CI 1.21-1.30) between those 
in the most deprived areas compared to those in the most affluent areas. The effect 
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of sex on uptake was not moderated when adjusted for deprivation or age providing 
new evidence that sex is an independent predictor of uptake in Ireland, as well as 
providing evidence for the first time in Ireland that deprivation is also an 
independent predictor of uptake.   
 
The final two elements of the PhD sought to identify and investigate what influences 
uptake and to determine whether these vary in men and women. Chapter 4 follows 
on from the systematic review in investigating factors associated with low uptake in 
males and females. By accessing a stratified sample (male and female users and 
male and female non-users) within the TTC-CRC-SP we were able to explore 
influences on individuals decisions associated with uptake through qualitative 
methods. Employing the Theoretical Domains Framework (TDF) as a means of 
guiding the design and analysis of the study, 47 people, 19 (10 males and 9 females) 
of whom were screening non-users, took part in an in-depth semi-structured 
interview. The study is the first to provided valuable in-depth data regarding what 
influences people’s decisions to take part, or not, in FIT-based population-based 
screening. The TDF is increasingly being recognised as a leading framework for the 
identification of influences on behaviour and this study was the first to use it as a 
means of understanding what influences individuals to participate in colorectal 
cancer screening.  
 
Six TDF domains were identified as influencing interviewees’ decisions on 
participation in FIT-based screening: ‘environmental context and resources’, ‘beliefs 
about capabilities’, ‘beliefs about consequences’, ‘social influences’, ‘emotions’ and 
‘knowledge’. Crucially, while evident in both users and non-users, these domains 
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did not all influence uptake in the same way in males and females. Negative 
attitudes and emotions towards screening and cancer dominated non-user decision-
making but differed by gender. Fatalism was particularly evident in male non-users 
while female non-users had particularly negative emotions towards colorectal cancer 
screening including disgust, anger and fear. Fear was also evident among males but 
acted as a catalyst in users and an impediment in non-users. Social influences on 
decision to take part in screening, such as the influence of a partner, were strong in 
male users (less so in male non-users) but other influences among female non-users 
(other family members and lack of influence of GP) negatively impacted on 
participation. Knowledge also differed with male non-users having poor colorectal 
cancer knowledge, often not knowing of others with cancer, in contrast to both male 
and female users. Female non-users often believed that they did not need to take part 
in screening because they had no family history of colorectal cancer, or indeed any 
symptoms of the disease.  
 
The final study investigated whether the potential influences on screening uptake 
identified in the qualitative study were associated with uptake at the population-
level. For this a quantitative study was designed and this is described in chapter 6. 
We carried out a cross-sectional survey sampling 7476 individuals (with equal 
numbers of users and non-users) in the TC-CRC-SP database in the latter half of 
2016. We achieved a 31% response rate overall (n=2299); 53% among users and 8% 
among non-users. In this analysis we focused on three areas; i) colorectal cancer 
knowledge and health literacy, (ii) beliefs about cancer and emotional attitudes to 
cancer and FIT based screening and (iii) social influences.  In multivariable 
analyses, stronger cancer fatalism and a particular disbelief among younger people 
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that “cancer can often be cured” were independently, and significantly, associated 
with lower uptake. Those with stronger negative emotional attitudes were also 
significantly less likely to take part in screening, while the influence of a partner on 
the decision to be screened was significantly associated with higher uptake. 
However evidence of differences in factors influencing male and female 
participation in screening was not found. The results of this study provide evidence 
of key barriers to uptake in FIT based population-based screening. As far as we are 
aware, this is the first study to examine the relationship between beliefs and 
emotions related to FIT-based cancer screening and for the first time in Ireland 
provides evidence of what may be key barriers to uptake which are potentially 
modifiable and therefore possible targets for intervention development.   
 
7.2 Strengths and limitations 
The strengths and limitations of the individual studies have been discussed in the 
relevant chapters. This section summarise these limitations and provides and 
overview of the limitations of the thesis overall.  
 
The main limitation of this PhD project lies in the population in which the fieldwork 
was conducted, namely Tallaght, a specific large urban town characterised by high 
levels of deprivation within county Dublin. Being urban and more deprived mean 
that our results may not be generalizable to other settings or populations. Given that 
deprivation is associated with uptake we would expect uptake in the TTC-CRC-SP 
to be lower than the national screening programme but this is not the case. The 
pattern of uptake in males and females is similar to that observed in the national 
screening programme. Living in a rural area has been associated with lower uptake 
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of colorectal cancer screening(6) and therefore our study may differ on this basis, 
being primarily urban.  While the TTC-CRC-SP is similar in design to the national 
screening programme several differences do exist. Invited participants in the 
national programme need to make contact to request a screening test kit, while in the 
TTC-CRC-SP the kit was sent with the initial invitation, and one would expect 
higher uptake in the latter instance. In addition the national screening programme 
requires a single sample for a successful test while the TTC-CRC-SP required two 
samples on consecutive days and one would expect lower uptake in the latter 
instance. The TTC-CRC-SP was also endorsed by the invitees GP and this is not the 
case in the national screening programme, however our systematic review would 
suggest that this is not important in terms of differences in male and female uptake.  
However given that this was the first and only population to be provided with free 
FIT based-colorectal cancer screening in Ireland it is nevertheless a valuable 
population in which to assess uptake. 
 
A further potential limitation is that the fieldwork in this thesis was carried out 
among people who had completed screening two years prior to recruitment of 
screening invitees. This may have resulted in difficulty for participants in recalling 
the experiences and decisions they made in relation to taking part in the screening 
programme. However had anticipated this and therefore provided recall aids, both 
within our in-depth interviews (chapter 4) and within the cross-sectional survey 
(chapter 5), which included images of the screening test kit.  
 
Saturation of data was achieved in all but one of the strata within the qualitative 
study sample and this was among male non-users (chapter 4). This was due the 
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difficulty of recruiting non-users in the study. We invited 50 users to achieve 28 user 
participants, while inviting 550 non-users to recruit 19 non-user participants. This 
highlights the difficulty of recruiting non-users in screening uptake research. A €50 
gift voucher was offered as a monetary incentive to participate and we informed 
potential invitees we would reimburse any travel expenses they may incur, although 
we carried out all interviews at participants homes at their request. It is possible that 
if we had succeeded in recruiting greater numbers of non-users, especially among 
males, then we may have identified further domains that potentially influence 
screening uptake. In this regard the influences on non-use in screening in those non-
users who agreed to participate in an interview may well be different from those of 
non-users who did not take part in an interview. The screening population from 
which we drew our sample operated in a specific area of Dublin as described above, 
and this may potentially mean that the identified domains influencing uptake may 
not be generalisable to other settings or populations, for instance in a rural 
population or more or less deprived populations.     
 
As within our study in chapter 6, our population-based cross-sectional survey also 
had a low response rate from screening non-users. While utilising the entire sample 
available to us we had a low response from non-users. Given this low response rate 
it is likely that our sample of non-users are a selected group. However we carried out 
similar analysis of associations between sex, deprivation and age, which was 
employed in our study of the entire screening population in chapter 4, and this 
produced identical risk estimates for uptake and this is reassuring. Once again 
however this highlights the difficulty of recruiting non-users in screening research. 
Issues may also exist in how we measured health literacy in our study. Health 
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literacy has been associated with lower uptake in some colorectal cancer screening 
populations(7–9) and our finding is contrary to those. We used a single item measure 
which has been validated in other populations (among veterans and patients 
attending primary care clinics in the US(10,11)) but it may have lacked sufficient 
sensitivity, or may not work in other settings. We may also have lacked sufficient 
discrimination to detect health literacy differences within our population due to the 
deprived nature of our sample and the fact that  health literacy is associated with 
markers of socio-economic status(12–14).  
Despite the limitations the thesis has several strengths. The fieldwork undertaken 
accessed the only available colorectal cancer screening population in Ireland 
available at the time given the national screening programme had just begun. It 
reports new data on FIT-based colorectal cancer screening which has not been 
reported elsewhere and is relevant to other national screening programmes, 
especially given the increasing move towards FIT as the frontline test in population 
based screening due to its improved sensitivity and practicality. Low uptake 
however is not just an issue for males; as overall uptake of FIT based screening 
seems suboptimal and the thesis reports not just on factor influencing male uptake, 
but also female uptake.  The thesis provides the first review, to the best of our 
knowledge, on international uptake overall and by gender, using FIT-based 
screening. Subsequent studies within the thesis have provided new data on factors 
influencing uptake in FIT-based screening and has identified areas for further 
research aimed at improving uptake. 
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7.3 Implications of Findings  
 
Wardle et el have argued  that any health technology in which uptake is unequal 
across groups runs the risk of creating or widening health inequalities(15). This is 
indeed the issue for colorectal cancer screening in Ireland and elsewhere. FIT is a 
relatively new technology and in Ireland this is the first time an organised 
population-based screening programme has offered a screening test which can be 
carried out at home. Furthermore this is the first time the male population has been 
invited to take part in organised cancer screening. The studies conducted for this 
PhD project point to disparities in uptake by sex. Given the higher colorectal cancer 
incidence and mortality among males, not just in Ireland but worldwide (16), 
tackling low uptake of, and disparities in, public health initiatives such as colorectal 
cancer screening is of vital importance.  
 
However it must be noted that we found consistently smaller differences in uptake 
by gender in comparison to the differences observed with deprivation. Gender based 
relative risk for non-participation among males were always significant (Chapter 3 
converted RR 0.95; Chapter 4 RR 0.96; Chapter 6 converted RR 0.96) yet noticeably 
smaller than the deprivation gradients in uptake (very disadvantaged RR 1.06 
compared to the affluent group RR1.26). 
 
Initially, it was intended that the interviews and survey would have been nested 
within the national programme (and this was agreed with the programme) but delays 
in programme implementation meant this became impossible.  Therefore the studies 
were done within the Tallaght programme instead.  Although that programme took 
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part in a defined area, the studies may still be informative for the national 
programme. The findings of this thesis are now becoming manifest in data from the 
BowelScreen programme, which is just beginning to come into the public domain. 
(5) The recently published first report from the programme revealed that uptake is 
40% (488,628 invited and 196,238 screened); this is considerably below the 
programme target (50-60%) and even below the international average reported in 
our systematic review and meta-analysis. Furthermore uptake in males in the 
national programme is far below that among females (36% vs 44% respectively). 
This also needs to be considered in the context of the detection rates of cancer within 
the programme; male detection rates were almost double that of female rates belying 
the increased risk of the disease among males (5) and the need to improve uptake 
among this group.  
 
In Ireland male colorectal cancer has been positively associated with population 
density (14% higher in the most densely compared to the least densely populated 
areas) and unemployment (11% higher risk in the areas with the highest levels of 
unemployment compared to areas with the lowest levels) (17). The All-Ireland 
Cancer Atlas, which was based on cancer diagnosed between 1995 and 2007, has 
also shown that in areas with the highest proportions of those aged over 75 who live 
alone, the risk of colorectal cancer is 19% higher in females and 10% higher in 
males, compared to areas with the lowest proportion of persons over 75 who live 
alone(17). Analysis of data among our screening population (TTC-CRC-SP survey) 
indicates that overall 24% of our sample were not in cohabiting relationships, but 
among non-users this was higher at 30%, increasing in those aged 59 or less to 46% 
(compared to 20% among users of the same age) and 36% among those aged 70 and 
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over (compared to 29% among users). Our finding that the influence of a partner is 
associated with increased uptake in colorectal cancer screening raises a serious issue 
about those who live alone in Ireland and their participation in colorectal screening. 
This is a not a readily modifiable factor and little research has been carried out in the 
area(18).  
 
A number of interventions have been tested aimed at increasing uptake of colorectal 
cancer screening, most often related to FOBT or endoscopic based tests. Strategies 
to improve uptake vary according to context (healthcare systems, and culture), type 
of test (faecal based or endoscopic tests) and target group (ethnicity, age, gender). In 
spite of this, evidence informing strategies to improve participation in low uptake 
groups is scarce and needs to be built upon (19). Interventions utilising client 
reminders and reduction of structural barriers in colorectal cancer screening have 
proven somewhat efficacious, although only for FOBT screening (20–22). While 
psychological variables are often associated with participation their utility as targets 
within interventions have proven less successful  (22).  Wardle et al have pointed out 
that more needs to be done to understand the social patterning of screening 
participation and to reduce social inequalities in screening (22), while Weller and 
Campbell have recommended strategies that incorporate male perspectives and 
attitudes towards preventative health services in order to overcome gender specific 
barriers to screening (19). 
 
Our work has established a foundation of evidence on FIT-based colorectal cancer 
screening uptake. Although much is still to do, we have a starting point from which 
we can now begin to develop strategies and interventions aimed at improving 
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uptake. While it would seem from our findings that potential interventions should 
focus on negative attitudes and beliefs about cancer and screening there is still much 
data remaining to be analysed, including data relating to defensive information 
processing. Potential interventions could focus and psycho-educational interventions 
or media based campaigns to reduce negative attitudes and beliefs about bowel 
cancer screening. However we are cautious in making recommendations before our 
behaviour change analysis is conducted which will provide us with the opportunity 
to establish stronger evidence on interventions which will potentially increase uptake 
in the national screening programme. It should also be noted that any interventions 
will likely only improve uptake in small incremental increases.   
 
The challenge now is the task of investigating how we can intervene in these 
negative beliefs and attitudes in order to improve uptake. The data collected in this 
thesis provides an opportunity to examine the behaviours of screening users and 
non-users in order to identify behaviours which may be modifiable and therefore 
amenable to the development of interventions to improve uptake. Domains which 
are likely to influence behaviour have been identified and can be targeted by 
relevant behaviour change theories (BCTs). Identification of BCTs can be informed 
by a published matrix which has mapped theoretical domains and behaviour change 
techniques using an expert consensus approach(23). All relevant techniques mapping 
onto the identified theoretical domains can be listed as potential intervention BCTs. 
This process can be performed separately for males and females in relation to the 
key target behaviours.  
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Active stakeholder engagement in this process would ensure that such research 
would address key questions and challenges being faced by stakeholders and would 
inform policy and practice. The process would require the engagement of key 
stakeholders in exploring findings and potential interventions in relation to how to 
operationalise these in order to improve uptake within a screening programme. How 
BCT’s can be targeted through an intervention could be explored in terms of 
operationalising intervention functions within current screening programme 
structures and design. The use of the APEASE criteria could be applied to assess the 
likely; (i) Affordability; (ii) Practicability; (iii) Effectiveness and cost-effectiveness; 
(iv) Acceptability; (v) Side-effects/safety and; (vi) Equity of the selected 
intervention functions(24,25).  
 
The potential to design interventions which will improve uptake in males and 
females, and indeed by deprivation, is now ripe for development given that we have 
a population that has only recently been exposed to national organised population 
based screening. Our findings indicate that fatalism is a key barrier to screening and 
will likely be a factor in any behaviour based intervention aiming to improve uptake. 
While no differences were observed in fatalistic beliefs about screening in males and 
females, there may well be differences in underlying factors through which fatalism 
operates in each gender, which we aim to explore in our future analysis of defensive 
information processing. Therefore it may well be a case that interventions (through 
messages in psycho-educational programmes or media campaigns) need to be 
tailored by gender or indeed at the varying levels of deprivation within communities.  
The planned next stage of this work will seek to establish how males and females 
differ in their attitudes to screening and will seek to understand the underlying 
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mechanism through which individuals, both at the level of gender and deprivation, 
avoid the opportunity to be screened for colorectal cancer.   
  
The work undertaken within this thesis is both warranted and appropriate given the 
roll out of the National colorectal cancer screening programme, BowelScreen. It is 
all the more relevant now given the results of the first round of screening which took 
place while the work in this thesis was being carried out. The National Screening 
Service have reported that uptake in the first round is low (40%) and male uptake 
lower again. Given the higher rates of detection of cancers among males in the first 
round of national screening in Ireland our study has pre-empted the need for action 
in improving uptake of FIT based colorectal cancer screening in the population. At 
the outset of round two of national FIT based screening our study provides valuable 
evidence which the national screening programme can use to begin to tackle low 
uptake, thereby helping to achieve the goals of the programme, in short to reduce 
colorectal cancer incidence, morbidity and mortality from the disease in the 
population.   
The National Screening Service should now begin to examine uptake by gender and 
how findings in this thesis, namely that beliefs about cancer and cancer screening, 
negatively influence participation decisions. Vital also is the need to explore the 
effect of deprivation on uptake nationally and if this moderates gender based uptake 
at the national level. The National Screening Service has already begun to place a 
focus on these findings and have taken note of the importance of this thesis to the 
successful roll out of the national BowelScreen programme. To this end 
BowelScreen has provided some funding to establish the next phase of this study to 
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establish an intervention prototype which aims to improve gender based uptake, 
described above.  
 
7.4 Recommendations for future research 
Chapter 2 identified issues related to increasing rectal cancer mortality in Ireland. 
We suggested that there is potential that this increase, which has not observed in 
most other European countries (26) may be a result of misclassification of colon and 
rectal cancer deaths particularly given the evidence that at least 30% of death 
certificates are likely to be incorrect and 20% of autopsies unexpected findings can 
only be diagnosed by histological examination (27). In addition the potential 
underuse of radiotherapy (particularly preoperative radiotherapy) and the underuse 
of multidisciplinary team meetings in the treatment of rectal cancer may also provide 
an explanation for the rise in mortality.  Further investigation is required to explore 
the extent and nature of misclassifications on death certificates in European 
countries in recent years, comparing countries with rising and static rectal cancers. 
But examination of the underuse use of pre-operative radiotherapy and multi-
disciplinary meetings require further investigation in considering the increase in the 
rates of rectal cancer mortality.  
Given FIT is now recommended as the test of choice in population based screening 
programmes it would be useful to update the systematic review in chapter 3. It is 
likely that more relevant studies of population-based screening have been published. 
The systematic review also suggests further investigation into factors associated with 
participation in FIT based screening.  
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While the systematic review did not find any differences in uptake by sex according 
to the number of samples that are required for a successful test, other authors (28) 
have reported improved uptake through simplification of the sampling strategy (i.e. 
using two rather than three samples). The strategy used in our screening population 
used 2 samples, and within the national screening programme only one sample is 
required. Reported lower uptake in the national screening programme compared 
with the TTC-CRC-SP indicates that perhaps further investigation is required.  
While the work discussed in this thesis has presented evidence on factors influencing 
uptake there is still a need to carry out further investigation. The thesis has identified 
significantly lower uptake in males but was unable to identify what drives these 
uptake differences, despite the identification of factors influencing uptake overall. 
Many other avenues exist in terms of the exploration of factors driving low uptake in 
males but these need to be allied with an exploration of uptake in females also. In 
chapter 4 and 6 we reported that male uptake was significantly lower than female 
uptake and that this was not attenuated by deprivation. However given our studies 
were carried out in a predominantly deprived setting we would suggest a re-
examination of this within the National BowelScreen programme as more complete 
population level deprivation data on screening uptake will be available.  
 In both our qualitative and quantitative cross sectional studies we identified the 
impact of the influence of a partner on screening decisions, especially among males. 
Research examining different household invitation strategies within the national 
screening programme would be useful to determine their impact on uptake. The 
other side of this finding is the fact that those not in cohabiting relationships, or 
living alone are less likely to take part and these present an opportunity for research 
into what barriers exist for this particular group, notwithstanding the difficult of 
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reaching this group in research. We have also identified a small number of male 
participants in our qualitative study who resisted doing the FIT test due to an 
underlying fear of the potential outcome of screening (i.e. a diagnosis of cancer). 
Such issues require further investigation.  
As discussed in the limitations section of this chapter and in chapter 5 and 6, there is 
a need to investigate further the effect of poor health literacy on colorectal cancer 
screening uptake in Ireland’s population. We therefore suggest a broader 
investigation of health literacy in the population, one which takes into account a 
greater range of deprivation classes. This could be carried out within the 
BowelScreen programme upon invitation, but should also investigate potential 
differences in screening information comprehension and subsequent decisions to 
participate in screening.  
As alluded to in the discussion of the findings of the qualitative study (Chapter 4) 
and the cross-sectional study (Chapter 6), the potential importance of the concept of 
defensive information processing and believe this should be a focus of future 
research aimed at investigating potential underlying differences in males and 
females processing of health information. Defensive information processing may 
underlie the findings on negative beliefs and emotional attitudes related to cancer 
and cancer screening and may be a potential avenue for explaining the mechanisms 
by which individuals justify non-use of important public health initiatives aimed at 
improving the health of the population. In addition, this may well provide evidence 
on the potential factors which underlie differences in male uptake. Investigating 
defensive information processing may provide an avenue through which we can 
understand how males and females deny the need to take part in FIT based 
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screening. This is one area of research that would be fruitful in the move towards the 
development of behaviour based interventions to increase uptake of FIT.  
Given the low response rate of non-users and the potential that they are a selected 
group it would be useful to undertake an investigation of non-users in the 
population. This would provide greater insight into the characteristics of non-users 
and the potential reasons for non-use which might provide opportunities to target 
particular groups of non-users who may be more amenable to, or ready for, uptake 
interventions. In the UK the use of omnibus surveys have provided opportunities to 
gauge cervical cancer screening history and future intent to be screened, providing 
valuable data on screening non-users (29). Such research should be considered 
within the Irish context.  
As discussed in the implication section above, future research on the development of 
interventions to improve uptake in males and females should be carried out to 
continue the progress made here on FIT-based colorectal cancer screening. This 
should involve the further analysis of the qualitative and quantitative data collected 
for this thesis and the review of interventions aimed at improving colorectal cancer 
screening uptake. Using relevant behaviour change techniques to identify 
interventions and engaging with stakeholders to ensure key questions and challenges 
are addressed would ensure the development and testing of a replicable intervention 
that illuminates the principles and processes underlying behaviour change within a 
colorectal cancer screening programme. 
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7.6 Conclusion 
This thesis shows that significant disparities in exist in male uptake of FIT-based 
colorectal cancer screening. Furthermore uptake within FIT-based screening 
programmes is low in general which is a cause of concern in relation to the aim of 
population based screening to reduce incidence and mortality from the disease.  
Factors influencing people’s non-use of FIT screening in the population include 
holding negative beliefs about cancer and negative emotional attitudes to the FIT-
based screening test.  FIT-based colorectal cancer screening is a relatively new 
technology and is now the screening test of choice and the marker against which 
new tests should be compared and assessed (30). The complexity of the problem of 
improving uptake should not deter us from seeking solutions through the 
development of interventions aimed at modifying non-users behaviour and attitudes 
to FIT-based screening. The aim of maximising screening uptake to maximise the 
reductions in incidence and mortality can only be achieved by tackling low uptake. 
This thesis has demonstrated the need for interventions aimed at improving uptake 
within FIT-based colorectal screening programmes.  
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Supplementary Table 1.1: Stratified Poisson regression by uptake in various rounds  
      
            Characteristic   Both rounds       Round 1 only       Round 2 only   
  RR 95%CI p   RR 95%CI p   RR 95%CI p 
Gender 
           Female 
    
- - 
     Male 0.87 0.83 - 0.90 0.000 
 
0.81 0.71 - 0.92 0.001 
 
0.92 0.82-1.03 0.142 
            Age 
           0-59 - - - 
 
- - - 
 
- - - 
60-64 1.16 1.09 - 1.23 0.000 
 
0.84 0.71 - 0.99 0.040 
 
0.96 0.83-1.12 0.637 
65-69 1.30 1.22 - 1.38 0.000 
 
0.94 0.79-1.13 0.537 
 
1.14 0.98-1.34 0.086 
70-74 1.20 1.11 - 1.29 0.000 
 
1.02 0.83-1.25 0.874 
 
1.11 0.92-1.33 0.282 
75+ 1.22 1.07 - 1.39 0.002 
 
0.73 0.43-1.22 0.224 
 
1.38 1.02-1.87 0.038 
            Deprivation 
           Very disadvantaged - - - 
 
- - - 
 
- - - 
Disadvantaged 1.35 1.22 - 1.50 0.000 
 
1.11 0.89-1.37 0.348 
 
1.07 0.89-1.29 0.454 
Marginally below average 1.80 1.64 - 1.98 0.000 
 
1.43 1.16-1.76 0.001 
 
1.28 1.07-1.53 0.006 
Marginally above average 1.90 1.70 - 2.11 0.000 
 
1.82 1.40-2.36 0.000 
 
1.37 1.07-1.75 0.011 
Affluent 2.34 2.04 - 2.67 0.000 
 
3.32 2.28-4.83 0.000 
 
2.69 1.92-3.78 0.000 
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Supplementary Figure 1.1: Consort diagram of interviewee recruitment  
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CRC Screening Interview Topic Guide
Tell me a bit about yourself
Live here always? All
Family All
Occupation All
General health/ other conditions All
How often would you attend a GP/ when was the last time you attended A&E All
Exercise/ diet All
Health information and general understanding All
What is your overall feeling about our health system?  Trust? All
First invitation: 
What were your first thoughts on receiving invitation? All
Was this different on second invitation? All
Aware of screening before? Any screening - CRC screening - local/ National screeningAll
Taking test – did you want to? All
Decisions
Why did you decide to do the test? All
Did you make an attempt to do the test? Non-users
Why did you decide not to do the test? Non-users
Others - did you speak or discuss the test with others? All
Do you regret not doing the test - discuss All
Test
How was it – easy/ difficult? All
Confident –  in doing test correctly (self testing vs GP testing) All
Comfortable - Time / sampling/ storage/ smell/ disgust/ information/ 
support/ assistance Users / attempters
What would make test easier? All
Were there other factors that made it difficult? All
Results
How long did it take to get your results?
What was your result? Users
What was it like waiting for the results?
Did you understand the result? Users
Were you confident result was correct?
What impact did the result have on you? Users
Screening - general
Screened before? - Mammogram/ cervical/ breastcheck - PSA - CRC All
How do you find those screening tests? All
Importance of screening you've taken part in? All
Importance of screening in general? All
What do you feel the purpose of screening is in general?
Bowel cancer
Experiences of bowel cancer (BC) All
Causes of BC All
Treatment for BC - effective/ ineffective All
Whos at risk of BC All
Your risk of BC All
Finally  
Men are less likely to be screened - why do you think this is? All
Finally - Will you  take part in the national screening programme, 
BowelScreen? All
Is there anything you'd like to add which we haven't discussed? All
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Domain Female users Male users
My paternal grandmother had it [colorectal cancer], and she was very bad, she ended up 
with a colostomy bag, which I just think is the most hideous thing in the world, myself. And 
she died a bad death, shall we say, so that certainly sticks in my mind. (P-10)
But I had a brother died of colon cancer, so the family took a bit of an interest then. 
Because we have a niece in England who kind of pushes a little bit, like, “You need to get 
this done.” So she got her dad, a brother of mine, to do it – he’s sadly passed away since. 
So there's an interest there and an interest to follow up alright, yeah. (P-31)
She had bowel cancer. Well, her bowel burst, actually, she’s lucky to be alive. I thought, oh 
no, I need to get this done, because there’s slight changes, do you know (P-9)
And certainly in light of the two guys, friends of mine who are in trouble now. So I would 
certainly be very conscious of it.  (P-28)
Yeah, because they give you instructions. But the instructions, you know, you have to poo 
on a piece of paper. It might just go down the loo. You are not going to be fishing it out. (P-
1)
 Easy to do, easy to do. Once you follow the… As I said, they explained the test really well. 
If you followed what they’d said, you’d no problem, no problem whatsoever. It was easy to 
understand. (P-27)
I’d think it would probably be more effective if it was maybe on a disc or a dish rather than, 
do you know, like… you know the way the screening is done, is like a swab, a tiny, tiny 
swab, and I think… I know, talking to people - I didn’t have a problem because I would be 
got back to presumably if it hadn’t been successful (P-5)
That’s not a problem, you have your own bathroom, you have your privacy, you do it all, seal 
it up, bring it down in a package. It’s not a problem, it’s so easy. (P-31)
No problem, no problem.  Like, well, you know, my attitude is if you have to do something 
you’ll find a way to make it easy for yourself kind of, you know what I mean.(P-4)
Oh it’s no problem, you just do it. I mean, maybe it’s a bit embarrassing given the nature of 
what you are doing, but it’s not really, because you do it privately....//Normally, doing 
anything like that I’d be conscientious enough about reading instructions. I don’t like to do 
things just, like, willy-nilly, you know. (P-36)
Well, I thought so. I mean, it’s pretty simple to do, just take the little stick and… 
[Laughter] . It’s not exactly rocket science. [Laughter ]. (P-7)
Yeah. I did exactly what I was asked to do, yeah....// It was easy enough, yeah. Yeah, you 
just prepare whatever you have to do upstairs and do it, yeah. (P-32)
But I always feel that if you had to get a cancer, it wouldn’t be one of the worst 
[colorectal cancer] , because it is treatable, and if it’s caught in time I think you have a 
better chance than you have if you got pancreatic cancer. I’d prefer to be told I had bowel 
cancer than pancreatic cancer. (P-3)
Well, I’d have thought it all depends on how advanced it is before it’s caught. It seems to 
be… like, you hear people have cancer, and they say, ‘Oh, they were just too far gone.’ 
Like, I think the frightening thing about cancer is you have it for so long and that you don’t 
know you have it, and then when they discover the cell, you know it’s… But I would 
believe, if they got it in time, if they were screening, and all that, that’s the way I believe in 
it. Well, it’s like anything, I suppose, if you get it in time. (P-26)
Well, if they are caught quickly… Like, if I hadn’t, God forbid, had it then, I would have 
been quite… I would have… after getting over the shock, I would say, ‘No, I’ll be alright.’ 
I’m convinced, if you can get it at the right time… I think the trouble is when it starts 
spreading, obviously, you know. So if you can prevent it, as I say, or…? (P-9)
What did come into my head, “At least if it comes out the wrong result for me, at least it’s 
known about and it can be treated.” So that was in there that, if I’m being invited to do this 
and I’m detected as positive, well then they will do something and they’ll treat me. I won't 
have to go to my doctor and then go to a consultant. This is what I was thinking.(P-31)
Social Influences
I might actually even be listening to a topic, or reading a topic, or a discussion about bowel 
cancer, or if I came to a bowel cancer awareness week or  breast cancer or bowel cancer 
or whatever, it would make me think, and it’s "oh I must follow up on that and have all that 
checked out for myself", even though there is no bowel cancer or breast cancer in my 
family. (P-3)
Yeah, she said it [female spouse]. I thought she had looked to get it done, I didn’t know 
anything about it the week beforehand. And she said, “No, just send it in the post, and they 
write the thing down.” And I thought, why not? It’s a free chance you get of a check-up. (P-
38)
That’s the way it was. But I did put it to one side. And I kept on to my husband as well to 
do it, but he wouldn’t do it. (P-6)
She nagged me into it [female spouse], so I did it. And when I got the results it was great. 
And I did the second one (P-35)
I thought brilliant....Great idea. Any of those tests for prevention, I would say, is a great 
idea. (P-1)
I was absolutely delighted; I thought it was a wonderful idea. I was absolutely thrilled to 
take part in it, I have to say....//Oh I was just happy to see that they confirmed my own 
view of how I was, you know. Absolutely delighted. (P-34)
Grand. It’s something else I don’t have to worry about. ‘I passed that, so I don’t actually 
have bowel cancer. Isn’t that great?’  (P-2)
Its great to have it checked because the  the more people you’ve met or have known that 
have had cancer, and the closer you are to getting it, the more frightening it becomes, 
especially when people die, obviously. (P-29)
Well, I look at my family background and my grandparents and my parents and my siblings 
and all of that, and bowel cancer is not a thing I would be scared of, quite honestly. I 
wouldn’t be. (P-3)
Well, I mean, there is a risk. I’d be very, very conscious of it. And even more so now. I’m 
probably due… I think it’s about two years since I had the colonoscopy, and it’s probably 
time to have another one. I would, certainly. I’d be conscious of it, very conscious of it.     
(P-28)
Er, it’s funny, I suppose it’s one of the cancers I would think, no, you won’t get that. Yeah, 
it’s just maybe to do with diet and lifestyle, is a lot to do with it probably. (P-6)
Well, at the moment, after doing this [colonoscopy] I think I’m okay. (P-29)
Knowledge   
Supplementary Table 2: Illustrative quotes for domains potentially influencing screening decisions in users, by gender
Environmental context        
and resources               
 Beliefs about capabilities       
Beliefs about 
consequences            
Emotions
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I know a neighbour up there who did the bowel thing with her husband. Husband was 
alright. Went there and was alright. She came in and nearly lost her life, because they 
punctured her bowel. Priests know. Their family was all called. It was dreadful. That put 
the [swear word]  up everybody in the estate (P-22) 
Because it said to do it at the weekend [FIT test]and put it in the fridge. So I just kept 
putting it off. I mean, in and out of the courts for the last… I mean, I’m going to the High 
Court now. The kids were all taken out because she abused them. Mad stuff, crazy stuff, 
about 10 years ago. So I’ve been down the courts for the last 12 years. (P-45)
I just didn’t want to.  Why didn’t I do it?  Yeah, because my  eldest young fellow… I got it 
the morning after my young fellow nearly died the night before and I just – ‘[Swear word] 
– I’m sick of hospitals’ – and it was all bowels – I just couldn’t. (P-19)
You have to put it in the fridge. That's the only thing. But I suppose you can put it in an 
extra bag and leave it in the fridge. Well, I have another fridge now. [Laughter] But at the 
time I was saying, "Oh God!" But that’s… I know it’s stupid and all but… (P-17)
That’s what put me off, the catching of it [faeces] . That would put me right off it. How 
would you catch it?//Or probably I’d just seen the size of the thing and panicked and 
thought, ‘I’m not putting that into that [container] .’ (P-13)
There’s nothing I could do about it. It wasn’t my fault. Probably wasn’t their fault. It was 
GPOs [swear word]  fault, or someone like the [swear word]  bleeding postman that 
comes around. They skip [swear word] half the doors around here. (P-42)
I think it’s just by luck if you are able to get yourself back on the road. I don’t honestly think 
they [medical profession]  know what they’re doing. I think so, anyway. (P-17)
The health system in general is crap, especially [name]  Hospital.  It’s the worst hospital 
ever. // I’ve nothing against the nursing staff.  The nursing staff at any hospital is brilliant, 
brilliant.  It just depends on the doctors. (P-19)
Well, when I saw what you had to do, I couldn’t cope with that [faecal sampling] . Yeah... 
I wouldn’t find it very… well, pleasant is not the word but…You know. I suppose nothing 
medical is, is it?....Nothing medical is pleasant. (P-15)
Yeah, you put the sheet down the toilet pot when you go to the toilet, naturally, and you have 
some and you put back into the bowl and send it off. Yeah...I’d do it myself now. I’ve no 
problem doing it now.  (P-39)
I didn’t. I tell you why. For hygiene reasons I didn’t do it. I thought, ‘Oh God, I’m not doing 
that.... I just thought, ‘I’m not doing that. That’s just too messy. I can’t be dealing with that.’ 
So I said, ‘No... not happening. (P-13)
To me, you know your own body.  And if I thought… I have a young one with Crohn’s 
disease, so I know if there’s something wrong with your bowel, I know exactly when to go.  
....I just didn’t want to...//My attitude is – I know it’s probably wrong, but if it’s not broken, 
don’t fix it. (P-19)
I don’t know if it’s one of the bad ones [colorectal cancer] .  I mean, my father-in-law 
died from lung cancer and that was a bad one.  I think bowel... I don’t know.  It’d probably 
be fairly invasive and end up with bags and all sorts of things. (P-18)
I’d say they'd be dead. Because there's no cure for cancer is there, not that I know of 
anyway. I mean, you get cancer, you’re…  eventually you're going to go, and that's the way 
of it, I think. There's very few people I know that have lived that had bowel – not that had 
bowel cancer but had cancer. They’ve all died. (P-47)
I don’t think it will be much... Bowel....I don’t think they have a good chance really. (P-7) Yeah. I don’t believe there’s any cure for it. I’ve often read, all down through the years, 
people getting cancer tend to get cured. But these people get it back after three or four 
years, then they kick the bucket. (P-42)
I think they should… the bowel should be taken completely out and put on a bowel bag, 
because unless you get to the root of it, to take the whole broken part out, you’ll never be 
right.  But that’s my opinion of it anyway. (P-19)
Supplementary Table 3: Illustrative quotes for domains potentially influencing screening decisions in non-users, by gender
Beliefs about 
consequences            
Yeah, I think there’s a, kind of, subconscious… in my case - and I say subconscious 
deliberately, because I certainly wasn’t conscious of it at the time - but I think, perhaps, 
there’s this subconscious idea that if I partake in this I’m going to be putting myself in the 
firing line to some degree. Do you know what I mean? I’m going to get news that I don’t 
particularly want to hear. I didn’t consciously feel that. But I suspect that with men, that 
 Because I was separated, you see. I was in the house. I got a judicial separation.  A lady 
judge told my wife she would have to sell the house and give half the proceeds to me, which 
wouldn’t be an awful lot of money, but I had two daughters living in the house. So if she sold 
the house, it would do more damage.... I’ve gone through all that myself. And I decided… I 
didn’t do anything about it. (P-40)
 I had to solve a problem with the mail in my house. ...// Every post I get is always opened. 
(P-40)
 Beliefs about capabilities       
Environmental context 
and resources              
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Domain Female non-users Male non-users
She was extremely lucky [neigbour who experienced a punctured bowel as a result of 
a colonoscopy ]. If she was here now, she’d sit there and she’d tell you the whole story, 
because I think she’s told me this now about three times. She was saying, “If you don’t feel 
you have to go, don’t go. If you really feel that you’ve done this test and there’s nothing, 
don’t go in.” (P-22)
My eldest daughter, now, she said I should do it. “Do the test. It’s not going to cost you 
anything. It’s not going to do you any harm.” She said, “If there’s anything, at least you’ll 
know". I said, “If there’s anything there, do you not think I would know?” Because you 
think you know everything yourself, don’t you? Which is wrong, we don’t. (P-44)
The mammogram one, she [GP] nagged me until I got that done, but she doesn’t nag over 
that one [FIT screening] . Do you know what I mean? (P-13)
Well, it was my mother, when I got the letter my mother said, “Throw that in the bin, you 
don’t want to know anything about yourself.” (P-16)
And I thought, ‘I’m not doing that’ [faecal sampling].  Yes... If it had been probably- oh 
God, it sounds disgusting. (P-13)
As I said, the C word is a bogey word to everybody, you know what I mean? (P-39)
I’m just fed up of hospitals. I go… Let’s say I go if I have to. But given a choice… (P-20) At the time it was, yeah, it was a fear of dying. Now I wouldn’t care, it wouldn’t bother me 
now. (P-47)
Then I have a very hazy recollection of being asked about bowel screening. I don’t know. I 
can’t find out that something else is wrong with me. Right now I cannot deal with that. I 
was a bit of the ostrich, bury your head in the sand, pretend it’s not happening. (P-21)
Yeah. But cancer’s a dirty word, you know what I mean? If you’re not… I don’t mean that 
in a semi-joking way. It’s a frightening word. A frightening word, because, as I’ve said, I’ve 
seen so much of it over the years. You know, it’s, kind of, will I, won’t I? (p-39)
But I think because of the word ‘cancer’ as well. I know no one wants it, but…//Yes, I 
have a big fear about cancer. (P-17)
You know -regarding cancer, it’s just a bad word. It’s a bad word....// I feel that the cancer, 
it’s just a nasty word. Its a nasty word that you dont want to hear. (P-46)
That, again, I couldn’t tell you [about colorectal cancer and risk] . I haven’t a clue, to be 
honest. Not a clue. (P-41)
Well, I don’t know. Because I haven’t even read about it, to tell you the truth, so I don’t 
know what really causes it in the first place. (P-44)
Yeah.  For the fact that it doesn’t run in the family.  I put myself at low risk,  because none 
of my family died of bowel cancer.  I know a few of them died of cancer all right, but not 
bowel cancer, so I’d put myself kind of in the low category of bowel cancer now. (P-19)
That would have been on my mind, opening that pack, and looking at it and thinking, ‘Well, I 
don’t have the symptoms that [sister] had. If I have, I’ll go.’ That was my attitude. ‘If I 
have, and I see any signs of anything that’s abnormal, I’ll go.’ So, if you don’t have it there, 
what can they tell you? Do you know what I mean? ...I’m not being cocky about myself 
with not being ill. If you’re every day going to the toilet and you haven’t got problems, and 
you’ve no pains, you must be okay for the moment. (P-22)
Knowledge   
Because, probably stupidly in my case, there’s absolutely no history [colorectal cancer]  in 
either my parents, grandparents, great grandparents. The other two that would be more of a 
risk to, i.e. the breast cancer or cervical cancer, I keep on top of that. So I’d say, hopefully, 
praise God, it’s pretty low. (P-13)
Now, the envelope inside the envelope, well, it was a packet rather than an envelope, a 
cushioned sort of thing so that it couldn’t be, you know, wouldn’t leak or anything like that. 
But you wiped your bottom and you sent this piece of paper off to the.. wherever, the lab. 
But I didn’t, I didn’t do it.” (P-40)
Social Influences
Now, saying that, my wife did it, okay, we both got it at the same time, the samples and 
stuff, the package. She did it first. And she said to me, “Did you do it?” “Aye,” I said. But I 
didn’t.  (P-46)
Emotions
Supplementary Table 3: continued…
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Supplementary Table 4: Characteristics of interviewees at time of interview
All participants 16 12 9 10
Age
Mean age 66 66 64 65
Age range 58-72 58-72 55-77 56-78
55-64 6 5 4 5
65+ 10 7 5 5
Marital status
Married 12 8 5 5
Single/ Divorced/ Separated/ Widowed 4 4 4 5
Health care access *
Private Health Insurance - Yes 10 6 - 2
Private Health Insurance - No 6 6 9 8
Medical card** - Yes 3 4 8 5
Medical card - No 3 2 1 3
Employment status (n)
Working 5 4 1 2
Retired 11 8 3 6
Not working due to injury or illness - - 5 2
**A medical card is provided to citizens who are on reduced means and entitles the holder to free health 
care under the public health system including primary care.
Male          
users
Female        
users
Male non-
users
Female non-
users
*Participants may be in multiple categories, i.e. hold a medical card and private health insurance
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Supplementary Table 5: Definitions of TDF domains which emerged as potentially influencing screening decision making 
Domain Definition
Environmental context and resources
Any circumstance of a person’s situation or environment that discourages or encourages the development of 
skills and abilities, independence, social competence, and adaptive behaviour
Beliefs about capabilities
Acceptance of the truth, reality, or validity about an ability, talent, or facility that a person can put to 
constructive use
Beliefs about consequences Acceptance of the truth, reality, or validity about outcomes of a behavior in a given situation
Social influences Those interpersonal processes that can cause individuals to change their thoughts, feelings, or behaviours.
Emotion
A complex reaction pattern, involving experiential, behavioural, and physiological elements, by which the 
individual attempts to deal with a personally significant matter or event
Knowledge An awareness of the existence of something
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Supplementary Table 3.1: Participant characteristics by gender and use or non-use of screening
All Male Female
n % n % P n % n % P n % n % P
Sex
Male 1,014 51.0 184 59.2 - - - - - - - -
Female 974 49.0 127 40.8 0.007 - - - - - - - - -
Total 1988 100 311 100
Age 
64 or less 950 48.7 183 59.6 463 46.49 97 53.3 487 50.94 86 68.8
65+ 1,002 51.3 124 40.4 0.000 533 53.51 85 46.7 0.910 469 49.06 39 31.2 0.000
Total 1952 100 307 100 996 100 182 100 956 100 125 100
Deprivation
Very disadvantaged 161 8.1 45 14.5 82 8.1 25 13.6 79 8.1 20 15.8
Disadvantaged 524 26.4 116 37.3 257 25.4 57 31.0 267 27.4 59 46.5
Marginally below average 1,034 52.0 122 39.2 0.000 532 52.5 84 45.7 0.022 502 51.5 38 29.9 0.000
Marginally above average 218 11.0 23 7.4 113 11.1 16 8.7 105 10.8 7 5.5
Affluent 51 2.6 5 1.6 30 3.0 2 1.1 21 2.2 3 2.4
Total 1988 100 311 100 1014 100 184 100 974 100 127 100
Health literacy
Adequate 1,641 84.7 242 80.4 819 82.8 145 81.0 822 86.6 97 79.5
Inadequate 297 15.3 59 19.6 0.059 170 17.2 34 19.0 0.558 127 13.4 25 20.5 0.034
Total 1938 100 301 100 989 100 179 100 949 100 122 100
Knowledge of others with CRC
No 1,307 67.7 192 63.8 666 67.3 116 65.5 641 68.1 76 61.3
Yes 624 32.3 109 36.2 0.180 324 32.7 61 34.5 0.651 300 31.9 48 38.7 0.128
Total 1931 100 301 100 990 100 177 100 941 100 124 100
Knowledge of others with cancer
No 374 19.3 63 20.7 186 18.8 32 17.7 188 19.9 31 25.2
Yes 1,564 80.7 241 79.3 0.560 805 81.2 149 82.3 0.729 759 80.2 92 74.8 0.166
Total 1938 100 304 100 991 100 181 100 947 100 123 100
Fear - Cognitive: Greatest health fear
Strongly agree/ agree 1,167 61.8 189 64.7 582 60.3 109 62.6 585 63.4 80 67.8
Uncertain 420 22.2 63 21.6 220 22.8 39 22.4 200 21.7 24 20.3
Disagree/ strongly disagree 302 16.0 40 13.7 0.536 164 17.0 26 14.9 0.773 138 15.0 14 11.9 0.580
Total 1889 100 292 100 966 100 174 100 923 100 118 100
Fear - Affective: Worry about cancer
Strongly agree/ agree 758 40.2 127 43.8 340 35.3 73 41.7 418 45.4 54 47.0
Uncertain 401 21.3 52 17.9 216 22.4 34 19.4 185 20.1 18 15.7
Disagree/ strongly disagree 725 38.5 111 38.3 0.343 408 42.3 68 38.9 0.257 317 34.5 43 37.4 0.512
Total 1884 100 290 100 964 100 175 100 920 100 115 100
Fear - Psychobiologic: Discomfort thinking about cancer
Strongly agree/ agree 989 52.4 172 58.9 472 48.9 102 58.6 517 56.1 70 59.3
Uncertain 387 20.5 55 18.8 212 22.0 35 20.1 175 19.0 20 17.0
Disagree/ strongly disagree 511 27.1 65 22.3 0.102 281 29.1 37 21.3 0.044 230 25.0 28 23.7 0.783
Total 1887 100 292 100 965 100 174 100 922 100 118 100
Non-User User Non-UserUser Non-User User
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Supplementary Table 3.1: continued….
All Male Female
n % n % P n % n % P n % n % P
Positive belief: Continue with normal activity
Agree 1,775 94.0 258 88.1 919 94.8 152 86.9 856 93.1 106 89.8
Disagree 113 6.0 35 12.0 <0.001 50 5.2 23 13.1 0.000 63 6.9 12 10.2 0.191
Total 1888 100 293 100 969 100 175 100 919 100 118 100
Positive belief: Cancer can often be cured
Agree 1,757 95.4 255 90.4 901 95.1 149 89.2 856 95.6 106 92.2
Disagree 85 4.6 27 9.6 0.001 46 4.9 18 10.8 0.002 39 4.4 9 7.8 0.100
Total 1842 100 282 100 947 100 167 100 895 100 115 100
Positive belief: Going to doctor as quickly as possible increases survival chance
Agree 1,822 96.1 281 96.2 930 95.9 167 96.0 892 96.3 114 96.6
Disagree 74 3.9 11 3.8 0.911 40 4.1 7 4.0 0.951 34 3.7 4 3.4 0.878
Total 1896 100 292 100 970 100 174 100 926 100 118 100
Negative belief: Treatment worse than  the cancer
Agree 960 52.2 168 59.6 404 42.7 87 51.8 556 62.2 81 71.1
Disagree 881 47.9 114 40.4 0.020 543 57.3 81 48.2 0.028 338 37.8 33 29.0 0.065
Total 1841 100 282 100 947 100 168 100 894 100 114 100
Negative belief: Would not want to know I have cancer
Agree 196 10.5 48 16.7 95 9.9 32 18.6 101 11.1 16 13.9
Disagree 1,674 89.5 239 83.3 0.002 867 90.1 140 81.4 0.001 807 88.9 99 86.1 0.376
Total 1870 100 287 100 962 100 172 100 908 100 115 100
Negative belief: Cancer diagnosis is death sentence
Agree 378 20.0 82 28.1 184 19.0 54 30.9 194 20.9 28 23.9
Disagree 1,516 80.0 210 71.9 0.002 783 81.0 121 69.1 0.000 733 79.1 89 76.1 0.454
Total 1894 100 292 100 967 100 175 100 927 100 117 100
Relationship status
Co-habiting 1,508 76.4 212 70.0 853 84.7 139 77.2 655 67.8 73 59.4
Not in cohabiting relationship 465 23.6 91 30.0 0.015 154 15.3 41 22.8 0.013 311 32.2 50 40.7 0.061
Total 1973 100 303 100 1007 100 180 100 966 100 123 100
Social Support
Poor 193 9.9 35 11.6 94 9.4 20 11.2 99 10.4 15 12.2
Moderate 828 42.5 129 42.7 404 40.4 79 44.1 424 44.6 50 40.7
Strong 928 47.6 138 45.7 0.625 501 50.2 80 44.7 0.385 427 45.0 58 47.2 0.660
Total 1949 100 302 100 999 100 179 100 950 100 123 100
User Non-User User Non-User User Non-User
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Table 3.2: Survey scale means 
  
No. of 
items 
Score 
range   
Overall mean 
± SD 
Male         
mean ± SD 
Female mean 
± SD 
       Cancer Fatalism inventory 
     Users 15 0-15 
 
2.90 ± 3.07 2.8 ± 3.04  3.01 ±  3.10 
Non-users 
   
4.15 ± 3.81 4.13 ± 3.80 4.17 ± 3.84 
P 
   
<0.001 <0.001 0.003 
       Emotional attitudes to screening scale 
    Users 5 5-20 
 
8.50 ± 3.04 8.40 ± 2.99 8.61 ± 3.08 
Non-users 
   
10.53 ± 3.38 10.46 ± 3.30 10.62 ± 3.52 
P 
      
       Social influence of partner 
     Users 2 1-4 
 
2.16 ± 1.11 2.47 ± 0.91 1.81 ± 1.20 
Non-users 
   
1.88 ± 1.07 2.17 ± 0.91 1.45 ± 1.15 
P 
   
<0.001 <0.001 0.001 
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Cross sectional survey instrument 
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A survey of 
participation in bowel 
cancer                                              
screening in men and 
women in Tallaght 
 
 
 
Reference number:  
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The Adelaide and Meath Hospital/ Trinity College Bowel Cancer  
Screening Programme: new research study 
 
  
Consent Form  
 
       
          
 
Please circle Yes or No on each line below to show whether or not you consent (agree) to the 
various parts of the study. 
 
I have received and read the information sheet. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
Yes / No 
I agree:  
 to take part in the project "BowelFIT - FIT uptake in CRC screening", by 
completing a questionnaire and returning it to the study team. 
 
 
Yes / No 
I understand that:  
 my participation is entirely voluntary, and I am free to leave the study at any time, 
without giving a reason. This will not affect my medical care in any way. 
 all information pertaining to me, or my family, will be protected by the principles of 
confidentiality and both national and EU Data Protection Legislation. 
 no one will be able to identify me in any reports/papers published from the study. 
 the study team will store my interview transcript permanently and confidentially 
(i.e. separately from my name and address)  
 my personal identification details will be destroyed two years after completion of 
the study 
 
 
 
Yes / No 
 
 
 
    
I give permission for study staff to: 
 anonymously share some of my data with collaborators from national and 
international research institutions, for further research into bowel cancer, and 
bowel cancer screening. 
 
  Yes / No 
   
  Yes / No 
I would like: 
 a copy of a summary of the final report 
 
Yes / No 
 
 
 
 
___________________________________ 
Name of participant (block caps) 
 
__________________________ 
Signature 
 
___________ 
Date 
 
___________________________________ 
Name of researcher (block caps) 
 
__________________________ 
Signature 
 
___________ 
Date 
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About the survey 
We want to find out why people take part in, or decide not to take part in bowel cancer 
screening when a test is sent to their home. There are a number of different names for bowel 
cancer. These include: 
Colorectal cancer 
Colon cancer, and  
Rectal cancer 
 
We have sent this survey to you because – a few years ago - you were sent a bowel cancer 
screening test by Tallaght Hospital. Please complete the survey even if you did not do 
the screening test. 
 
If you complete and return the survey you will be entered into a draw for a €500 shopping 
voucher.  
 
Completing the survey 
Taking part in the study is voluntary. The survey will take about 30 minutes to complete. 
Please try to answer all of the questions that apply to you. There are no right or wrong 
answers, so please just tell us what you think. 
 
 
Confidentiality 
Please be assured that all the information you provide will be kept in the strictest confidence.  
 
Questions 
 For more information about the study, please telephone free phone no. 1800 283 
097. If we are unable to answer, please leave a message and we will call you back. 
 For someone to talk to, please call the Irish Cancer Society’s National Cancer 
Helpline on FREEPHONE 1800 200 700. 
 If you have questions about bowel cancer screening please contact BowelScreen on 
FREEPHONE 1800 45 45 55. 
 
When you are ready to begin the survey, please turn the page. 
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Section A: A reminder of the bowel cancer screening test  
In this section we are interested in finding out if people remember being invited by 
Tallaght Hospital to take part in bowel cancer screening. 
Please answer all of the questions in this section by putting a ‘’ in the boxes that 
apply to you. 
 
During 2008- 2012 you were invited by Tallaght Hospital to take part in bowel cancer 
screening every two years using a new home based screening test called a FIT (faecal 
immunochemical test). The invitation and test kit was sent to your home by post. The test 
involved you going to the toilet and taking a small sample of your stool using a sampling 
device and placing it in a small plastic vial. You were required to store this in your 
refrigerator overnight, take another sample from another stool the following day and post 
both samples to a laboratory. Your results were posted to you and if you received a positive 
result you were asked to go to the hospital for a colonoscopy. If you received a negative 
result you were recalled for a second screening test two years later. An image of the FIT test 
is below.  
 
A1. Do you remember receiving a screening test kit? Please tick one box only 
 
                                                                                                       Yes  
                                                                                                        No   
 
A2. Did you return a screening test? Please tick one box only 
 
Yes, I returned a screening test kit twice 
Yes, I returned a screening test only once between 2008-2010 
Yes, I returned a screening test only once between 2010-2012 
  
No, I never returned a screening test  
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Section B: About you  
In this section we want to find out something about the people who are completing 
this survey. 
Please answer all of the questions in this section by putting a ‘’ in the boxes that 
apply to you or by writing in the spaces provided. 
 
B1.  What year were you born?               Year  
 
B2. What is your gender? Please tick one box only 
 
Male  
Female   
 
B3. What is the highest level of education you have completed?  
Please tick one box only 
 
Primary school  
Secondary school  
Third level (e.g. college or university)  
Post-graduate (e.g. Diploma, Masters, Doctorate)  
 
B4. What is your current marital status? Please tick one box only 
 
Married / living with partner / civil partnership   
Single / never married   
Married-Separated 
Divorced 
 
 
Widowed 
 
 
 
 
B5. What is your current work status? Please tick one box only 
 
Working for an employer   
Self-employed   
Unemployed   
Looking after family / home   
Unable to work due to cancer, another illness or injury   
Retired   
Student   
Other, please tell us:_________________________   
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B6. Did you have a medical card during 2008-2012?  
Please tick one box only 
 
Yes, all of the time  Yes, part of the time       No  
   
 
B7. Did you have private health insurance during 2008-2012?                                                 
    Please tick one box only 
 
Yes, all of the time  Yes, part of the time       No  
   
 
B8. How many people are so close to you that you can count on them if you have serious 
problems? 
 
None   1 or 2  3-5   6 or more   
 
 
B9. In general, how much concern do people show in what you are doing in your life in 
general? 
 
A lot of 
concern & 
interest 
 Some 
concern & 
interest 
  
Uncertain 
 Little 
concern & 
interest 
 No concern 
& interest 
 
     
     
 
 
B10. How easy can you get practical help from neighbours if you should need it? 
 
Very easy   Easy   Possible   Difficult   Very difficult  
 
 
 
B11. Have you, or any friends or family members that are close to you, ever been 
diagnosed with bowel cancer (this may also have been called colorectal, colon or 
rectal cancer)?  
Please tick one box only  
 
 
Bowel cancer 
Yes, me 
 
 
Yes, someone close to me 
 
 
Yes, both me and someone 
close to me 
 
Yes, but would prefer not to say 
whom 
 
No 
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B12. Have you, or any friends or family members that are close to you, ever been 
diagnosed any other cancer?  
Please tick one box only  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B13.  Below are some statements about how people may feel about life in general. 
 Please tell us how much you agree or disagree with each statement. 
Please tick one box only on each line  
 
 
 Strongly 
disagree 
Disagree Neutral Agree Strongly 
agree 
In uncertain times I usually expect 
the best 
     
If something can go wrong for me, it 
will 
     
I’m always optimistic about the 
future 
     
I hardly ever expect things to go my 
way 
 
     
I rarely count on good things 
happening to me 
     
Overall, I expect more good things to 
happen to me than bad 
     
 
 
 
 
 
 
 
 
 
 
 
 
Other cancers 
Yes, me 
 
 
Yes, someone close to me 
 
 
Yes both me and someone close 
to me 
 
Yes, but would prefer not to say 
 
 
No 
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Section C: You, your health and the health system  
In this section we are interested in finding out about your overall health and your 
feelings about the health system.  
Please answer all of the questions in this section by putting a ‘’ in the boxes that 
apply to you. 
 
C1. In general, during the years 2008-2012 would you say your health was...?  
Please tick one box only 
 
Very good  Good   Fair   Bad  Very bad   
 
 
C2. In your lifetime have you ever smoked more than 100 cigarettes? 
       
Yes  No   
 
If YES, do you smoke now? 
Yes  No   
 
If NO, in what year did you give up? 
              Year  
 
C3. What is your weight without clothes? 
 
 __________ stones __________ pounds (or __________ kilos) 
 
C4. What is your height without shoes? 
 
 __________feet ___________inches (or __________cm) 
 
C5. In a typical week in the summer and the winter how much activity do you do?  
 Write in the number of hours per week; insert 0 if less than 1 hour. 
  
 Summer Winter 
Vigorous activity (e.g. running, fast 
swimming, fast cycling)  
 Hours in 
a week 
 Hours in 
a week 
Moderate activity (e.g. brisk walking, 
heavy housework, heavy gardening, 
gym, ordinary swimming or cycling) 
  
Hours in 
a week 
  
Hours in 
a week 
Light activity (e.g. walking, general 
housework, cooking, shopping, 
gardening) 
 Hours in 
a week 
 Hours in 
a week 
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C6.  During 2008-2012 did you have any of the following conditions? 
  
Yes   
No 
Angina/ coronary artery disease   
Asthma   
Back pain or other chronic back condition   
Bronchitis, chronic/ Chronic obstructive pulmonary disease 
(COPD) 
  
Cancer   
Cholesterol, elevated (high)   
Colon problems (e.g. diverticulitis, irritable bowel, Crohn’s 
disease) 
  
Congestive heart failure   
Diabetes   
Hearing loss   
Hypertension (high blood pressure)   
Kidney disease   
Nerve condition (e.g. Parkinson’s disease, multiple sclerosis)   
Osteoarthritis (degeneration of joint cartilage and the underlying 
bone) 
  
Osteoporosis   
Poor circulation (e.g. peripheral vascular disease)   
Rheumatic disease ( e.g. rheumatic disease such as fibromyalgia 
or lupus) 
  
Rheumatoid arthritis (inflammation in the joints)   
Stomach problem (e.g. gastritis, peptic disease)   
Stroke   
Thyroid disorder   
Vision disorder (excluding wearing glasses)   
Other, specify: 
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C7. The following questions are about how much you trust your GP and hospital doctors. 
 Please read each statement and tell us how strongly you agree or disagree with 
them. 
 Please tick one box only on each line 
 
 Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
Sometimes my GP cares more about 
what is convenient for him/her than 
about my medical needs 
     
My GP is extremely thorough and 
careful 
     
I completely trust my GP’s decisions 
about which medical treatments are 
best for me 
     
My GP is totally honest in telling me 
about all of the different treatment 
options available for me 
     
All in all, I have complete trust in my 
GP 
     
Sometimes hospital doctors care more 
about what is convenient for them than 
about my medical needs 
     
Hospital doctors are extremely 
thorough and careful 
     
I completely trust hospital doctors’ 
decisions about which medical 
treatments are best for me 
     
 Hospital doctors would never mislead 
me about anything 
     
All in all, I trust hospital doctors 
completely 
     
 
C8. The Health Service Executive or the HSE is responsible for carrying out health 
service  policy and managing and administering the health service in Ireland. Please 
tell us how  much trust you have in the HSE? 
Very high trust             Rather high trust              Not high          No trust at all          No 
opinion 
 
 
C9. How confident are you filling out medical forms by yourself?   
            Please tick one box only 
 
Extremely   Quite 
a bit 
  Somewhat   A little bit   Not at 
all 
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Section D: Attitude to screening 
In this section we want to find out about your attitudes to bowel cancer screening. 
Please answer all of the questions in this section, even if you did not do the test, by 
putting a ‘’ in the boxes that apply to you. 
 
D1. Please think back to when the bowel cancer test kit was sent to you in the post (i.e. 
 during 2008-2012) and tell us how strongly you agree or disagree with each of the 
 following statements. Please tick one box only on each line 
 
 Strongly 
agree 
Agree Neutral Disagre
e 
Strongly 
disagree 
When I received the bowel cancer test, I 
felt able to complete it 
     
Completing the bowel cancer test made 
sense to me 
     
I felt the bowel cancer test was a 
practical test to do when I received it  
     
If I got an abnormal result on my bowel 
cancer test I would accept an invitation 
for additional testing 
     
 
 
D3.  Please think back to when the bowel cancer test kit was sent to you in the post (i.e. 
during 2008-2012) and tell us how strongly you agree or disagree with each of the 
following statements. Please tick one box only on each line  
 
 Strongl
y agree 
Mildly 
agree 
Don’t 
know 
Mildly 
disagree 
Strongly 
disagree 
I wanted to do what my partner thought 
I should do about bowel cancer 
screening 
     
My partner thought I should have bowel 
cancer screening 
     
My doctor thought I should have bowel 
cancer screening 
     
I wanted to do what my doctor thought I 
should do about bowel cancer 
screening  
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D2. Please think back to when the bowel cancer test kit was sent to you in the post 
(during 2008-2012) and tell us how strongly you agree or disagree with each of the 
following statements. 
Please tick one box only on each line 
 Strongly 
agree 
Agree Disagre
e 
Strongly 
Disagree 
I did not want to keep small amounts of stool 
in my house 
    
I would not have had the privacy to do the test      
I would only have done the test if I had 
symptoms of bowel cancer 
    
It would have been unlikely that I had the time 
to do the test 
    
Doing the test was disgusting     
Doing the test was tempting fate     
I would have been embarrassed if others knew 
I had done the test 
    
Doing the test made me worry more about 
bowel cancer 
    
I was afraid of getting an abnormal result from 
my test 
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Section E: Beliefs about cancer 
In this section we want to find out about what people believe about cancer. 
Please answer all of the questions in this section, even if you did not do the test, by 
putting a ‘’ in the boxes that apply to you. 
 
E1.  Please think back to when the bowel cancer test kit was sent to you in the post (i.e. 
during 2008-2012) and tell us how strongly you agree or disagree with each of the 
following statements.  
Please tick one box only on each line  
 
 Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
I avoided information about cancer from 
the TV, newspapers and radio 
     
I avoided talking to other people about 
cancer 
     
I did not want any more information 
about cancer 
     
I didn’t see the point of going to a doctor 
unless I was really sick 
     
I didn’t go to a doctor unless it was really 
serious 
     
If I felt healthy, I did not go to the doctor 
for a routine check-up 
     
When I was sick, I tried to cure myself 
rather than go to the doctor 
     
I relied more on home remedies than on 
doctors 
     
I tended to avoid thoughts of bowel 
cancer 
 
     
I liked to ignore the idea that I could get 
cancer 
     
I hadn’t faced the idea that I could get 
colon polyps 
     
I did not need to be screened for bowel 
cancer because I had regular bowel 
movements 
     
I did not need to be screened for bowel 
cancer because I included enough 
vegetables in my diet 
     
I did not need to be screened for bowel 
cancer because I didn’t eat too much red 
meat 
     
I did not need to be screened for bowel 
cancer because I took good care of 
myself 
     
I did not need to be screened for bowel 
cancer because I exercised regularly 
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 Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
I wanted to wait to get tested for bowel 
cancer until my other health concerns 
were under control 
     
I wanted to wait to get tested for bowel 
cancer until a time when I was not as 
busy 
     
I would have eventually got tested for 
bowel cancer, but had other health 
priorities at the time 
     
I wanted to get screened for bowel 
cancer, but I was waiting for a better test 
     
It’s just not true that everyone 50 and 
older needs to be screened for bowel 
cancer 
     
Bowel cancer screening could not be all 
that important because few people I 
know had done it 
     
Bowel cancer screening couldn’t be that 
important because my doctor had never 
told me I had to do it 
     
The medical evidence that bowel cancer 
screening is needed for everyone over 
50 is not convincing 
     
There is not enough evidence yet to 
support the use of bowel cancer 
screening by all adults aged 50 years 
and older 
     
Few people get bowel cancer      
The claims that bowel cancer screening 
can prevent cancer are exaggerated 
     
The recommendation that bowel cancer 
screening must be repeated regularly for 
everyone over 50 years is overstated 
     
I couldn’t do EVERYTHING that you’re 
supposed to do for your health; it would 
be a full-time job 
     
Science always corrects itself; what is 
good today is bad tomorrow 
     
If you avoided all the things they say are 
bad for your health, you couldn’t do 
anything 
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E2.  Below are some statements which are sometimes made about cancer. For each 
statement  please tell us if you agree or disagree with each.  
Please tick one box only on each line 
 Agree Disagree 
I think if someone is meant to have bowel cancer, it doesn't 
matter what kinds of food they eat, they will get bowel cancer 
anyway 
  
I think if someone has bowel cancer, it is already too late to get 
treated for it 
  
I think someone can eat fatty foods all their life, and if they are 
not meant to get bowel cancer, they won't get it 
  
I think if someone is meant to get bowel cancer, they will get it 
no matter what they do 
  
I think if someone gets bowel cancer, it was meant to be 
 
  
I think if someone gets bowel cancer, their time to die is soon 
 
  
I think if someone gets bowel cancer, that's the way they were 
meant to die 
  
I think getting checked for bowel cancer makes people scared 
that they may really have bowel cancer 
  
I think if someone is meant to have bowel cancer, they will have 
bowel cancer 
  
I think some people don't want to know if they have bowel 
cancer because they don't want to know they may be dying 
from it 
  
I think if someone gets bowel cancer, it doesn't matter whether 
they  
find it early or late, they will still die from it 
  
I think if someone has bowel cancer and gets treatment for it, 
they will probably still die from the bowel cancer 
  
I think if someone was meant to have bowel cancer, it doesn't 
matter what doctors and nurses tell them to do, they will get 
bowel cancer anyway 
  
I think if someone is meant to have bowel cancer, it doesn't 
matter if they eat healthy foods, they will still get bowel cancer 
  
I think bowel cancer will kill you no matter when it is found and 
how it is treated 
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E3. Below are some statements which are sometimes made about cancer. For each 
statement please tell us how strongly you agree or disagree with each.  
Please tick one box only on each line 
 
 Strongly 
agree 
Agree Disagre
e 
Strongly 
disagree 
These days, many people with cancer can expect to 
continue with normal activities and responsibilities   
    
Most cancer treatment is worse than the cancer 
itself  
    
I would NOT want to know if I have cancer      
Cancer can often be cured      
Going to the doctor as quickly as possible after 
noticing a symptom of cancer could increase the 
chances of surviving  
    
Some people think that a diagnosis of cancer is a 
death sentence. To what extent do you agree or 
disagree that a diagnosis of cancer is a death 
sentence  
 
 
   
 
 
 
E4.  Here are some more statements which are sometimes made about cancer. Please 
tell us how strongly you agree or disagree with each.  
Please tick one box only on each line 
 
 Strongl
y agree 
Agree Uncertai
n 
Disagree Strongly 
disagree 
Of all the diseases there are, I am 
most afraid of cancer 
     
I worry a lot about cancer      
It makes me uncomfortable to think 
about cancer 
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E5.  Which, if any, of the following events happened to you during the period 2008-
2012? 
Please tick yes or no for each event. 
 
Event Yes No  Event Yes No 
Death of a spouse/ 
partner 
  Son or daughter leaving 
home  
  
Divorce   Trouble with in-laws    
Marital separation   Outstanding personal 
achievement 
  
Prison term   Spouse begins or stops 
work 
  
Death of a close family 
member 
  Begin or end school or 
college  
  
Personal injury or illness   Change in living 
conditions  
  
Marriage  
 
  Revision of personal 
habits  
  
Let go or fired at work  
 
  Trouble with boss    
Marital reconciliation    Change in work hours 
or conditions  
  
Retirement  
 
  Change in residence   
Change in health of 
family member  
  Change in schools    
Pregnancy  
 
  Change in recreation    
Sex difficulties    Change in church 
activities  
  
Gain of new family 
member  
  Change in social 
activities  
  
Business readjustment    Took out a moderate 
loan or mortgage  
  
Change in financial state  
 
  Change in sleeping 
habits  
  
Death of a close friend  
 
  Change in number of 
family get-togethers   
  
Change to a different line 
of work 
  Change in eating habits    
Change in number of 
arguments with partner   
  Change in 
responsibilities at work 
  
Took out a large 
mortgage or loan  
  Foreclosure on 
mortgage or loan 
  
Please go to the next column 
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Section F:    Future intentions 
The Tallaght Bowel Cancer Screening Programme has now finished. There is a new 
national screening programme called BowelScreen. In this section we want to find out 
about your future intentions to take part in BowelScreen. 
Please answer all of the questions in this section by putting a ‘’ in the boxes that 
apply to you. 
 
 
F1.  The following statements are about your decisions to take part in future bowel cancer 
screening. Please tell us how strongly you agree or disagree with each statement. 
 Please tick one box on each line 
 
 Strongly 
agree 
Agree Neutral Disagre
e 
Strongly 
disagree 
In the future I would not want to get tested for bowel cancer because.....  
The test might find something wrong      
It is too embarrassing      
It is inconvenient or too hard to 
schedule  
     
The stool test might be disgusting      
A special diet or emptying my bowel 
is too much trouble 
     
It might be painful      
I do not have symptoms      
It is too expensive      
There is no one to drive me home 
from the test 
     
It would be embarrassing to talk to 
my doctor about screening 
     
I do not have health insurance or a 
medical card 
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In the future I would want to get 
tested for bowel cancer because..... 
Strongly 
disagree 
Disagree Neutral Agree Strongly 
agree 
Finding cancer early gives me a 
better chance at a cure 
     
Receiving clear findings would give 
me piece of mind 
     
Screening can find cancer early      
My family would be happy if I got 
screened 
     
Getting screened is part of taking 
care of myself 
     
If polyps are found and removed, 
cancer can be prevented 
     
 
 
I am very confident that I can.... 
Strongly 
disagree 
Disagree Neutral Agree Strongly 
agree  
make a decision about whether to get 
screened for bowel cancer 
     
complete bowel cancer screening      
complete bowel cancer screening 
even if I am nervous about it 
     
complete bowel cancer screening 
even if I are embarrassed about it 
     
complete bowel cancer screening 
even if I don’t think I need it 
     
find time to complete bowel cancer 
screening 
     
talk to my doctor about bowel cancer 
screening 
     
complete any necessary preparation 
for bowel cancer screening 
     
get support from family and friends 
to help me complete bowel cancer 
screening 
     
complete bowel cancer screening 
even if I think my health is good 
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Please write in the space below if you there is something else you would like to tell us about 
the bowel screening test  
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this survey 
 
 
Please sign the consent form, and return it with this survey, in the enclosed pre-paid 
envelope to: PO BOX ADDRESS TO BE INSERTED. 
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Increasing late stage colorectal cancer and rectal
cancer mortality demonstrates the need for
screening: a population based study in Ireland,
1994-2010
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Abstract
Background: This paper describes trends in colorectal cancer incidence, survival and mortality from 1994 to 2010
in Ireland prior to the introduction of population-based screening.
Methods: We examined incidence (National Cancer Registry Ireland (NCRI) and mortality (Central Statistics Office)
from 1994 to 2010. Age standardised rates (ASR) for incidence and mortality have been calculated, weighted by the
European standard population. Annual percentage change was calculated in addition to testing for linear trends in
treatment and case fraction of early and late stage disease. Relative survival was calculated considering deaths from
all causes.
Results: The colorectal cancer ASR was 63.7 per 100,000 in males and 38.7 per 100,000 in females in 2010. There
was little change in the ASR over time in either sex, or when colon and rectal cancers were considered separately;
however the number of incident cancers increased significantly during 1994-2010 (1752 to 2298). The case fractions
of late stage (III/IV) colon and rectal cancers rose significantly over time. One and 5 year relative survival improved
for both sexes between the periods 1994-2008. Colorectal cancer mortality ASRs decreased annually from 1994-2009 by
1.8% (95% CI -2.2, -1.4). Rectal cancer mortality ASRs rose annually by 2.4% (95% CI 1.1, 3.6) and 2.8% (95% CI 1.2, 4.4) in
males and females respectively.
Conclusions: Increases in late-stage disease and rectal cancer mortality demonstrate an urgent need for colorectal
cancer screening. However, the narrow age range at which screening is initially being rolled-out in Ireland means
that the full potential for reductions in late-stage cancers and incidence and mortality are unlikely to be achieved.
While it is possible that the observed increase in rectal cancer mortality may be partly an artefact of cause of death
misclassification, it could also be explained by variations in treatment and adherence to best practice guidelines;
further investigation is warranted.
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Background
Over 1.23 million colorectal cancers are diagnosed world-
wide annually [1] with 609 000 deaths [1]. Colorectal
cancer is highly preventable if diagnosed early and
treated. Screening has been available for many years
through several modalities, including colonoscopy, sig-
moidoscopy, and faecal-based tests [2-4]. Faecal-based
tests, notably faecal occult blood testing (FOBT), are
generally the route through which colorectal cancer
screening programmes are being delivered internation-
ally [5,6]. More recently faecal immunochemical test-
ing (FIT) has been recommended for screening due to
its improved sensitivity and specificity in detecting hu-
man haemoglobin and the fact that there is no need for
test recipients to undergo dietary restrictions (which
may be required for guaiac-based tests). Studies which
have used FIT suggest improved uptake compared to
other screening tests such as FOBT, possibly due to the
absence of dietary restrictions, the need for fewer samples,
absence of the need for storage if a one sample test, and
ease of use [7]. However the authors state that these re-
sults are inconclusive and require further investigation
from the patient’s perspective [7]. Recent European and
US guidelines recommend FIT as the initial screening test
in population-based screening programmes [8,9].
Screening aims to detect colorectal disease either at a
precancerous stage (when removal of polyps may prevent
cancers developing) or when cancers are at an early stage
(when treatment is more effective and patients may also
benefit from improved quality-of-life). Screening therefore
has the potential to reduce mortality, provided the service
is of high quality and coverage is high [8].
Although many European countries have established
screening programmes, until 2013, no programme was
in place in Ireland. In 2009, a health technology assess-
ment of population-based colorectal cancer screening
found that biennial FIT at ages 55-74 would be consid-
ered the optimal screening strategy in Ireland in terms
of potential for reducing incidence and mortality, and
cost-effectiveness [10]. The National Cancer Screening
Service launched BowelScreen, a national population-
based programme, in December 2012. This paper aims to
describe the population burden of colorectal cancer by exam-
ining trends in colorectal cancer incidence, mortality and
survival during 1994-2010, prior to nationwide screening.
Methods
We examined incidence for 1994-2010 and mortality for
1994-2009 (2009 was the latest year for which mortality
data was available at the time of the study). Information
on incident cases was abstracted from the National Cancer
Registry Ireland (NCRI). The NCRI records all cancers di-
agnosed in the population usually resident in Ireland
through active case finding by tumour registration officers.
The completeness of registration for all invasive cancers
diagnosed to end 2008 was estimated to be over 97% [11].
The NCR has permission under the Health (Provision
of Information) Act 1997 to collect and hold data on all
persons diagnosed with cancer in Ireland. The use of
that data for research is covered by the Statutory Instru-
ment which established the Registry Board in 1991. All
datasets were anonymised prior to analysis.
Site of tumour was recorded according to the Inter-
national Classification of Diseases 10th revision (ICD10),
and analysis included all primary invasive cancers of the
colon (C18) and rectum (C19-C20) with a date of diag-
nosis during 01/01/1994 and 31/12/2010. For each diag-
nosed cancer, summary stage was derived from primary
tumour (T), regional nodes (N) and distant metastasis
(M) as recorded in pathology reports or, in the absence
of these, from clinical staging, according to TNM 5th
edition [12]. Where a patient was classified as MX (“distant
metastases cannot be assessed”), the M category was
defaulted to “M0” (no distant metastasis). For example,
a patient with stage composite T3N1MX was treated as
T3N1M0, stage III (Dukes C). Data on treatment re-
ceived during the first year post-diagnosis was defined
as planned first course of tumour directed treatment
administered within one year of the diagnosis date (-30
to 365 days) and aimed at removing, destroying or prevent-
ing further tumour growth and included four treatment
scenarios: (Surgery (Y/N), chemotherapy(Y/N), radio-
therapy(Y/N), or not treated [ICD9CM and ICD10-
AM]). Analyses of stage and treatment included cases
diagnosed during 1995-2009, as this information was in-
complete for 2010 cases and unreliable for 1994 cases,
the first year of national registration. Colorectal cancer
deaths (C18-20) were obtained from the Central Statis-
tics Office (CSO) [13].
Age-standardised rates (ASR) for incidence and mortal-
ity were weighted by the European standard population
using the direct method [14]. Trends presented as annual
percentage change (APC) in ASRs of incidence (1994-
2010) and mortality (1994-2009) were calculated using
Joinpoint regression [15]. Joinpoint regression was also
used to test for linear trends in treatment (1995-2009) and
case fraction of early (stage I/II) and late (stage III/IV) dis-
ease (1995-2009). For descriptive purposes, age category
percentages and treatment category percentages were
given for three diagnostic periods: 1995-1999, 2000-2004
and 2005-2009.
In the Irish cancer registry, follow-up of cases is pas-
sive, where registered cancer cases are linked to death
certificates provided by the CSO [16]. For survival ana-
lysis, the dataset was divided into three diagnostic pe-
riods: 1994-1998, 1999-2003 and 2004-2008. Survival
time was censored at 31 December 2009 to ensure all
cases had at least one year follow-up, and because this
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was the latest date for which death ascertainment was
complete. Our manuscript was drafted in late 2013, a
point in time when we were confident that all deaths
certificates from the CSO were matched to the cancer
registry database. Cases which were preceded by another
cancer (other than non-melanoma skin cancer) were
excluded from survival analysis as were autopsy-only
cases, death certificate only cases (DCO), colorectal can-
cers concurrent with other invasive malignancy and colo-
rectal cancers diagnosed 2009-2010. Relative Survival
(RS), the ratio of observed survival among a group of cases
to the expected survival among the general population of
the same age, sex and country, was computed based on
deaths from all causes and using national life-tables [17].
Results
Incidence
The colorectal cancer ASR was 63.7 per 100,000 in males
and 38.7 per 100,000 in females in 2010. There was little
change in the ASR over time (Figure 1) in either sex, or
when colon and rectal cancers were considered separately.
However, the number of colorectal cancer cases in Ireland
increased from 1752 in 1994 to 2298 in 2010, an annual
rise of 2.1% (95% CI 1.8, 2.4; p < 0.001). The increase was
somewhat higher in males (983 in 1994; 1343 in 2010;
APC = 2.3%, 95% CI 2.0, 2.7) than females (769 in 1994;
955 in 2010; APC = 1.8%, 95% CI 1.4, 2.1).
In males, 62% of cases were in the colon; this was 71%
in females. Increases in cases were observed in both colon
(APC males = 2.6%, 95% CI 2.0, 3.2; APC females = 1.8%,
95% CI 1.4, 2.3) and rectal cancer (APC males = 1.9%, 95%
CI 1.0, 2.4; APC females = 1.7%, 95% CI 1.4, 2.5).
Age distribution
Sixty nine percent of cases in males and 67% in females oc-
curred in those aged ≥65; similar proportions in each sex
were diagnosed aged 55-64 (males: 20%; females: 19%) and
<55 (males: 11%; females: 14%). Over the three periods
1995-1999, 2000-2004 and 2005-2009 there was no change
in the age distribution of either colon or rectal cancer in fe-
males or rectal cancer in males (data not shown).
Stage
During 1995-2009 early stage (I/II) colon cancers de-
creased by -1% annually in males (95% CI -1.8%, -0.1%)
and in females by -0.7% (95% CI -1.4%, -0.1%). Conversely
late stage (III/IV) colon cancers increased by 1.3% in
males (95% CI 0.6%, 2.1%) and by 1.6% in females (95% CI
0.9%, 2.3%). Similarly early stage rectal cancers decreased
by -2.1% (95% CI -2.8%, -1.4%) in males and -1.8% (95%
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Figure 1 Age standardised incidence rate and incident cases of colorectal cancer by site of primary tumour and sex, 1994-2010.
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CI -2.9%, -0.7%) in females, while late stage disease in-
creased significantly (males: APC = 2.0%, 95% CI 1.2%,
2.7%; females: APC = 1.8%, 95% CI 0.7%, 2.8%; Figure 2).
Unstaged colon cancers decreased significantly in males
by -2.2% (95% CI -4.1%, -0.2%; p-trend <0.05) and by -3.3%
in females (95% CI -5.7%, -1.0%; p-trend < 0.05) annually.
There was no significant change in unstaged rectal cancers
in males (APC 0.6%, 95% CI -2.3%, 1.2%; p-trend = 0.5) or
females (APC= 0.2%, 95% CI-2.3%, 2.8; p-trend = 0.8).
Treatment
Use of cancer-directed surgery (i.e. resection) for colon can-
cer increased from 76% in 1995-1999 to 79% in 2005-2009
(APC 0.3%, 95% CI 0.0, 0.6; p = 0.027), while for rectal can-
cer there was little change, remaining at 74% over the same
period (APC -0.1%, 95% CI -0.5, 0.3; p = 0.54) (Figure 3).
Use of chemotherapy for colon cancer rose significant from
21% in 1995 to 40% in 2006, thereafter levelling off to 38%
up to 2009(APC= 5.7%, 95% CI 4.3, 7.1; p < 0.001). Simi-
larly, in rectal cancer, chemotherapy use increased signifi-
cantly from 22% in 1995 to 48% in 2002 (APC= 11.1%, 95%
CI 8.7, 13.5; p < 0.001), reaching 49% by 2009 (Figure 3).
Use of radiotherapy for rectal cancer increased significantly
from 18% in 1995 to 37% in 2001, thereafter levelling off to
just under 40% (APC 12.3%, 95% CI 9.1, 15.7; p < 0.001).
The proportion of rectal cancer patients who received pre-
surgery radiotherapy increased from 2% in 1995 to 13% in
2002 (APC 38.7%, 95% CI 28.7, 49.5; p < 0.001). Thereafter,
the proportion receiving this combination increased at a
slower rate from 18% in 2003 to 26% in 2009 (APC 9.9%,
95% CI 1.9, 18.4; p = 0.02) (Figure 3).
Survival
Relative survival improved over time for both sexes for
colon and rectal tumours. From 1994-1998 to 2004-2008
1-year colon cancer survival in males increased by 8
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Figure 2 Case fraction for stage of disease at presentation, by gender and site of tumour for diagnostic period 1994-2009.
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null hypothesis is that the APC = 0%: Alternative hypothesis is APC≠ 0%. The APC is the slope of a log-linear regression curve from 1994-2009.
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percentage points to 77% (95% CI 75%, 78%), and in fe-
males by 5 percentage points to 73% (95% CI 71%, 75%).
Five-year colon cancer survival increased by 8 percent-
age points to 58% (95% CI 56%, 61%) in males and by 7
percentage points to 59% (95% CI 56%, 62%) in females
over the same time (Figure 4). One-year rectal cancer
survival improved in males by 9 percentage points to
81% (95% CI 79%, 82%) and in females by 6 percentage
points to 80% (95% CI 78%, 83%); 5-year rectal cancer
survival in males improved by 9 percentage points to
55% (95% CI 52%, 59%) and in females by 9 percentage
points to 61% (95% CI 57%, 65%; Figure 5).
Mortality
In 2005-2009, on average 400 females (255 colon; 145
rectum) and 552 males (313 colon; 239 rectum) died
from colorectal cancer annually. Colon cancer deaths
declined over time in both sexes (males: 360 in 1994;
302 in 2009; APC = -1.7%, 95% CI -2.4%, -1.0%; females:
321 in 1994; 240 in 2009; APC = -2.1%, 95% CI -3.0%,
-1.2%). Rectal cancer deaths rose significantly in males
from 148 in 1994 to 262 in 2009 (APC = 4.6%, 95% CI
3.4%, 5.9%) and in females from 94 in 1994 to 141 in
2002 (APC = 4.4%, 95% CI 3.0%, 5.9%).
Colorectal cancer age-standardised mortality rates (ASR)
decreased by -1.8% (95% CI -2.2%, -1.4%) annually during
1994-2009. Colon cancer ASRs fell in both sexes (males:
APC= -3.7%, 95% CI 4.4%, -3.0%; females: APC= -4.2%,
95% CI -5.1%, -3.2%), but rectal cancer ASR (mortality) rose
(males: APC= 2.4%, 95% CI 1.1%, 3.6%; females: APC=
2.8%, 95% CI 1.2%, 4.4%; Figure 6).
Discussion
Over the past 20 years the number cases of colorectal
cancer has increased significantly in Ireland; however
once adjusted for changes in the age distribution of the
population over time the rate has remained stable. Inter-
nationally colorectal cancer rates have stabilised in eco-
nomically developed countries and Ireland is no exception
in this regard [18]. In comparison to other European
countries, in 2008 Ireland had a higher incidence rate than
the EU average and 23% higher than the rate in the United
Kingdom [19]. In the European region incidence has in-
creased in males at a greater rate than female incidence
during the period 1988 to 2008 [20]. Survival was just
below the EU average but similar to the United Kingdom
[21]. The improvements in survival reported in this paper
were also seen in other European countries during the
1990s and early 2000s [21]. European 5 year survival of
colon cancer increased from 54.2% in the period 1999-
2001 to 58.1% in 2005-2007, and from 52.1% to 57.6% for
rectal cancer over the same period [22]. Although Irish
survival improved, it is still lower than the European aver-
age [22]. Our data indicates that survival continued to im-
prove for cases diagnosed during 2005-2009. While we did
not have detailed information on the dose and intensity of
chemotherapy and radiotherapy regimens, better uptake
in and application of treatment options during 1995-2009
correlate with the improvement in survival.
Stage
One of the striking findings of this study was that almost
half of cases had relatively late stage at diagnosis (stage
III/IV) and, over the period under investigation, the pro-
portion with stage III/IV disease increased from 42% to
50%. The increase in stage III/IV cancers is likely to be
as a result of more comprehensive investigation in the
peri-operative period, with improvements in imaging
and diagnostic methods, resulting in a significant shift
in stage allocation from stage I/II to stage III/IV over
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the years 1995-2009. Another possibility is that the
number of nodes taken at resection increased over the
period 1995-2009, thereby leading to a situation where
the probability of finding a positive node(s) increased
commensurately, which would have tipped the balance
in favour of stage III/IV over stage I/II according to
UICC-TNM, 5th edition. However, we do not have
details on node count to support this hypothesis. This
question will be addressed in a more comprehensive
study of stage migration in colorectal cancer at this
registry.
If effective, screening has the potential to change the
stage distribution of colorectal cancer in the population. As
regards FIT-based screening, which is being implemented
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Figure 6 Age standardised mortality rate and number of deaths for colorectal cancer by site of primary tumour and sex, 1994-2009.
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in Ireland, Cole et al reported that colorectal cancers were
detected at significantly earlier stages in those invited to
participate in a screening programme using FIT [23]. In a
health technology assessment for Ireland, it was estimated
that, by year 10 of a programme, the percentage of cases
diagnosed at stages I/II would increase from 46% to
53% and stages III/IV decrease from 54% to 47% [10].
These estimates were based on screening targeted at
those aged 55-74 with a best case scenario uptake of
53% (based on the UK experience of FOBT screening)
[24]. Similar uptake has been achieved in pilot FIT
screening in Ireland [25]. The BowelScreen programme,
which has recently commenced, is initially inviting indi-
viduals aged 60-69. While the stated intention is to even-
tually include 55-74 year olds, this is likely to take a
number of years due to the development of colonoscopy
capacity. Therefore the estimates of potential reductions
in late stage disease are very unlikely to be achieved by
year 10 of the programme.
Mortality
In 2008 Ireland ranked midway of 30 European coun-
tries in relation to mortality, similar to the EU average
but marginally higher than the United Kingdom [19].
Annual decreases in age standardised mortality rates for
colorectal cancer in males and females were observed in
this study. However this concealed significant increases
in the mortality rate for rectal cancers of 2.4% in males
and 2.8% in females. Scrutiny of European data reveals
that most countries have experienced static mortality rates
over the past 15-20 years. However a few, in addition to
Ireland, have described increases. These include Spain,
with an APC of 3.5% during 1994-2005, Malta with an
APC of 5.2% during 1994-2008 and among selected regis-
tries in Germany with an APC of 17.1% during 1998-2007
[26]. In terms of potential explanations for these trends,
the first that must be considered is whether it might be an
artefact of coding of rectal cancer deaths. We have shown
that there was a significant decline in the annual death
rate for pooled colorectal sites. Yet, there was a steeper
decline in the rate of colon deaths, with a compensatory
increase in the rate for ‘rectum’ deaths. This suggests that
there may have been a subtle shift in death certificate cod-
ing allocation from ‘colon’ to ‘rectum’ over the period we
have examined. It has long been recognised that physi-
cians tend to report non-specific cancer sites on death
certificates; thus, if physicians change how they record
cause of death on the death certificate over time, this
may induce an apparent change in mortality rates [27]. In
1981, Percy et al reported that misclassification led to over
reporting of colon cancer deaths and underreporting of
rectal cancer deaths [27]. More recently, in the US, Yin
et al reported inaccurate coding of underlying cause of
death, with the vast majority of misclassifications being
colon cancers incorrectly classified as rectal cancers [28].
Further investigation is warranted to explore the extent
and nature of misclassification on death certificates in
European countries in recent years, perhaps comparing
countries with rising and static rectal cancer mortality
rates.
Another possible explanation of the observed increase
in rectal cancer mortality is patterns in treatment utilisa-
tion. Pre-operative radiotherapy has been recommended
for resectable rectal cancer in recent years [29,30] and in
line with this the proportion who received pre-operative
radiotherapy has increased markedly since 2000, in Ireland
and in other countries [31]. However Carsin et al have
reported low use of radiotherapy in Ireland (27%) [31]
compared to US and EU populations (46%-62%) [32-34].
Moreover, although data from trials suggests that pre-
operative use is more effective, a significant proportion
treated with radiotherapy in Ireland receive it post-
operatively rather than pre-operatively [31]. These
observations raise the possibility that underuse of radio-
therapy, particularly preoperative radiotherapy, may be
a contributor to rectal cancer mortality trends. More-
over, while the current study found that radiotherapy
use was continuing to rise, any impact of this on mor-
tality rates will not be seen for several years.
In terms of surgery, evidence-based guidelines have
been published in Ireland aimed at standardising surgical
management of rectal cancer [30]. An audit of all rectal
cancers diagnosed in 2007 found that, while guidelines
were in place, best practice was frequently not adhered
to [35]. Surgery for rectal cancer can result in significant
morbidity if undertaken without appropriate and accur-
ate pre-operative staging. Accurate localisation of the
tumour [36-38], use of MRI (magnetic resonance im-
aging) [39] and ERUS (Endo-rectal ultrasound) [40-42]
as diagnostic tools, and recording of accurate pre-
operative histological data [43,44], are all essential for
successful treatment. However the national audit re-
vealed that there were often inadequate investigations
and/or recording of such data [35]. In addition while
multi-disciplinary meetings (MDM) have been shown
to improve outcomes for rectal cancer [45,46], treatment
options were only discussed at MDMs for around half of
patients. Moreover patients treated at low volume centres
were less likely to be discussed at MDMs and to have
neo-adjuvant therapy [35]. Further evidence suggests
that comorbidity, rather than age, in elderly rectal can-
cer patients increases risk of death after surgery [47].
Therefore age alone should not dictate the use of re-
storative rectal resection [47]. However, our analyses
indicate lower use of surgery in elderly than younger
patients (≥75; 81%; <75: 92-99%) as well as larger in-
creases in age standardised mortality in those aged 70
and older [13]. These observations, combined with
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likely under use of best practice, may provide a possible
explanation for the observed trends in mortality.
Biennial FIT-based screening in the 55-74 age group in
Ireland could reduce colorectal cancers deaths in the
population from as early as the second year of the
programme [10]. However, as noted earlier, screening is
being introduced in those aged 60-69, suggesting that it is
likely to take some considerable time to have any impact
on the trends in rectal cancer mortality reported here.
Conclusion
Age standardised incidence has remained static in
Ireland over the period 1994-2010, but 1-year and 5-year
survival continues to increase in both sexes. The propor-
tion of cases with late stage disease has increased over
time, as have mortality rates for rectal cancer. These
trends indicate the need for efficient and timely roll-out
of BowelScreen. However the narrow age-range at which
BowelScreen will operate in the first instance means that
the potential benefits of screening, in terms of more
advantageous stage distribution and reductions in colo-
rectal cancer incidence and mortality in the population,
are unlikely to be achieved in the short-term.
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Comparison of Uptake of Colorectal Cancer
Screening Based on Fecal Immunochemical
Testing (FIT) in Males and Females: A Systematic
Review and Meta-analysis
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Abstract
Background: Colorectal cancer is the third most common
cancer in males and the second in females worldwide. Incidence
and mortality are higher in men than women. Colorectal cancer
screening is effective in reducing mortality. Internationally, fecal
immunochemical testing (FIT) is increasingly being recom-
mended as the primary screening test. This systematic review and
meta-analysis aimed to determine whether uptake of FIT screen-
ing differs between men than women.
Methods: We searched PubMed and Embase for peer-
reviewed articles published in English during 2000–2013 for
randomized controlled trials (RCT) or observational studies of
screening using FIT that quantiﬁed numbers invited and par-
ticipating by gender. Meta-analysis was performed using a
random effects model.
Results: Six hundred and eighty-ﬁve citations were identiﬁed,
19 meeting the inclusion criteria. Random effects meta-analysis
found male uptake was signiﬁcantly lower than female uptake
[odds ratio (OR), 0.84; 95% conﬁdence interval (CI), 0.75–0.95;
P < 0.01]. This generally persisted throughout subgroup analysis
of studydesign (RCTs vs. observational studies and study quality),
screening organization (methods of invitation, number of sam-
ples, age range of screening, recommendations, and reminders),
and setting.
Conclusions: Meta analysis of FIT screening studies indicates
signiﬁcantly lower uptake among men.
Impact: Further investigation is required into factors inﬂuenc-
ing acceptability and participation of FIT screening in both sexes.
Cancer Epidemiol Biomarkers Prev; 24(1); 39–47. 2014 AACR.
Introduction
Colorectal cancer is the third most common cancer diagnosed
inmales and the secondmost common in females (1).Worldwide
more cases and deaths occur in males than females, with the age-
standardized incidence rate 44% higher (20.6 vs. 14.3 per
100,000) and age-standardized mortality 45% higher in males
(10.0 vs. 6.9 per 100,000; ref. 1). Most colorectal cancers are
considered to arise from precancerous polyps; if left in situ polyps
can progress to cancer over a 10- to 15-year period (2). However,
colorectal cancer canbeprevented, or treated effectively if detected
early, through screening (3). Evidence indicates efﬁcacy of screen-
ing in reducing cancermortality and, in some instances, incidence
(4–8).
A number of countries have implemented population-based
colorectal cancer screening programs (9–11). Screening can be
delivered through procedures conducted in a clinic or doctor's
ofﬁce, such as colonoscopy or ﬂexible sigmoidoscopy (FS), or
through noninvasive methods that are suitable to be undertaken
in an individual's home, such as fecal occult blood testing (FOBT)
or fecal immunochemical testing (FIT). Currently, most programs
that use fecal-based tests use FOBT (11, 12). However, FIT is a
more speciﬁc and sensitive test (8) and recent guidelines recom-
mend it as the initial screening modality (3, 13). In order for a
screening program to be effective in reducingmortality it needs to
be well organized and requires high uptake (3). It is well estab-
lished that uptake is higher for noninvasive, than more invasive,
colorectal cancer screening tests (14). In addition, recent evidence
suggests uptake is higher with FITs than FOBTs (15). Furthermore,
some studies suggest gender differentials in uptake; uptake is
higher among men for more invasive procedures and higher
among women for noninvasive tests (16–18). What remains to
be established is whether there is gender difference in uptake of
screening based on FIT.
The aim of this study was to conduct a systematic review and
meta-analysis to determine whether uptake of FIT-based screen-
ing differs by gender. A secondary aim of the study was to assess
factors that may inﬂuence any gender-based differences.
Materials and Methods
Search strategy and selection criteria
Citations published in peer-reviewed English journals during
January 2000 toDecember 2013 that reporteduptakeof FIT-based
screening inmales and females, were identiﬁed fromPubmed and
Embase using a structured search strategy. MeSH terms included
"neoplasms," "malignancy," "early detection of cancer," "com-
pliance," "adherence," "colon" and "rectum." Text word search
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terms included variations of "colorectal," "bowel," "colon," "rec-
tal," "gastric," "cancer," "neoplasm," "malignant," "participa-
tion," "compliance," "uptake," "attendance," "FIT," "fecal,"
"fecal," "immunochemical," "test," "kits," "FOBT," "iFOBT,"
"occult," "blood," and "test." One author (N. Clarke) carried out
the initial screening from the search strategy to remove ineligible
citations such as duplicates, conference proceedings, letters, com-
mentary, and editorials. Two authors (N. Clarke and A. Osborne)
then independently determined eligibility based on the inclusion
and exclusion criteria by reading the full text of the remaining
articles. To be included in the review, FIT was required to be used
as a primary screening (i.e., initial) test; studies in which FIT was
used for triage of people with a positive primary screening test
(e.g., FIT following gFOBT) were excluded. Studies which offered
individual participants a choice of different screening tests, such as
FIT or colonoscopy (i.e., in which the participant decided which
test to undergo) were excluded. Studies or trials with a single
group/test or multiple arms/tests and in which the screening test
was assigned by the investigator were eligible for inclusion. In
those withmultiple arms, FIT had to be the primary test in at least
one arm and only the arm(s) using FIT were included in the
analysis. Studies were included if they reported: randomized
controlled trials (RCT—experimental studies inwhich individuals
are randomly allocated to receive or not receive an intervention
and then followed to determine the effect of the intervention) in
which one arm involved screening by FIT; observational studies
(studydesigns that are not randomized control trials) inwhich FIT
was the primary screening test; or screening programs inwhich FIT
was the primary screening test. Studies were included if they
reported numbers of people invited and screened by FIT by
gender. Differences of opinion on study eligibility were resolved
through discussion among the authors. A standardized form was
developed to abstract data from eligible studies, including invi-
tation and uptake ﬁgures by gender, study design, screening age
range, invitation and recruitment methods, use of recommenda-
tions and reminders, and number of samples required.
Quality assessment
Eligible studies were assessed for methodologic quality using
two instruments: the Cochrane risk of bias tool (19) for RCTs and
the Newcastle–Ottawa Scale for observational studies (20). The
Cochrane risk of bias tool assesses bias on six domains covering
selection, performance, detection, attrition, reporting, and any
other bias. For our review, we assessed only selection bias (ran-
dom sequence generation), reporting, and other bias (compara-
bility of confounding factors and appropriate use of statistical
tests). Assessments of performance and detection bias were not
carried out as many screening trials are unblinded; it is therefore
likely that participants are aware of the arm to which they are
assigned (21). Attrition bias or incomplete outcome data (includ-
ing nonresponse, noncompliance or withdrawal) was not
assessed because noncompliance was the outcome of interest.
Cohort (study of groups of individuals, some of whom are
exposed to an intervention and followed over time to determine
the effect of the intervention on the outcome of interest) and
cross-sectional studies (observation of a deﬁned population at a
single point in time or during a speciﬁc time interval where
outcome and exposure are determined simultaneously) were
assessed using the Newcastle–Ottawa Scale by awarding stars as
an overall rating of three methodologic factors: selection [sample
representativeness (1 star) and sample size (1 star)], comparabil-
ity [authors controlled for or reported confounding factors for
uptake by sex and age (1 star), and for other factors such as
education, marital, income, or employment status (1 star)] and
outcome [clear description of statistical analysis (1 star) and
measurement of association or difference with conﬁdence inter-
vals (CI) and P values and use of appropriate statistical test
(1 star)]. After risk of bias assessment, RCTs were also assessed
for quality using the same criteria as observational studies. Studies
were assessed overall based on the number of stars they had been
awarded of a possible six, with 5 to 6 stars being considered high
quality, 3 to 4 stars moderate quality, and 2 or less stars low
quality.
Statistical methods
Within each study, participants were invited to complete one
test. Studies that compared screening tests (multiple arms in
RCTs) did not offer more than one choice of screening to each
participant. Uptakewas deﬁned as the number of persons targeted
(i.e., persons invited to participate in screening) who returned a
completed FIT kit.
Studieswere combined in ameta-analysis, conducted inReview
Manager 5 (The Cochrane Collaboration). Because of the high
level of heterogeneity, a random effects model was used. Sub-
group analysiswas also carriedout to determinewhether the effect
estimates varied by study characteristics. Subgroups were deﬁned
on the basis of study quality (high, moderate, or low), study
design (RCT or observational), age range of those invited to
screening (40–75, 50, or older with no upper age limit), number
of FIT samples required for test completion (1 or 2 or more
samples), letter of invitation (with advance notiﬁcation or with-
out advance notiﬁcation), test delivery method (test mailed to
recipient or test collected by recipient), use of recommendations
or endorsement of test (yes or no), and use of reminders (remind-
er provided or no reminder provided). Studies that did not report
on these methods or that used different methods were excluded
from relevant analysis. Only one study reported multiple screen-
ing rounds. This study (22)was very large (comprising 92%of the
invited population and 87% of the screened population when all
studies were combined) and reported six screening rounds (22).
In the primary analysis, this study was included with data from
2004 (round 1). Six sensitivity analyses were conducted to deter-
mine their impact on the effect estimate: (i) excluding this study
entirely; (ii) using round 2 data (2005), (iii) using round 3 data
(2006), (iv) using round 4 data (2007), (v) using round 5 data
(2008), and (vi) using round 6 data (2009).
Results
Study selection and characteristics
In total, 685 potentially eligible citations were identiﬁed.
Following review, 19 studies were eligible for inclusion in the
review and meta-analysis (22–40). A ﬂow chart of the search
strategy results is provided in Fig. 1. Study characteristics are
summarized in Table 1. Six were RCTs, 12 were cross-sectional
studies, and one was a cohort study. Nine studies originated from
Europe, three from Asia, three from North America, three from
Australia, and one from South America. Fifteen studies were
population-based (i.e., studies in which screening is systemati-
cally offered by invitation to a deﬁned population).
Across the 19 studies, a total of 2,650,358 [round 1; Park and
colleagues (22)] individuals were invited to participate in FIT
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screening and 407,451 were screened (uptake ¼ 15.4%). Exclud-
ing the largest study (22), 384,979 were invited and 169,586
screened (uptake ¼ 44.1%).
Meta-analysis
Uptake in males and females combined ranged from 11%
(round 1; ref. 22) to 90% (Table 2; ref. 26). Meta-analysis of all
included studies indicate signiﬁcantly lower male uptake [odds
ratio (OR), 0.84; 95% CI, 0.75–0.95; P < 0.01; Fig. 2).
Park and colleagues (22) account for 85% (round 1; round 2:
92%) of the entire screening population in the meta-analysis. In
round 1 of this study, uptake was signiﬁcantly higher in males
than females (OR, 1.16; 95% CI, 1.15–1.17; P < 0.01; Table 2),
while in the subsequentﬁve rounds uptakewas signiﬁcantly lower
in males than females (Table 2).
When the meta-analysis was repeated replacing the round 1
results of Park and colleagues (22) with those from each of the
subsequent ﬁve rounds, this had little impact on the overall risk
estimate which ranged between 0.83 and 0.84 (round 2: overall
meta-analysis OR, 0.84; 95% CI, 0.77–0.90; P < 0.01; round 3:
overall meta-analysis OR, 0.83; 95% CI, 0.77–0.90; P < 0.01;
round 5: overall meta-analysis OR, 0.83; 95% CI, 0.77–0.90;
P < 0.01; and round 6: overall meta-analysis OR, 0.83; 95% CI,
0.77–0.90; P < 0.01). When Park and colleagues (22) was exclud-
ed entirely from the meta-analysis, male uptake remained signiﬁ-
cantly lower (OR, 0.83: 95% CI, 0.74–0.92; P < 0.01).
Quality assessment
Of the 19 studies, seven were deemed to be of low quality, and
12were consideredmoderate quality, while nonewere deemed to
be of high quality. Results are summarized in Table 3. Moderate
quality studies had signiﬁcantly lower uptake inmales (OR, 0.81;
95% CI, 0.76–0.85; P < 0.01) while low-quality studies had
nonsigniﬁcantly lower uptake in males (OR, 0.89; 95% CI,
0.63–1.26; P¼ 0.51); however, there was no signiﬁcant difference
in these subgroups (P ¼ 0.58; Table 4). In addition, we repeated
the meta-analysis restricted to moderate quality studies only; the
lower uptake inmales persisted and the effect sizewas very similar
to that seen when all studies were included (moderate quality
studies only: OR, 0.83; 95% CI, 0.71–0.96; P ¼ 0.01).
Study design
Uptake was signiﬁcantly lower in males than females in both
RCTs (OR, 0.83; 95% CI, 0.71–0.97; P¼ 0.02) and observational
studies (OR, 0.83; 95% CI, 0.76–0.91; P < 0.01; Table 4). There
was nonsigniﬁcantly lowermale uptake in studies whichwere not
part of an organized screening program (OR, 0.74; 95% CI, 0.51–
1.07; P ¼ 0.11) as was the case for studies which were not
population-based (OR, 0.88; 95% CI, 0.73–1.07; P ¼ 0.20).
Setting
Uptakewas signiﬁcantly lower amongmales in studies based in
Europe and Australia, nonsigniﬁcantly lower in studies based on
North America and South America, and not different in studies
based in Asia (Table 4) but, overall, subgroup differences for
setting were nonsigniﬁcant (P ¼ 0.16).
Letter of invitation
The recruitment methods used in the 16 studies that described
this were heterogeneous. Invitations were made from a central
screening location (n¼ 10), general practitioner (GP) clinics (n¼
4), or through an index subject invited for cervical cancer screen-
ing (n¼ 1; Table 1). Nine studies used a letter of invitationmailed
to subjects while three studies used an advance notiﬁcation letter
of invitation, mailing letters to inform subjects they would be
invited, and subsequently mailing a letter of invitation to partic-
ipate. One study used an advanced notiﬁcation letter inviting
subjects to complete a bowel cancer survey, subsequently mailing
a test to responders. Subgroup differences for invitation methods
were nonsigniﬁcant (P ¼ 0.41). Male uptake was signiﬁcantly
685 citations
Embase and PubMed
2000–2013
109 Duplicates excluded
359 full text obtained
and reviewed for
eligibility
157 conference abstracts excluded
60 Non–English language/
editorials/guidelines, etc.,
excluded
19 articles eligible for inclusion
Figure 1.
Study ﬂow diagram: result of
search strategy.
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lower in studies that did not use an advance notiﬁcation letter of
invitation (OR, 0.77; 95%CI, 0.73–0.82;P<0.01)while therewas
nonsigniﬁcantly lower male uptake in studies using a letter with
advance notiﬁcation (OR, 0.89; 95% CI, 0.64–1.23; P ¼
0.47; Table 4).
Test delivery method
Several studies (n¼7) required the participant to collect the test
from a GP, nurse, or pharmacist, while nine studies mailed the
test. Subgroup differences for test delivery methods were nonsig-
niﬁcant (P¼ 0.65). Male uptake was signiﬁcantly lower in studies
which mailed the test to participants' homes (OR, 0.79; 95% CI,
0.75–0.83; P < 0.01) and nonsigniﬁcantly lower in studies which
required participants to collect the test (OR, 0.83; 95% CI, 0.66–
1.05; P ¼ 0.13; Table 4).
Screening recommendations
Eight studies used recommendations or endorsement of
screening, either by a GP, nurse, or local Mayor. Subgroup
differences were nonsigniﬁcant for use or nonuse of recom-
mendations (P ¼ 0.54). Those studies that provided a screening
recommendation had nonsigniﬁcantly lower uptake in males
(OR, 0.85; 95% CI, 0.68–1.05; P ¼ 0.13) while there was
signiﬁcantly lower male uptake in studies that did not use
recommendations (OR, 0.79; 95% CI, 0.76–0.82; P <
0.01; Table 4).
Table 2. Uptake ﬁgures by male and female for the 19 studies in meta-analysis with ORs, 95% CI, and P value
Total Males Females
Invited Screened Invited Screened Invited Screened
Author/year n n (%) n n (%) n n (%) OR (95% CI) P
Park et al., 2011 Round 1 (22) 2,265,379 237,865 (10.5%) 969,813 105,710 (10.9%) 1,295,566 123,148 (10.2%) 1.16 (1.15–1.17) P < 0.05
Park et al., 2011 Round 3 (22) 4,406,700 691,754 (15.7%) 2,062,961 307,381 (14.9%) 2,343,739 384,373 (16.4%) 0.89 (0.89–0.90) P < 0.05
Park et al., 2011 Round 6 (22) 4,625,557 1,211,896 (26.2%) 2,150,635 535,508 (24.9%) 2,474,922 675,654 (27.3%) 0.88 (0.88–0.89) P < 0.05
Cole et al., 2002 (23) 2,400 857 (35.7%) 1,094 375 (34.2%) 1,306 482 (36.9%) 0.89 (0.75–1.05) P ¼ 0.18
Cole et al., 2003 (24) 1,212 425 (35.1%) 592 196 (33.1%) 620 229 (36.9%) 0.85 (0.67–1.07) P ¼ 0.33
Crotta et al., 2004 (25) 2,961 1,631 (55.1%) 1,403 710 (50.6%) 1,558 921 (59.1%) 0.71 (0.61–0.82) P < 0.05
Fenocchi et a1., 2006 (26) 11,734 10,573 (90.1%) 3,663 3,282 (89.6%) 8,071 7,291 (90.3%) 0.92 (0.81–1.05) P ¼ 0.22
Chen et al., 2007 (27) 56,968 22,672 (39.8%) 21,502 9,481 (44.1%) 35,466 13,191 (37.2%) 1.33 (1.29–1.38) P < 0.05
van Rossum et al., 2008 (28) 10,322 6,157 (59.6%) 5,037 2,820 (55.9%) 5,285 3,337 (63.1%) 0.74 (0.69–0.80) P < 0.05
Parente et al., 2009 (29) 78,083 38,693 (49.6%) 37,838 18,314 (48.4%) 37,950 20,379 (53.7%) 0.81 (0.79–0.83) P < 0.05
Levy et al., 2010 (30) 297 235 (79.1%) 131 131 (80.9%) 166 129 (77.7%) 1.22 (0.69–2.15) P ¼ 0.50
Cai et al., 2011 (31) 31,963 24,409 (76.4%) 16,169 11,962 (74.0%) 15,794 12,447 (79.0%) 0.76 (0.73–0.81) P < 0.05
Gregory et al., 2011 (32) 375 192 (51.2%) 181 86 (47.5%) 194 106 (54.6%) 0.75 (0.50–1.13) P ¼ 0.17
Senore et al., 2012 (33) 37,691 7,281 (19.3%) 17,223 2,719 (15.8%) 20,468 4,562 (22.3%) 0.65 (0.62–0.69) P < 0.05
Hol et al., 2012 (34) 4,407 1,092 (24.8%) 2,221 472 (21.3%) 2,186 620 (28.4%) 0.68 (0.59–0.78) P < 0.05
Quintero et al., 2012 (35) 26,599 9,089 (34.2%) 12,156 4,145 (34.1%) 14,443 4,944 (34.2%) 0.99 (0.94–1.05) P ¼ 0.82
Ferrari et al., 2012 (36) 42,245 1,744 (41.3%) 20,311 7,980 (39.3%) 21,934 9,461 (43.0%) 0.85 (0.82–0.89) P < 0.05
McDonald et al., 2012 (37) 66,225 38,720 (58.5%) 32,318 18,058 (55.8%) 33,907 20,662 (60.9%) 0.81 (0.79–0.84) P < 0.05
Kluhsman et al., 2012 (38) 200 145 (72.5%) 50 29 (58.0%) 150 116 (77.0%) 0.40 (0.21–0.80) P < 0.05
Gupta et al., 2013 (39) 1,593 648 (40.7%) 600 232 (38.7%) 993 416 (41.9%) 0.87 (0.71–1.08) P ¼ 0.20
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Figure 2.
Forest plot corresponding to themain random effectsmeta-analysis of 19 estimates quantifying the relationship between gender and uptake of FIT-based colorectal
cancer screening.
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Screening age range
Subgroup differences were nonsigniﬁcant for screening studies
targeting different age ranges (P¼ 0.28). Uptake was signiﬁcantly
lower in males when screening was targeted at those of ages 40 to
75 years (OR, 0.79; 95% CI, 0.74–0.84; P < 0.01) while uptake
targeted at those of ages 50 years and over with no upper age limit
was similar in males and females (OR, 0.92; 95% CI, 0.70–1.19;
P ¼ 0.51; Table 4).
Fenocchi and colleagues (26) and Ferrari Bravo and colleagues
(36) reported uptake by age and gender. In the former, uptakewas
nonsigniﬁcantly lower in males in people of ages 50 to 69 years
(OR, 0.93; 95% CI, 0.81–1.07; P ¼ 0.32) and those of ages 70
years or older (OR, 0.71; 95% CI, 0.41–1.29; P ¼ 0.22). In the
latter, uptake in males was signiﬁcantly lower in those of ages 50
to59 years (OR, 0.76; 95%CI, 0.72–0.81;P<0.01) and in those of
ages 60 to 69 years (OR, 0.94; 95% CI, 0.88–0.99; P ¼ 0.02), but
didnot differ in those of ages 7071 years (OR, 1.05; 95%CI, 0.87–
1.27; P ¼ 0.56).
Number of FIT samples required
Fourteen studies reported the number of samples requested; 10
studies requested one sample and four requested two or three
samples over varying time intervals. The subgroup differences for
the number of samples required were nonsigniﬁcant (P ¼ 0.42).
TheOR formale uptakewas signiﬁcantly lower in both subgroups
(one sample: OR, 0.84; 95% CI, 0.71–0.98: P ¼ 0.03; two/three
samples: OR, 0.78; 95% CI, 0.74–0.82; P < 0.01; Table 4).
Screening reminders
Ten studies reported the useof reminders (varying from2weeks
to 6 months; Table 1) and two studies reported using no remin-
ders. Male uptake was signiﬁcantly lower in both subgroups
(Table 4) with no difference in these subgroups (P ¼ 0.51).
Discussion
This systematic review andmeta-analysis is the ﬁrst to examine
whether there are gender differences in uptake of FIT-based
colorectal cancer screening. It provides valuable information for
screening agencies relating to the implementation and delivery of
program.Overall, uptake inmaleswas 16% lower than in females,
and this was statistically signiﬁcant. Although there was notable
heterogeneity between studies in terms of design and screening
organization, as well as overall uptake, lower uptake in males
persisted across subgroups by study design, setting, methods of
invitation and delivery, use of recommendations, screening age
range, number of samples, and use of reminders.
Of note was the similar uptake in males and females in studies
based in Asia, which contrasted with studies from other settings.
Studies from Asia had similar uptake in males and females,
whereas studies from Europe reported lower uptake among men.
Although subgroup differences were nonsigniﬁcant across coun-
tries, much of the data required for inclusion in subgroup analysis
was not reported in the studies from Asia. Therefore, the possi-
bility that cultural or social factors may be responsible for differ-
ential uptake inmales and females cannot be entirely discounted.
It will be interesting to observe uptake of FIT-based screening in
future studies within countries in Asia in comparisonwith Europe
and Australia.
There was also no signiﬁcant difference in male and female
uptake in studies of low quality. Most of these required the
participant to collect the test, so the effect estimate may reﬂect
this. Test collection from a GP clinic, pharmacist, or distribution
center (nurse) requires theparticipant tomake face-to-face contact
with a health professional and may act as an encouragement or
endorsement of the test in addition to providing access to infor-
mation about the test and how to carry it out. Studies of low
quality also had quite high overall uptake, and the effect estimate
may reﬂect this rather than the low quality per se.
Although there was no formal difference in subgroups deﬁned
bywhether or not therewas a recommendationor endorsement of
the test, it was noteworthy that uptakewas only signiﬁcantly lower
in males than females in studies in which no recommendation
was used. Other evidence suggests that lack of a doctor recom-
mendation is an important barrier to colorectal cancer screening
(41). Our ﬁndings suggest that contact with, or endorsement of
the test through ahealth professional (GP, nurse, and pharmacist)
may serve to encourage men to complete the screening test. This
Table 3. The Newcastle–Ottawa scale of included studies: reviewers judgment
Sample
representativeness
(selection)
Sample
size
(selection)
Counfounding
controlled
(comparability)
Statistical
tests
(outcome)
Total stars
and quality
rating
Park et al., 2011 (22)    3/6 moderate
Cole et al., 2002 (23)    4/6 moderate
Cole et al., 2003 (24)    4/6 moderate
Crotta et al., 2004 (25)   2/6 low
Fenochi et al., 2006 (26)  1/6 low
Chen et al., 2007 (27)  1/6 low
van Rossum et al., 2008 (28)    4/6 moderate
Parente et al., 2009 (29)   2/6 low
Levy et al., 2010 (30)  1/6 low
Cai et al., 2011 (31)    4/6 moderate
Gregory et al., 2011 (32)   2/6 low
Senore et al., 2012 (33)    3/6 moderate
Hol et al., 2012 (34)    4/6 moderate
Quintero et al., 2012 (35)    4/6 moderate
Ferrari et al., 2012 (36)    4/6 moderate
McDonald et al., 2012 (37)    3/6 moderate
Kluhsman et al., 2012 (38)  1/6 low
Gupta et al., 2013 (39)   3/6 moderate
Kelley et al., 2013 (40)    4/6 moderate
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has been noted elsewhere, where male compliance with medical
procedures is increased when encouraged by a medical profes-
sional (42).
Although subgroup differences were (once again) nonsigniﬁ-
cant, studies that were not population-based did not have signif-
icantly lower uptake in males. Although the studies which were
not population-based differed in many ways, in three of four the
screening invitation was endorsed through a GP or GP practice
while two required the participant to collect the test. Therefore it
cannot be ruled out that the nonsigniﬁcantly lower uptake in
males may be a result of test collection and GP recommendation.
Age is an important predictor of colorectal cancer risk. Here,
male uptake was not signiﬁcantly different from female uptake in
studies targeting those of ages 50 years and over with no upper age
limit. However, this may be a result of the fact that some studies
involved test collection (3 of the 5 studies) and/or recommenda-
tions to complete the test by a GP (4 of the 5 studies), as opposed
to oldermen beingmore likely to participate in screening. Further
investigation is required to assess if there is differential uptake
between younger and older males in FIT-based screening and, if
so, what may be driving such differences.
Cole and colleagues (24) have reported that participation in
their study was signiﬁcantly improved (increase in relative risk of
participation of 30%) through simpliﬁcation of the sampling
method (using two rather than three samples); this did not differ
by gender, age, or socioeconomic status. In this meta-analysis,
therewere no subgroupdifferences in effect estimates according to
whether studies required a single, or more, samples. Further
investigation is required to assess if there is differential uptake
in males and females when different FIT sampling strategies are
used.
Although there is tentative evidence from this review that
requiring participants to collect the test, using a GP recommen-
dation and using an advance notiﬁcation results in similar uptake
in males and females, the general lack of signiﬁcant subgroup
differences suggest that study design or screening organization
may not be the important drivers of poorer male uptake. How-
ever, these elementsmayhelp informdevelopment of a taxonomy
of compliance in particular groups, such as those based on sex or
other background characteristics. Further research in identifying
and expanding on such taxonomy is warranted. Given the dearth
of evidence regarding reasons for nonparticipation in FIT
Table 4. Summary of primary and subgroup random effects meta-analysis
Subgroup Number of studies OR 95% CI I2 P
Primary meta analysis 19 0.84 (0.75–0.95) 99% <0.01
Study quality
Moderate 14 0.81 (0.76–0.85) 95% <0.01
Low 5 0.89 (0.63–1.26) 96% 0.51
Subgroup differences — 0% 0.58
Study design
RCTs 6 0.83 (0.71–0.97) 91% 0.02
Observational 13 0.83 (0.76–0.91) 98% <0.01
Subgroup differences 0% 0.99
Study setting
Europe 9 0.78 (0.73–0.84) 95% <0.05
North America 3 0.79 (0.49–1.28) 68% 0.35
Asia 3 0.97 (0.73–1.28) 100% 0.81
South America 1 0.92 (0.81–1.05) — —
Australia 3 0.86 (0.76–0.98) 0% 0.03
Subgroup differences — 38% 0.16
Letter of invitation
Letter without advance notiﬁcation 9 0.77 (0.73–0.82) 87% <0.01
Letter with advance notiﬁcationa 3 0.89 (0.64–1.23) 92% 0.47
Subgroup differences — 0% 0.41
Test delivery
Test mailed 9 0.79 (0.75–0.83) 45% <0.01
Test collected 7 0.83 (0.66–1.05) 99% 0.13
Subgroup differences — 0% 0.64
Recommendation
Recommendation provided 8 0.85 (0.68–1.05) 99% 0.13
No recommendation provided 7 0.79 (0.76–0.82) 45% <0.01
Subgroup differences — 0% 0.54
Screening age range
40–75 14 0.79 (0.74–0.84) 92% <0.01
50þ (5) 5 0.92 (0.70–1.19) 99% 0.51
Subgroup differences — 13% 0.28
Number of samples
1 sample (10) 10 0.84 (0.71–0.98) 99% 0.03
2 or more samples (4) 4 0.78 (0.74–0.82) 13% <0.01
Subgroup differences — 0% 0.42
Screening reminders
No reminder provided 2 0.85 (0.75–0.96) 73% 0.01
Reminder provided 10 0.81 (0.73–0.89) 87% <0.01
Subgroup differences — 0% 0.51
NOTE: Values in bold indicate P < 0.05.
aAdvance notiﬁcation indicates pre-invitation letter, followed by invitation letter.
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screening in males and females, and the fact that FOBT and FIT
may be considered somewhat similar from the point of view of
screening invitees, it is worth considering what is known about
drivers of home-based FOBT screening (non)participation. An
early review of colorectal cancer screening uptake using FOBT
reported that the main factors for noncompliance with screening
were: conﬂicts with work or family, inconvenience, being too
busy, or being away, lack of interest and costs (43). In addition,
the same review reported that noncompliancewas associatedwith
having no current health problems, being too embarrassed to
complete the test, feeling the test was too unpleasant, being
anxious and not wanting to know the test results (43). These
ﬁndings are in line with Chapple and colleagues (44) in the UK
FOBT screening program.
The evidence base for reasons underlying gender-based differ-
ences in colorectal cancer screeninguptake is very limited, and even
less is known about uptake in FIT based screening speciﬁcally.
Recently Ritvo and colleagues (45) suggested that males may
procrastinate about colorectal cancer screening, but that, underly-
ing this, is a deeper fatalism about cancer disease and a disbelief in
the preventative–protective elements of screening. It has also been
reported that males use primary care services less frequently than
women (46) perhaps making them less inclined to be screened
when offered the opportunity. In addition, White and colleagues
(46) suggest that, in Europe, the general absence of male targeted
health care programs may hinder men's ability to identify as
participants in health care. These observations indicate that studies
are now required exploring cultural norms surrounding, psycho-
logic and other barriers to, and facilitators of, FIT screening and
how these may differ between the sexes. It would be useful to
explore these barriers and facilitators through theory-based
research into gender differences in preventive health behaviors.
Conclusion
Uptake of FIT-based colorectal cancer screening amongmales is
signiﬁcantly lower than among females. Although studies differed
in design and screening organization methods, poorer male
uptake persisted throughout subgroup analysis. Further investi-
gation is required into why men are less likely to attend FIT
screening and what factors may act as barriers or facilitators to
screening uptake in men and women.
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Abstract
Objective: Faecal immunochemical tests (FITs) are increasingly being used in population-based
colorectal cancer-screening programmes. Uptake of FIT is lower in men than women; however, the
reasons for this are not well understood. We aimed to explore gender differences in inﬂuences on
decisions to participate in FIT screening.
Methods: This is a qualitative study using in-depth face-to-face interviews of four groups of screen-
ing invitees (male and female screening users and male and female screening non-users), purposively
sampled from the database of a population-based FIT screening programme. Recruitment continued
until saturation was reached. Interviews were audio recorded and transcribed verbatim. Thematic
analysis using the framework approach was employed with the theoretical domains framework guid-
ing analysis.
Results: Forty-seven screening invitees were interviewed. Six theoretical domains inﬂuenced screening
uptake: ‘environmental context and resources’, ‘beliefs about capabilities’, ‘beliefs about consequences’,
‘emotions’, ‘social inﬂuences’ and ‘knowledge’. Male non-users were often fatalistic, less knowledgeable
and misinformed about cancer and FIT screening compared with other groups. Female non-users
expressed negative attitudes, beliefs and emotions towards FIT screening, cancer, social inﬂuences and
the medical profession and were over-conﬁdent about their health.
Conclusions: Negative attitudes and emotions to screening dominated non-user decision-making
but differed by gender. Opportunities to improve uptake in men and women exist. Greater national
discussions on the beneﬁts of FIT screening, and development of screening materials tackling nega-
tive attitudes and beliefs while recognising male/female differences, may improve screening uptake.
Copyright © 2016 John Wiley & Sons, Ltd.
Background
Worldwide, colorectal cancer is the second most common
cancer diagnosed in women and the third most common in
men although men have higher incidence and mortality
from the disease [1]. Screening is effective in reducing
colorectal cancer incidence and mortality [2–7]. Current
guidelines recommend population-based screening of
asymptomatic people aged 50–74 years or ≥50 years
annually or biennially using non-invasive methods
(guaiac-based faecal occult blood test (FOBT) or faecal
immunochemical test (FIT)) or every 5–10 years using
other procedures (ﬂexible sigmoidoscopy/colonoscopy)
[8,9]. Many population-based screening programmes
employ FOBT as the initial screening test. However, FIT
is increasingly being recommended because it has higher
speciﬁcity and sensitivity [8] and higher uptake [10,11].
In order to be effective in reducing incidence and mor-
tality, population-based screening programmes require
high uptake. Men have higher uptake of endoscopy-based
screening procedures, while women have higher uptake of
non-invasive tests such as FOBT and FIT [12–14]. For
FIT speciﬁcally, a recent systematic review and meta-
analysis estimated that the odds of screening participation
were signiﬁcantly lower in men compared with women
(odds ratio, 0.84; 95% conﬁdence interval, 0.75–0.95)
[15]. However, the drivers of lower male uptake did not
appear to be related to screening programme design or
organisation [15].
Lower-colorectal cancer-screening uptake in men has
been associated with poorer knowledge of colorectal
cancer and screening [16,17], lower perceived severity
of colorectal cancer, fatalistic beliefs about cancer,
procrastination, lower beliefs about capabilities of
Copyright © 2016 John Wiley & Sons, Ltd.
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successfully completing testing and machismo and homo-
sexual sensitivities [16,18,19]. Higher uptake in women
has been associated with having a family member with
colorectal cancer [20], while lower uptake has been asso-
ciated with fear of endoscopic-based procedures and fear
of a positive diagnosis [16]. However, this evidence re-
lates to FOBT or endoscopic-based tests; evidence on rea-
sons for gender differences in uptake of FIT speciﬁcally is
lacking.
We used a qualitative approach to explore differences
in male and female inﬂuences on use and non-use of a
population-based FIT colorectal cancer-screening
programme.
Methods
Design
In-depth semi-structured interviews were conducted
among people invited to participate in the Tallaght
Hospital/Trinity College Dublin Colorectal Cancer
Screening Programme (TTC-CRC-SP), a population-
based FIT-based colorectal cancer-screening programme
in Tallaght, one of the most disadvantaged areas of Ireland
[20,21]. Approximately 10 000 people aged 50–74 years
were identiﬁed through primary care practices and invited
by mail to participate in screening; the FIT kit was sent
with the initial invitation. Round 1 operated during
2008–2010 (uptake was 51%) and round 2 during
2011–2012 (uptake was 47.5%) [22]. In both rounds,
uptake was signiﬁcantly lower among men than women
(e.g. round 2: 44.5% vs 50%; odds ratio 0.79; conﬁdence
interval 0.73–0.89) [22]. The TTC-CRC-SP ceased in
December 2012 after two screening rounds, and in 2013,
a national FIT-based screening programme (BowelScreen)
began (http://www.bowelscreen.ie).
Theoretical framework
The theoretical domains framework (TDF) [23] was used
as a framework for examining potential inﬂuences on
whether individuals accepted an invitation to participate
in the TTC-CRC-SP. The TDF integrates 33 psychologi-
cal and organisational theories to provide a comprehen-
sive framework of possible inﬂuences on behaviour [23].
It consists of 14 domains [23]: knowledge, skills,
social/professional role and identity, beliefs about capabil-
ities, optimism, beliefs about consequences, reinforce-
ment, intentions, goals, memory attention and decision
processes, environmental context and resources, social
inﬂuences, emotion and behaviour regulation.
Recruitment and interviews
A purposive sample was drawn from the TTC-CRC-SP
database (Supporting Information Fig. S1). ‘Users’ were
deﬁned as those who had taken part in either or both
screening rounds; ‘non-users’ did not take part in any
screening round. Screening invitees were stratiﬁed into
four groups according to participation status (users/non-
users) and gender (male/female). Each group was sorted
alphabetically in Microsoft Excel by surname and fore-
name and a random number assigned to each person
(using the RAND [Random number generator] function).
We re-sorted each group from lowest to highest number
and approached people in sequence, starting with the
lowest numbered individual. The study was approved by
the St James/Adelaide Meath Hospital incorporating the
National Children’s Hospital Research Ethics Committee
(REC Reference 2013/12/05).
Potential interviewees were contacted by mail and
invited to be interviewed. Those who returned a reply slip
were telephoned by the male interviewer (NC) who
answered any questions and arranged a convenient time
and place for the interview. All participants provided
written informed consent. Interviews were conducted face
to face, at the participant’s home, the local hospital or
another venue, according to the interviewee’s preference,
during May–August 2014. Everyone who accepted and
was available to take part was interviewed. Recruitment
continued until saturation was reached (i.e. no new themes
emerging across all interviews). Interviews were audio
recorded with the interviewee’s permission and lasted
15–90 min (mean=41 min).
Topic guide
The topic guide (Supporting Information Table S1) was
informed by the TDF. Questions were developed for each
domain to explore potential inﬂuences on screening invi-
tees’ decisions regarding FIT screening use.
Analysis
Transcripts were imported into NVivo 9. Data were
analysed thematically using the framework approach; this
involved familiarisation, construction of a thematic frame-
work (the TDF domains), indexing and sorting data and
reviewing data extracts [24]. Two researchers independently
read four transcripts, coded these to the TDF domains and
then discussed coding to reach consensus. The remaining
interviews were then coded to the TDF by one researcher
(NC). A health psychologist (PG) was consulted when nec-
essary. Domains were compared and contrasted by strata.
Selected illustrative quotes are presented in Tables 1 (users)
and 2 (non-users), with additional quotes in Supporting
Information Tables S2 (users) and S3 (non-users).
Results
Interviews were conducted with 47 people, 28 users of
FIT-based screening (16 male and 12 female) and 19
non-users (9 male and 10 female). Interviewees’
1457Impact of gender on decision to participate in FIT screening
Copyright © 2016 John Wiley & Sons, Ltd. Psycho-Oncology 25: 1456–1462 (2016)
DOI: 10.1002/pon
characteristics are summarised in Supporting Information
Table S4.
Six TDF domains were identiﬁed as inﬂuencing inter-
viewees’ decisions on participation in FIT-based screen-
ing: ‘environmental context and resources’, ‘beliefs
about capabilities’, ‘beliefs about consequences’, ‘social
inﬂuences’, ‘emotions’ and ‘knowledge’ (Supporting
Information Table S5).
Environmental context and resources
Screening users
A prominent inﬂuence on screening behaviours was
salient events in interviewees’ lives. These acted as a
catalyst encouraging screening participation in male and
female users. Generally, these related to others diagnosed
with cancer or other gastric/bowel conditions and were a
context within which screening was validated as a positive
health behaviour.
Resources and materials relating to the FIT kit also
inﬂuenced participation. Most female users found the test
equipment simple and easy to use. In a few instances,
women raised concerns with the kit (e.g. paper for catch-
ing stool, sampling tool and packaging for storing the
sample in the refrigerator); these issues were overcome
and did not act as barriers to participation. Male users
were very positive about the screening resources and
materials provided.
Screening non-users
Female non-users referred to salient events related to colo-
rectal cancer, other cancers or other gastric conditions;
these events were seen in a negative light and presented
as reasons not to participate (Table 2). Male non-users
Table 1. Illustrative quotes for domains potentially inﬂuencing screening decisions in users, by gender
Domain Female compliers Male compliers
Environmental
context and
resources
She had bowel cancer. Well, her bowel burst, actually, she’s lucky to
be alive. I thought, oh no, I need to get this done, because there’s
slight changes, do you know. (P-9)
And certainly in light of the two guys, friends of mine who are in
trouble now. So I would certainly be very conscious of it. (P-28)
Beliefs about
capabilities
Well, I thought so. I mean, it’s pretty simple to do, just take the little
stick and… It’s not exactly rocket science. (P-7)
It was easy enough, yeah. Yeah, you just prepare whatever you have
to do upstairs and do it. (P-32)
Beliefs about
consequences
But I always feel that if you had to get a cancer, it wouldn’t be one of
the worst [colorectal cancer], because it is treatable, and if it’s
caught in time I think you have a better chance than you have if
you got pancreatic cancer. (P-3)
If they got it in time, if they were screening, and all that, that’s the way
I believe in it. Well, it’s like anything, I suppose, if you get it in time.
(P-26)
Social inﬂuences If I came to a bowel cancer awareness week or breast cancer or
bowel cancer or whatever, it would make me think, and it’s ‘oh I
must follow up on that and have all that checked out for
myself’. (P-3)
She nagged me into it [female spouse], so I did it. (P-35)
Emotions I thought brilliant....Great idea. Any of those tests for prevention, I
would say, is a great idea. (P-1)
The more people you’ve met or have known that have had cancer,
and the closer you are to getting it, the more frightening it
becomes, especially when people die, obviously. (P-29)
Knowledge I suppose it’s one of the cancers I would think, no, you won’t get
that…it’s just maybe to do with diet and lifestyle, is a lot to do
with it probably. (P-6)
Well, at the moment, after doing this [colonoscopy] I think I’m okay.
(P-29)
Table 2. Illustrative quotes for domains potentially inﬂuencing screening decisions in non-users, by gender
Domain Female non-compliers Male non-compliers
Environmental
context and
resources
I got it the morning after my young fellow nearly died the night
before and I just… I’m sick of hospitals…and it was all bowels. (P-19)
So I just kept putting it off. I mean, in and out of the courts for the
last… I mean, I’m going to the High Court now [custody battle]. So
I’ve been down the courts for the last 12 years. (P-45)
Beliefs about
capabilities
Well, when I saw what you had to do, I couldn’t cope with that
[faecal sampling]. (P-15)
Yeah…I’d do it myself now. I’ve no problem doing it now. (P-39)
Beliefs about
consequences
It’d probably be fairly invasive and end up with bags and all sorts of
things. (P-18)
I’d say they’d be dead. Because there’s no cure for cancer is there,
not that I know of anyway. (P-47)
Social inﬂuences Well, it was my mother, when I got the letter my mother said, ‘Throw
that in the bin, you don’t want to know anything about yourself.’
(P-16)
And she [wife] said tome, ‘Did you do it?’ ‘Aye,’ I said. But I didn’t. (P-46)
Emotions I thought, ‘I’m not doing that’ [faecal sampling]. Yes… If it had been
probably- oh God, it sounds disgusting. (P-13)
At the time it was, yeah, it was a fear of dying. (P-47)
Knowledge That would have been on my mind, opening that pack, and looking at
it and thinking, ‘Well, I don’t have the symptoms that [sister] had. If
I have, I’ll go.’ (P-22)
But you wiped your bottom and you sent this piece of paper off to
the…wherever, the lab. (P-40)
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also mentioned salient events acting as barriers to
screening; these were generally unrelated to medical
matters or illness (e.g. relationship breakdown and child
custody battle).
Uniquely, female non-users had poor trust in the medi-
cal profession, particularly their local hospital, and this
inﬂuenced their decision not to take part. Some male
non-users had issues with the environmental context,
speciﬁcally delivery of mail, implying the screening invi-
tation did not reach them.
Female non-users’ attitude to FIT test materials was of-
ten negative and related to the sampling kit (e.g. catching
of the stool using the paper provided and using the sam-
pling stick) and packaging for storing the sample in their
refrigerator (e.g. concerns about food contamination).
Male non-users had few or no issues with the resources
and material.
Beliefs about capabilities
Screening users
Both male and female users had strong conﬁdence in their
ability to do the test, describing how they carefully
followed the test instructions and pointing out ‘it’s not
rocket science’.
Screening non-users
Male non-users generally believed they would have had
no problems conducting the test despite not participating.
Female non-users raised several issues impacting on their
perceived ability to carry out the test, including an inabil-
ity to deal with faecal matter and lack of conﬁdence in
sampling stool with the equipment provided. Others sug-
gested that they felt conﬁdent to recognise illness in them-
selves observing that they did not participate in screening
because they felt they were not ill or that they had no
bowel symptoms; several made statements such as ‘you
know your own body’ and ‘if it’s not broke don’t ﬁx it’.
Beliefs about consequences
Screening users
Both female and male users were very positive about the
implication of a colorectal cancer diagnosis, often stating
that they considered that early detection is the key to
successful treatment.
Screening non-users
Both female and male non-users were generally negative
about the implication of a colorectal cancer diagnosis.
Many female non-users discussed undergoing surgery
and the potential need for a colostomy bag in negative
terms. Male non-users often held fatalistic beliefs that a
diagnosis inevitably resulted in death.
Social inﬂuences
Screening users
Male users spoke about the positive inﬂuence of female
partners in their decision to participate. Female users
discussed social inﬂuences outside the family on their
screening participation including the impact of media cam-
paigns for other cancer screening and quitting smoking.
Screening non-users
Female non-users raised a range of social inﬂuences that
were generally negative and inﬂuenced their decision not
to participate in screening (e.g. a neighbour who experi-
enced colonoscopy-related complications, lack of en-
couragement from one’s General Practitioner (GP) and
discouragement by one’s mother). While there were fewer
social inﬂuences on male non-users’ screening decisions,
some discussed a female relative’s unsuccessful attempt
to encourage them to participate.
Emotions
Screening users
Male and female users spoke of their decision to be
screened with positive emotional affect feeling it was a
‘brilliant idea’. Although male users sometimes men-
tioned fear of cancer and embarrassment (with respect to
the test), these did not inhibit their participation. Instead,
fear of cancer was a catalyst to screening, providing
‘peace of mind’ in knowing that one has a ‘pretty good
chance of not getting it’.
Non-users
Female non-users expressed negative emotions around
screening including disgust (related to handling faeces or
storing the sample in the fridge), anger (timing, e.g. re-
ceiving test while grieving a spouse’s death) and fear (of
cancer). Some female non-users described emotional
burnout due to other conditions leaving them emotionally
unequipped to deal with a potential colorectal cancer
diagnosis, leading them to decide not to participate. Male
non-users expressed negative emotions relating to a fear of
cancer, and dying (considered as potential consequences
of screening) inﬂuencing their decision not to participate.
Knowledge
Screening users
Generally, female users considered their risk of develop-
ing colorectal cancer as low, based on their family history
of the disease and lifestyle (which they considered
‘healthy’). Some male users considered they had low risk
because they had previously had a colonoscopy (either
having a negative result or polyps removed) and therefore
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were in no immediate danger or because they had a
healthy diet and lifestyle; others considered that they had
high risk because of other gastrointestinal conditions
(e.g. Crohn’s disease). Overall, users had a very consid-
ered view of their colorectal cancer risk and felt screening
participation would sustain a low risk or reduce a high
risk. Male and female users often knew other people with
colorectal cancer, and this motivated them to participate in
screening.
Screening non-users
Female non-users generally believed that their risk was
low, mainly because they had no family history or symp-
toms of the disease (generally understood as frequent
bowel motions). This perceived low risk led them to
believe they did not need to be screened. Male non-users
generally stated they did not know their risk of developing
colorectal cancer and were often unsure if they knew
anyone with colorectal cancer.
Female non-users were often unclear about the screen-
ing procedure and sometimes described having not read
the information sent with the test kit. Male non-users
stated that they were clear about how the test was carried
out but upon discussion, several had misunderstood how
to complete it.
Discussion
We used qualitative methods to explore inﬂuences on men
and women’s decisions to participate in FIT-based colo-
rectal cancer screening. Considering FIT-based screening
is increasingly being used in population-based
programmes and that uptake is variable (19–76% in
population-based programmes, average 44% [15]); this
study provides valuable information on factors inﬂuencing
non-participation, examining these differences by gender.
Six TDF domains emerged as inﬂuencing individuals’
decisions on FIT-based screening participation. Although
all of these domains were evident for users and non-users,
issues within domains differed between groups, or the
same issues played out differently in the two groups and
sometimes by gender.
Negative attitudes, beliefs and emotions pervaded deci-
sions of non-users, while positive attitudes, beliefs and
emotions were evident among users. Negative attitudes
are associated with lower colorectal cancer screening
participation [25,26]. Our study found differences in these
attitudes and beliefs by gender especially among male and
female non-users. These included differences in salient
events (medical matters in women and non-medical
matters in men), response to materials and resources (test
kit, storage and faecal sampling in women and non-test-
related factors in men), perceived consequences of screen-
ing and diagnosis (men’s fatalism) and social inﬂuences
(negatively impacting on women’s decisions, but less
apparent in males).
Fear of cancer and fatalistic beliefs result in low adher-
ence to screening recommendations [27], but fear may
have different effects on screening decision-making
around participation [28]; this has not been explored by
gender. In our study, although male users had some fear
around a cancer diagnosis, this did not impede participa-
tion, whereas in non-users, fear was an impediment to
screening. Fatalism has been associated with poor screen-
ing uptake [19,29–31], and those with greater fatalistic
beliefs are more likely to believe they have a greater risk
of cancer and that it is a more severe disease [31]. Where
our study extends these are that we found; fatalistic beliefs
were present among male non-users only and inﬂuenced
their decision not to participate.
Non-users, particularly male non-users, had poorer
knowledge of colorectal cancer than users and less often
knew of others with cancer. Knowledge about cancer gen-
erally, and knowing someone with colorectal cancer, is
positively associated with screening intention and partici-
pation [25,32,33], while low health literacy has been iden-
tiﬁed as inﬂuencing non-participation [34]. Our ﬁndings
suggest that health literacy and social supports that provide
opportunities to learn about illnesses or screening may be
especially poor among male non-users thereby inﬂuencing
non-participation. Von Wagner et al. [35] have suggested
the use of a wider range of communication strategies in
raising awareness of screening, and we concur with this.
Disgust inﬂuenced women’s, but not men’s, decisions
to participate in screening. Different forms of disgust,
such as trait disgust (the stable tendency to experience
disgust) and state disgust (current emotional experience),
might inﬂuence particular types of decisions such as
taking part in screening. A recent study found that while
women had higher scores for both forms of disgust,
between-gender differences were not signiﬁcant, but the
authors acknowledged methodological limitations [36].
There is a need for research identifying how screening
information could address anticipated disgust [36,37],
and our ﬁnding suggests this should be considered with
gender differences in mind.
There were few differences between male and female
users in inﬂuences on screening decisions, but female
relatives often inﬂuenced male users’ decisions to be
screened, but this inﬂuence did not operate in the other
direction. Spouses play an important role in colorectal
cancer screening decision-making [38,39], and women
have been described as the guardians of men’s health
[40]; our study appears to be the ﬁrst to show that this
positive inﬂuence operates only for men. Among male
non-users, while social inﬂuences were fewer, female
relatives had sometimes attempted to inﬂuence them,
albeit unsuccessfully. Further investigation of female in-
ﬂuence on male screening decision-making is warranted.
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Male non-users were less clear about their non-
participation than female non-users, citing external cir-
cumstances or that they had forgotten or did not have time.
Those who cited external circumstances or forgetting as
reasons for non-participation could have been masking
their true reasons. Elsewhere, it has been reported that un-
screened men often procrastinated about screening, being
vague and emotionally distant around screening decisions
[19]. In our study, a small number of male non-users
revealed that they unconsciously resisted doing the test
because of an underlying fear of the potential outcome
of screening. Further investigation on resistance to screen-
ing in men is warranted.
This is the ﬁrst study to employ the TDF within a
qualitative study investigating inﬂuences on FIT-based
colorectal cancer-screening decisions. Although inter-
viewees were recruited from a population-based screening
programme, this operated in a speciﬁc area in one city,
and it is possible that themes/inﬂuential domains may
not generalise to other settings/populations. Our sample
was drawn from a screening programme that had ﬁnished
2 years prior to recruitment, and interviewees may have
had difﬁculty with recall, although we provided recall
aids. One (male) interviewer conducted all interviews,
and while this provided consistency across interviews, it
is possible that the interviewer’s gender inﬂuenced inter-
viewees’ responses. Finally, while we reached saturation
of themes across the entire dataset, and in all strata except
male non-users, the relatively small number of non-users
who were interviewed is a limitation. Recruitment of
non-users was challenging: 550 individuals were
approached in order to obtain interviews with 19 people.
It is possible that if more non-users had participated,
further domains might have been identiﬁed as inﬂuencing
screening decisions.
Conclusions
Our study provides novel information on inﬂuences on
FIT uptake in men and women. Further investigation is
required of whether and how the inﬂuences identiﬁed in
this study operate independently and together at the
population-level. Our ﬁndings may be used to inform the
development of gender-speciﬁc interventions designed to
improve uptake in FIT-based screening programmes.
Moreover, the opportunity exists, within Ireland at least,
where colorectal cancer screening is relatively new, to
open a national discussion on the beneﬁts of FIT-based
screening, tackling the issues raised in this study and
ultimately seeking to improve screening participation in
both genders.
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This study aimed to investigate the effects of sex and deprivation on participation in a population-based faecal
immunochemical test (FIT) colorectal cancer screening programme. The study population included 9785 individ-
uals invited to participate in two rounds of a population-based biennial FIT-based screening programme, in a rel-
atively deprived area of Dublin, Ireland. Explanatory variables included in the analysis were sex, deprivation
category of area of residence and age (at end of screening). The primary outcome variable modelled was partic-
ipation status in both rounds combined (with “participation” deﬁned as having taken part in either or both
rounds of screening). Poisson regression with a log link and robust error variance was used to estimate relative
risks (RR) for participation. As a sensitivity analysis, data were stratiﬁed by screening round. In both the
univariable and multivariable models deprivation was strongly associated with participation. Increasing
afﬂuence was associated with higher participation; participation was 26% higher in people resident in the
most afﬂuent compared to the most deprived areas (multivariable RR = 1.26: 95% CI 1.21–1.30). Participation
was signiﬁcantly lower in males (multivariable RR = 0.96: 95%CI 0.95–0.97) and generally increased with
increasing age (trend per age group, multivariable RR = 1.02: 95%CI, 1.01–1.02). No signiﬁcant interactions
between the explanatory variables were found. The effects of deprivation and sex were similar by screening
round. Deprivation and male gender are independently associated with lower uptake of population-based FIT
colorectal cancer screening, even in a relatively deprived setting. Development of evidence-based interventions
to increase uptake in these disadvantaged groups is urgently required.
© 2016 Published by Elsevier Inc.
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1. Introduction
Colorectal cancer is the second most common cancer diagnosed in
women and the third in men worldwide (Globocan, 2012). Worldwide
men have higher incidence (world age standardised rate (ASR) 20.6 vs.
14.3) and mortality (ASR 10.0 vs. 6.9) from the disease (Globocan,
2012). Highermortality has also been observed among lower socio-eco-
nomic groups in the US and Europe (Manser and Bauerfeind, 2014).
Screening is efﬁcacious and effective in reducing colorectal cancer
incidence and mortality in the population (Atkin et al., 2010; Brenner
et al., 2014a, 2014b; Burch et al., 2007; Hewitson et al., 2008; National
Cancer Institute, 2012). A range of screening tests are available, which
detect either pre-malignant adenomatous polyps or colorectal cancers,
including endoscopic-based procedures (colonoscopy and ﬂexible sig-
moidoscopy) and faecal-based tests (faecal occult blood test (FOBT)
and faecal immunochemical tests (FIT)). Current guidelines recommend
population-based screening of asymptomatic people aged 50 years and
over on an annual or biennial basis using non-invasive methods (FOBT
or FIT) or every 5 to 10 years using other - invasive - approaches
(ﬂexible sigmoidoscopy or colonoscopy) (European Colorectal Cancer
Screening Guidelines Working Group et al., 2013; Levin et al., 2008).
Screening programmes require high uptake among their target popula-
tion in order to maximise the health beneﬁts, (Essink-Bot and Dekker,
2015; European Colorectal Cancer Screening Guidelines Working
Group et al., 2013; Weller et al., 2009) and uptake of non-invasive
methods is generally higher than invasive methods (Khalid-de Bakker
et al., 2011). Therefore, many population-based screening programmes
use FOBT as the initial screening test. However, FIT is increasingly being
recommended as it has higher sensitivity and speciﬁcity, does not re-
quire dietary and medicinal restriction (European Colorectal Cancer
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Screening GuidelinesWorking Group et al., 2013; Levin et al., 2008) and
has been associated with higher uptake than FOBT-based screening
(Digby et al., 2013; Vart et al., 2012). Nevertheless, in current FIT-
based screening programmes uptake remains low overall (Clarke et
al., 2015). Moreover, uptake is signiﬁcantly lower among men than
women and a recent systematic review concluded that screening pro-
gramme design or organisation (i.e. use of letters of invitation, use of
screening recommendation, test delivery methods, use and number of
reminders, number of samples required and screening age range) do
not appear to be the important drivers of lower male uptake (Clarke
et al., 2015). Given the differences observed in uptake in males and fe-
males in Europe, Australia and Asia (signiﬁcantly lower male uptake
in Europe and Australia but similar uptake in males and females in
Asia) it is possible that other gender-speciﬁc socio-cultural factors
may be important in inﬂuencing screening acceptability.
In the UK socio-economic deprivation has been shown to affect par-
ticipation in FOBT-based colorectal cancer screening (vonWagner et al.,
2011). Results froma Scottish study showed that use of FIT as theprima-
ry screening test improved uptake compared to FOBT, particularly
among the most deprived and men, although many participants had
been exposed to FOBT for a number of years prior to the offer of FIT
(Digby et al., 2013). As far as we are aware these are the only studies
that have examined how FITmight reduce disparities over FOBT screen-
ing. In addition relatively little is known about whether there are depri-
vation gradients in uptake of FIT-based screening and, in particular,
whether gender and deprivation might operate independently in
inﬂuencing participation.
Understanding socio-demographic predictors of screeningparticipa-
tion is important because unequal access across groups runs the risk of
creating or widening health inequalities (Wardle et al., 2015a). During
2008–2012 a population-based FIT-based screening programme ran in
Tallaght, a district of Dublin (McNamara et al., 2014). In this setting,
we investigated the effect of sex and deprivation on FIT-based screening
uptake.
2. Methods
2.1. Study setting
Tallaght is one of the largest towns in the County of Dublin and has a
population of just under 70,000 people (CSO, 2011). The area is identi-
ﬁed as one of the most disadvantaged in Dublin (and, therefore, in Ire-
land). Ireland has a mixed public-private healthcare system. Care
within the public system is available to all citizens. Unless an individual
has a “medical card” (which is available to those on reduced means)
they must pay to see a GP and make modest co-payments for hospital
in-patient and out-patient services. Just under half of the population
have private health insurance; this generally covers hospital care. The
screening programme, and any associated follow-up investigations or
treatment, was provided free of charge to all invitees.
The Tallaght Hospital/Trinity College Dublin Colorectal Cancer
Screening Programme (TTC-CRC-SP) offered two rounds of biennial
screening. 9785 individuals between the ages of 50–74, and resident
in Tallaght,were identiﬁed through seven primary care practices and in-
vited to participate in screening (Engling and Haase, 2013). Individuals
were sent a FIT kit with an initial invitation letter. The invitation pack
also contained information on colorectal cancer and an Irish Cancer So-
ciety help-line telephone number was also provided. The programme
was not promoted beyond the invitation letter; therefore all invitees re-
ceived identical information. Participation in theprogrammewas free to
all participants, as was treatment if cancer was detected. Reminders
were sent to non-responders. The ﬁrst screening round was completed
during 2008–2010 and the second during 2011–2012. At the com-
mencement of round two individuals were excluded if they had left
the catchment area after round one, had been diagnosedwith colorectal
cancer in round one or were known to have died. Non-responders to
round one invitation were included sent an invitation to participate in
round two.
For analysis we included the available explanatory variables which
were sex, age and deprivation category of the area in which the individ-
ual lived (Engling and Haase, 2013). The National Cancer Registry geo-
coded the addresses of residence of those invited to participate in the
TTC-CRC-SP, in order to enable individuals to be assigned to an area-
level deprivation category based on the Pobal Haase Pratschke (HP)
Deprivation index (Engling and Haase, 2013). This index (based on
the 2006 and 2011 census waves), which is assigned to small areas, is
based on the following characteristics of the population resident in the
area: population density, age dependency ratio, lone parent ratio, pri-
mary education only, third level education, unemployment rate and
proportion living in local authority rented housing (Engling and
Haase, 2013). The index is divided into 8 categories ranging from ex-
tremely disadvantaged to extremely afﬂuent. Age (at completion of
the two screening rounds) was divided into ﬁve categories for analysis:
(i) b60, (ii) 60–64, (iii) 65–69, (iv) 70–74 and (v) 75+. As all invitees
were included in both rounds some invitees were older than the initial
screening criteria age range at the outset of round 2 (i.e. thosewhowere
aged 74 years during round 1 were aged 75 or over during invitation to
round 2).
The outcome variable was uptake status (participant or non-partici-
pant) and the primary analysis was based on the two screening rounds
combined. In the primary analysis, participants were deﬁned as those
who took part in either or both screening rounds; non-participants
took part in neither round. Uptake was calculated as the percentage of
individuals who completed a screening test out of the total number in-
vited to participate. We excluded individuals from the analysis if: they
had died prior to screening; they self-referred to screening; they were
medically unsuitable for screening; the recorded address was incorrect;
or a deprivation category could not be assigned to their address (Fig. 1).
A sensitivity analysis was undertaken to investigate uptake separately
by screening round.
All analysis was conducted using Stata 11. We compared character-
istics of participants and non-participants using chi-square tests. As the
outcome was common (N10%), (Bonita et al., 2006) we did not use
logistic regression for estimation, rather we modelled participation sta-
tus using Poisson regression with a log link and robust error variance
(Zou, 2004) to estimate relative risks (RR) for participation. All three
explanatory variables were ﬁtted separately, then simultaneously. Var-
iables were included in the ﬁnal multivariable model if the p value from
the associatedWald test was b0.05.We tested for interactions between
the explanatory variables byﬁtting cross-product terms to amodel con-
taining all main effects.
Three sensitivity analyses were conducted.We stratiﬁed the data by
screening round and analysed the following three outcomes separately:
uptake in round 1 (participants in round 1 vs. non-participants in round
1); uptake in round 2 (participants in round 2 vs. non-participants
in round 2); and uptake in both rounds (participants in both rounds
vs. non-participants in either round (those who participated in only
one round of screening were excluded from this sensitivity analysis))
(Fig. 1).
3. Results
Table 1 summarises the characteristics of the 9151 screening
invitees included in the analysis. Of these, 46% were male. The mean
age at the end of screening was 62 years (Inter Quartile Range (IQR):
57–66. Invitees were resident in only ﬁve of the eight possible depriva-
tion categories (very disadvantaged, disadvantaged, marginally below
average, marginally above average and afﬂuent). None of the study par-
ticipants were resident in areas classiﬁed as extremely disadvantaged,
very afﬂuent and extremely afﬂuent (Engling and Haase, 2013); and al-
most half (48%) were from very disadvantaged or disadvantaged areas.
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Overall, uptake in males was signiﬁcantly lower than uptake in fe-
males (p b 0.001). This was also seen for round one only (p = 0.002).
There was no difference in uptake in males and females in round two
only (p = 0.146). Among invitees, the distribution of deprivation did
not differ by sex (p = 0.145; similar to the national population (CSO,
2014)) but the distribution of age did (p = 0.002); 38% of female invi-
tees were aged b60 compared to 35% of males, with a slightly higher
proportion of males in the 70–74 age group (13% vs 11%).
Uptake in both screening rounds combinedwas 60%; 41% of invitees
took part in both rounds, 8% in round 1 only and 10% in round 2 only;
40% did not take part in either round. A higher percentage of females
participated in screening (both rounds combined: females 62% vs.
males 56%) (Table 1). This translated into a signiﬁcantly lower relative
risk of participation in males than females in univariable analysis
(RR = 0.96: 95% Conﬁdence Interval (CI) 0.95–0.98) (Table 2). Uptake
was signiﬁcantly higher in all age groups compared to those aged less
than 60 (Test of linear trend across groups: RR = 1.02: 95%CI 1.01–
1.02; p (trend) b 0.001) (Table 2). Deprivation was strongly associated
with uptake; compared to those in very deprived areas the relative
risk for those resident in afﬂuent areas was 1.22 (95% CI 1.17–1.27;
Table 2). In a test for trend the relative risk of uptake increased by 6%
for each category of increasing afﬂuence (RR = 1.06: 95% CI 1.05–
1.06; p (trend) b 0.001).
In the multivariable model sex remained a signiﬁcant predictor of
uptake after adjusting for deprivation and age;males had a 4% lower rel-
ative risk of participation than females (RR = 0.96: 95% CI 0.95–0.97;
Wald test p b 0.001)). Age was also a signiﬁcant predictor of uptake
(Wald test p b 0.001); those in older age groups had higher relative
risks of participation than those aged b60 (although the effect was not
signiﬁcant in those aged over 75). In a test for trend, uptake increased
by 2% (RR 1.02: 95% CI 1.01–1.02; p (trend) b 0.001) for each increasing
age category. Deprivation was a strong predictor of uptake (Wald test
p b 0.001) and the relative risk of participation was 26% higher in
those resident in afﬂuent compared to very disadvantaged areas
(RR = 1.26: 95% CI 1.21–1.30) (Table 2). In a test for trend, the relative
risk of uptake increased by 6% per unit increase in afﬂuence (RR=1.06:
95%CI 1.05–1.07). Therefore the effect of deprivation was not attenuat-
ed by age or sex. No signiﬁcant interactions were found between the
socio-demographic variables (age*sex; p (interaction) = 0.35;
sex*deprivation; p (interaction) = 0.16; deprivation*age; p (interac-
tion) = 0.17) (data not shown).
In the sensitivity analysis, the effects of deprivation and sex were
most pronounced in screening round 1. For round 1, relative risk of
participation was more than three-times higher in those resident in af-
ﬂuent compared to very deprived areas (multivariable RR = 3.32: 95%
CI 2.28–4.83) andmales had almost 20% lower relative risk of participa-
tion than females (multivariable RR = 0.81: 95% CI 0.71–0.92). For
round 2, deprivation was a signiﬁcant predictor of uptake, but sex was
not. Participation in both rounds was signiﬁcantly associated with
TTC-CRC-SP Database of potential screening invitees
(n=9785)
Males
(n=2364)
Females 
(n=3087)
Participated 
in round 1 
only
(n=319)
Participants
(n=5451)
Participated 
in round 2 
only
(n=433)
Participated 
in both 
rounds
(n=1612)
Participated 
in round 2 
only
(n=493)
Participated 
in round 1 
only
(n=418)
Participated 
in both 
rounds
(n=2176)
Males 
(n=1829)
Females 
(n=1871)
Non-
participants
(n=3700)
Deceased (n=201)
Self-referred to screening (n=16)
Did someone else’s test (n=16)
Medically unsuitable (n=94)
Wrong address (n=245)
Deprivation index un-assignable (n=62)
Fig. 1. Consort diagram of TTC-CRC-SP.
Table 1
Characteristics of screening invitees.
Participant characteristics Total Male Female
N (%) N (%) N (%)
Participation
Participation overall 5451 (60) 2364 (56) 3087 (62)
Both rounds 3788 (41) 1612 (38) 2176 (44)
Round 1 only 737 (8) 319 (8) 418 (8)
Round 2 only 926 (10) 433 (10) 493 (10)
Non-participant 3700 (40) 1829 (44) 1871 (38)
Agea
Mean age (IQRb) 62 (57–66) 62 (58–67) 61 (57–66)
b60 3276 (37) 1419 (35) 1857 (38)
60–64 2633 (30) 1212 (30) 1421 (29)
65–69 1899 (21) 896 (22) 1003 (21)
70–74 1048 (12) 522 (13) 526 (11)
75+ 66 (1) 27 (1) 39 (1)
Deprivationc
Very disadvantaged 1193 (13) 521 (12) 672 (14)
Disadvantaged 3068 (34) 1374 (33) 1694 (34)
Marginally below average 3851 (42) 1800 (43) 2051 (41)
Marginally above average 872 (10) 416 (10) 456 (9)
Afﬂuent 167 (2) 82 (2) 85 (2)
a Age was not available for 229 invitees.
b IQR: Inter quartile range.
c Missing categories from POBAL HP deprivation index: Extremely Disadvantaged, Very
Afﬂuent and Extremely Afﬂuent.
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afﬂuence (afﬂuent vs. very deprived multivariable RR = 2.34: 95% CI
2.04–2.67), female sex (males vs. females multivariable RR = 0.87:
95% CI 0.83–0.91), and older age (over 75 vs. b60): multivariable
(RR = 1.22: 95% CI 1.07–1.39) (Supplementary Table 1).
4. Discussion
Poor screening uptake and socio-economic status are a largely
unmet challenge in research and threaten potential increases in in-
equalities in cancer mortality (Wardle et al., 2015a). Our study shows
- for the ﬁrst time as far as we are aware - that deprivation is the stron-
gest socio-demographic predictor of uptake in population-based FIT-
based screening. This effect remained after adjustment for gender and
age, and persisted across screening rounds. Given that our study was
based in a predominantly deprived area of a large European city it was
also notable that there was a signiﬁcant difference in uptake even
within the least afﬂuent sectors in our study population (i.e. uptake
was signiﬁcantly higher among people resident in disadvantaged com-
pared to very disadvantaged areas). A nationwide FIT-based screening
programme, BowelScreen, began to roll-out in Ireland in late 2013
(www.bowelscreen.ie). Given our study was conducted in an area
which does not contain the extremes of the deprivation index (i.e. ex-
tremely deprived and extremely afﬂuent) we would speculate that, in
BowelScreen, the differences in uptake observed may be even larger
than those seen in our study.
Associations between poor uptake of colorectal cancer screening
(using a range of tests other than FIT) and lower socioeconomic status
(measured at both the individual and area level) have been reported
in the literature (Gimeno García, 2011; Javanparast et al., 2010; Solmi
et al., 2015; von Wagner et al., 2011; Walsh et al., 2012). Our results
are consistentwith– and extend - these. Others have found that, overall,
FIT-based screening is usually associatedwith higher uptake than FOBT-
based screening (which has traditionally been used in population based
screening programmes) (Vart et al., 2012). If we compare uptake rate by
area –level deprivation category in this study,with those reported in the
English FOBT-based screening programme, rates in the current study
exceed those in England in every deprivation category. While some
caution is needed here, as the deprivation indices and categorisations
differ in the two populations, our ﬁndings tentatively suggest that use
of FIT may result in higher uptake (compared to FOBT-based screening;
(vonWagner et al., 2011)) even among those resident inmore deprived
areas.
Solmi et al. found that after controlling for several socio-demograph-
ic, economic and health variables there was an independent association
between limited wealth and lower probability of participation in
colorectal screening (Solmi et al., 2015). In a decomposition analysis
the authors report that health literacy contributed to 8% of the inequal-
ity in screening uptake; inadequate health literacy was associated with
lower screening uptake and this was independent of individual-level
measures of socio-economic status (Solmi et al., 2015). Health literacy
is the degree to which individuals have the capacity to obtain, process
and understand basic health information and services in order to
make appropriate health decisions (Institute of Medicine (US)
Committee onHealth Literacy, 2004). Educational attainment and social
status are positively associated with health literacy (Sørensen et al.,
2015). While we did not have data on education in our study, data is
available on the levels of educational attainment for the area in which
our study was carried out. More than one-third (33%–39% across sub-
areas) of the adult population of Tallaght have only primary education,
more than twice the national average (16%; Engling and Haase, 2013).
In the UK having adequate health literacy has been associated with
higher participation in FOBT-based colorectal cancer screening (OR =
1.20: 95% CI 1.00–1.44) (Kobayashi et al., 2014). Von Wagner et al.
have suggested that written invitations, the route through which indi-
viduals are invited to participate in colorectal cancer screening in the
UK, may be difﬁcult to process and understand for adults with limited
health literacy (von Wagner et al., 2009). In our study individuals
were invited to participate in writing and the invitation contained a
printed leaﬂet with information about the screening test and how to
complete it. However the possibility does exist that differences in health
literacy between those resident in deprived and more afﬂuent areas
could explain some of our ﬁndings. While health literacy is correlated
with reading ability they are different. Further research on uptake,
education, reading and health literacy is warranted in exploring the
potential underlying mechanisms of poorer uptake in males and more
deprived areas in this screening population.
Our study also shows that male sex is associated with lower relative
risk of participating in FIT-based screening and that this effect is inde-
pendent of age and deprivation. This extends ﬁndings from our recent
systematic reviewwhich observed that men had lower FIT uptake in al-
most every setting, but whichwas unable to determine if this effect was
Table 2
Absolute uptake by participant characteristics (numbers and %) and univariable and multivariable relative risks (RR) for participation in FIT-based colorectal cancer screening with 95%
conﬁdence interval and p values: primary analysis based on two screening rounds combined.a
Invited Participated Univariable model Wald Multivariable modelb Wald
N N (%) RR 95%CI p RR 95%CI p
Sex
Female 4958 3087 (62) 1.00 − − −
Male 4193 2364 (56) 0.96 0.95–0.98 b0.001 0.96 0.95–0.97 b0.001
Age
b60 3276 1874 (57) 1.00 − − −
60–64 2633 1618 (61) 1.03 1.01–1.04 1.03 1.01–1.04
65–69 1899 1260 (66) 1.06 1.04–1.08 b0.001 1.06 1.04–1.08 b0.001
70–74 1048 650 (62) 1.03 1.01–1.05 1.03 1.01–1.05
75+ 66 44 (67) 1.06 0.99–1.14 1.05 0.98–1.12
Test of trendc 1.02 1.01–1.02 1.02 1.01–1.02
Deprivation
Very disadvantaged 1193 548 (46) 1.00 − − −
Disadvantaged 3068 1643 (54) 1.05 1.03–1.08 1.06 1.04–1.08
Marginally below average 3851 2542 (66) 1.14 1.11–1.16 b0.001 1.14 1.12–1.16 b0.001
Marginally above average 872 588 (67) 1.15 1.12–1.18 1.16 1.13–1.19
Afﬂuent 167 130 (78) 1.22 1.17–1.27 1.26 1.21–1.30
Test of trendc 1.06 1.05–1.06 1.06 1.05–1.07
a Participation deﬁned as taking part in either or both screening rounds.
b Mutually adjusted for sex, age and deprivation
c Linear trend across categories.
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independent of other socio-economic factors (Clarke et al., 2015). Men
in Ireland have signiﬁcantly poorer health literacy and functional litera-
cy thanwomen, (Doyle et al., 2012) suggesting that health literacy could
also explain the observed lower uptake in men. However, other factors
could be in operation. For example, Miles et al. have reported that poor
self-rated health signiﬁcantly mediated the relationship between up-
take and socio-economic status (Miles et al., 2011). In a qualitative
study nested within the TTC-CRC-SP, we found that several factors
appeared to inﬂuence non-use of FIT-based screening, and that these
factors differed by gender; drivers of non-participation in males includ-
ed fear of cancer, fatalism, lack of knowledge and being misinformed
whereas negative attitudes, beliefs, emotions and social inﬂuences in-
ﬂuenced females non-use (Clarke et al., 2016). In a study on late stage
colorectal and lung cancer diagnosis, females had higher fatalism scores
than males, (Lyratzopoulos et al., 2015) and those with lower income
and lower educational attainment also had higher levels of fatalism.
Other studies have found associations between cancer fatalism, lower
income/educational attainment, poor self-rated health (Miles et al.,
2011; Powe and Finnie, 2003) and lower screening uptake. We have
also found differences in fatalistic beliefs in our qualitative work in
this population (Clarke et al., 2016) suggesting differences may exist
at the screening population level in cancer fatalism between men and
women (or, indeed by deprivation status). This however needs to be in-
vestigated further.
However, these explanations are speculative and further research is
required to better understand what underlies the observed differences
in uptake. It would be particularly useful to examine if a gender differ-
ence exists in screening information comprehension and subsequent
decisions to participate in FIT-based screening – both in Ireland and
more widely. It is important also to understand the mechanisms by
which fatalistic beliefs and lack of cancer knowledge (which are not
necessarily exclusive of one another) may contribute to low screening
uptake and how these may differ by sex and socio-economic status.
Some evidence is beginning to emerge on success in intervention trials
aimed at tackling the socioeconomic gradient in colorectal cancer
screening uptake through mailed materials (Wardle et al., 2015b). Fu-
ture investigations should examine if poorer health literacy in males
(and/or themost disadvantaged groups of the population)may be ame-
nable to interventions to improve screening uptake in this population.
In themeantime, we concur with vonWagner et al. (2009) that screen-
ing programmes should seek to simplify messages and make screening
information more accessible to different sectors of the population.
Our study had several limitations. Firstly there was limited data
available to us and the variables on which we did have information
were not modiﬁable. In addition screening history was not available to
us and as suchwe could not determine the extent towhichprior screen-
ing may have inﬂuenced uptake. However when the TTC-CRC-SP
started, no other organised colorectal screening programme was in op-
eration in Ireland, so any previous related tests participants may have
had would have been opportunistic or diagnostic. We were also unable
to determine any effect of multiple invitations in individual households
on uptake.
In conclusion, our study shows that FIT-based screening uptake is
lower in more deprived sectors of the population and in men, and that
these are independent effects. It is important to investigatewhat under-
lies these ﬁndings to inform the development of interventions to reduce
and, ideally, eliminate these disparities. Failure to intervene effectively
will ultimatelymean that these groupswill experience a disproportion-
ately greater burden of colorectal cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ypmed.2016.10.012.
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